var title_f11_33_11792="Conditions of turbulent flow";
var content_f11_33_11792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Turbulent flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four circumstances under which gas flow tends to be turbulent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11792=[""].join("\n");
var outline_f11_33_11792=null;
var title_f11_33_11793="Normal breast histology";
var content_f11_33_11793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal male breast tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal adult male breast tissue demonstrating a duct lined by a single layer of epithelial cells and surrounded by a loose stroma devoid of inflammatory infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn D Braunstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11793=[""].join("\n");
var outline_f11_33_11793=null;
var title_f11_33_11794="Acute histoplasmosis chest CT";
var content_f11_33_11794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary histoplasmosis on chest CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAZsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyi6J81xnvVfJqxdY85/rVcjjIoAQk5NNJPGDS9aZmgBSaQnrzSUE8UALnikJOPU0A84oHC4FACK21hyeKc0jMSzMSx6n1pg560ZyfpxQAucjmm96X1pCDzQAADjJwM9aQgbjzxS4wv0pOMmgBUxk84PanZ55PvTEPX3p78HIHbmgBM5prE560q9MimnrQAoYjnNID1pKUDg0AKTyOaRj0oIwRSlW25xxmgBCTkc0jEnNB4NDDjp3oAB160meTTsc0h70AIelNPWnHoaQjkfSgBtO7DNNIp3pQAf40hHNLxxRxmgBtKaOMUcUAIKDRS54oAO9NFPByRjrSetADT0o7daDRxQAmOKO5paM0AIe1KRnJoPGKKAExxSqKOD0pVPNADsCkxTj0ptACU7GTSU4UACj3qKSOQuSEcj1AqcDqa1bZSYEIz0oAhvCfPk+tVsmrF3/r3+tVielACZNMJPrTu/NNPGBzQAmSKQ5PQZNBpwKiL/bOQQR0FACzbVkZYmZkB4ZhgmosnBpR1pMcGgAyaMn1oA4oFAC7m45pCxzSgYoCksAASx6AdTQAmTjigE1r23hrWpzAF0q8RJiAsskLKnPfd0xXZ6d8Mo8K2ra1HEw+9DDEWPX+8DigDzUZ9amjjkmmWOJHkc9FUZJr3G28P+GNOtfJh0SC7IJzLdqWb88ip7e1s7OUSafp9nZyesKYOPTmgDySz8F+Jr2ESWeiXskZ4DBBj+dbdh8LdelG+/ktrJR1Dvlvyr0OaWWTdvd8ZzkcVEwLpvYkDrkk/nQBzUfwqs0j3XWvurEcCOAN/Wl/4Vpom0keIb3PYfYl/wDiq6UjDDIB/lTLSaO7jLIsigNt2shUj8KAMBfhnoRK58Q3+CCc/Y1/+Kpj/DHSDGDH4huSeMBrQD/2auw+yv8ALsQt6Gp4dPnKsHtS2Oc4NAHn118LPnAs9bhYY5MqhcVi3fw38RQZ8mOG5UHgxvnNeumwlIwbV8nuFNMawuUwFhk5zyATigDxk+AvFa9dCvT9FB/rUMvgvxLET5miXqn3Qf417VJHcRyfOsy8d8imHzQeJXwOcc0AeLr4K8TMcDRL4n/cH+NTDwB4rLADQL/J6fIP8a9kLys2TI/PoalWOaSRf3jsR2BNAHjkXw18XyKWOiXEYzjMmB/WrsXwp8Stjz1toB6vJ0FetMlydy+VKcntmlmtJccQTYA64NAHmVv8JrslRc6xYxnOCFbJFXx8IoVyJtdQMOm2MH+tdsunTbsiCZtp/unmrT2EpAZraTPcbTxQBwCfCfTypLeIJB/27j/Gmn4U6eR8mvSEnpm3H+Ndbcw+V/eHTqMVUkLbhtxg0AcnN8K1ZittrUTccb1C/wBayr/4Ya/bQNLbiC6UHjy3GTXfBfmJGG4xnPSnR8A/eyOep5NAHlFx4M8R2WHn0e8jA5DbR+fWsWSFo3ZZkkR8871wc17yks28He/Toe9NuYbe9T/iYWNvdgHH71MnHocUAeCSIB0qPbivcNS8NeGtThKHTY9OkAO2S2Uj8SO9cXrvw8urSF5tJu01GJScoEKuBj0PU0AcHjmk21dvdOvbEK19ZXNsG4UzRlM/nVXFADMUYp5xxSEe1ADQKeqbuR26mk7U4cEYoAQ0hFPYDrjANIaAExSilPXpRigBVGa27Tb9mjySDjpisaMda27Qn7NH8o6elAFC8H7+T61WA9cVau/+PiT61WPagBmOaTGVJBFONNLKAQ3fGGHb8O9ADCDu5GQKDyDSk8KASQOKDQAmMUlO6mjA25JP86AEwamgt5p32W8Mkz9dsaFj+QruPCXgG4u5LO+1zZBpb4kMPmbZZUPTHoD616DpWnaboM88nh6CS0R+N5lLv/30efwoA4LTvhhfSWVvc6nf21iJDlrfBMoXHXpiu20PRdE0PYbDTIZblMEXU5LNn6dK0S247pHYs3PJyTUTZ8wnkcUASz3M8wIkmdkGPkBOB9BVXGDn/JqRAAMZ4+vOaNgXO88+1AELYAJBz7VKMb+VBGOvY1PDYPcAFAeT16VsWehL1uH2qR93dzQBgiF5FbaeM9KFtZnyAhIHGK62KytYQQV/4EWqNyoBMOEUfxZoAw4dGlnGZGCDFaMOmwQL82129cGrJlJYruHTHWmbtyYdsD2PFAFuGJUdNigAryT0FXYYCqxumSw4PJ5+tZC3CxuvzHZ3rQtr9FkAwcHGCTmgDYttPeeKSQSqgB+62aqTW5XPzAnPrVmG4SQs3mAk8EVMiQkoSu7LDFAFK40O/miP+ivKMZHymsKTwVqxcH7PJhu2Dx9a9U1a7lg8touhUHG6sVtVvepLjngAmgDkLTwRql48cUqiCMdWcECulsfBMtnxHLBz1OCa1FvL0qr7pDu/hwfzq9Zm4nlBZ3Q98k8/QUAchf2M1sXjO3eGxkccZ/lUVxZu2NzL8vOOetbWvhTd3EM5bkD+LqO2azkIEgxIGbGTmgCO2sZQqspHJwetTCBxKxYh19OatRuY0DPj72Dg9RSSTwrJxKmCc8mgDF1XSYZY3kljXB46VytxpEEj7UYRj1Nei3L+baybwCB3U9a5WYWpnxIdjE4AJoA5g6FMu7ynRl9QDVQ2k8H3hlemcGvREsP9HV4mUof4QefxqvJbquFYAkHHI6UAcD93h8g+tOUDbjPXtXYXem202GkhYenPWs650UFC1tlVH97v9KAOckU8jI7/AFprArhkJXB7Gr1zbSQMRIpB9jVI45BGATQBLetDqNottq1vHfw53BJSRjjsRzXE6j8N0vJpJdGvre2UrlbWfcTu9FI/rXZlSMY5PrmgAhW2ttOM56mgDwzVdLvdLn8jUbaW3lyQN6kBvoehqkR1r6A1K1t9atre115Wu7NSCq+YVZPcN2rz7xt4FazuZ7zw+hn0sAERBy8kXHOfUUAef49qdyMYoxxSEe/NADhnketDKRx3o7ClJJA6mgBKWkp1ADk4zWzaORbRj2rGXg1oQHEK/SgCK7/17/WqwO4A9jVm7H79xjvVc44oAaxOaV0dAGcJiRAynOSB/SljWNpkWWTy0Y8v12j1qMqFAwcgjP0oATnNJg/hTsdKuaXp9zql9FZ2ETy3EhxhRnaO5PoKAJfD2iX+v6tFpulxLJdSBmVWcKMAZJJr1nwJ4XTwsk02rWlvc6yzEI2Q6wLjpnoT71raV4Y0jwvJjRZJri6OQ17LgPtIGUAHGOtWyPmYFzub9aAIZmmmZWZhk8fSlPAIPUUoRVZS7Hr2qZ4A7jDHBBBJoAppuwJNuc8AHtUiJJIeea1NP0eS7ZCzFYuma3bLSbaMgIJJ5Qcfdzg/hQBztro93PGGVAE4OScVs6do/ksCVEjH+EV2Wl6BA0UDX9y/myAEQx449jTfE2r6J4at9oeFborkKXGcZxk0AYc9pNHHmRUjQcnFZF3ctFMBGC2PU1ymsfEnSmkkjkv2lAkzhRgD2rgvE/xI1Ce7VdEna1tkGPuglj680Aer32sW1lE8l/PHGRyVLc4+lchqXxT061k2WtlNdYyCdwUY/GvG72+ub24kmup5JJHOSWPWq340Aetn4sWxJxo0wPY+cP8AClPxZtnQhtGnOf8Apuv+FeR7sd+KQHigD1eX4kx3cqiOzktEUZJ8wNmrUfxTtY4Yojp8rsMB5DIPm+g7V48W9CaTPA5oA960b4laZcXbbYZIAq5xIchjmu80XxdEGiM0REbtkHOeK+SkZgT83PtW1Z+J9XtLZIIL11iQ/KpAOPxNAH1/rPjvSoQrfYpbpuBjIXH50zTfiFb3bBbbSpFH/XRf8K+T18V67cyqj37tuI42j/CvbPATXMOgLcXqlrh85ZhjAoA9RvfHUNq2DYyN6kSDj9Kpn4jRBgBpkp9xKP8ACvPdSubZXB37yTyM1QWdnnHlkqMYwOaAO21jxJdX0pmS0AD8CNmGQO3NVobvUt4cW0ag8DLg5rBsrec5dpmHtWxaRSrkZYYGfWgC7Pqd/FtXyYwVbPXqKwtW1S6luEe4ChgDt8vgda3tgKYk+ZmPX0FQzaVDcy4Py8df8KAMmy8ZXmnwSxiBZN/XcecVw3iD4p3Mdy3l6VEccBnINdlrmipaQuyszEDv1rzfVfD8V9kOXV/7wHSgCzD8ZLwAedp6kjp5bBQK0rT4ywSTQpcaXLHGSA8vmhtvvjFeRatYvp968Dg5HQnvVKgD7E8O3UevoJNGkjuVABYhh8ufX0rrLywD6DHa3axx3XZ15Kc9fyr4k8P+INV8PXoutGvprOYDGUPB+o6H8a7nRvjF4nt70S6rdLqUJI3JIoUj6YoA9z1XSZ7WINcKstu5ZI2TnPufSuav9FmDPLAVK55B4xWp4Y+I/hfxDbyW8epSabfSKy/Z7rBVx9egP411CaIs+nXFzauFlV2JhRg8ZAA+6Rnn8aAPLnhkWRQwAKnj/wDVTDG47dO9dnPp9te7GYNFN34wRXN3tsYJWi5+Vup7igDPO8IqkKAv6fWpIZ5IZBIjKreuOv4VOy4TK9+q9aY0SlVYcmgDkPFfgdtduBd6FFGl/Kw8yBmCq57sD0B9q8nuIJba4kguIzHNGxVkbqCK+h0IhUGORlkB6jtXP+KvCEHieOa+imKawkYCRoo2S88596APFOaUHBzjNPliaKV45BtdGKsPQg4IpmOKAFwQaXJOc0AZHPUcj3pw557UAJVlJMKBUSqDT/KPoaAJLvBncj1qvVi5/wBa2OPaoGyRgZOewoAarZR1CA5YHcRyMdhSY5FSM7ybWdssFCj0wOlS2NtLeXtvawANPPIsUak4BYnA5oAn0XSL7Wb9LPS7Z7i4fHyoM7Rn7x9BXt/h3RoPC+jLp0SxSX5Li5vE4MmT9wHuo/Wn+EfC0Pg+1JEjtrNxB5d2yyBkHzZAT07VfKHLZ5J689aAII1Pm45K9+ehppV2LGM4OeSeatGPBAUkE+9XdO0/7XuPmhYEOGAbGaAKVtC07osMTM3qf6Vr2elIm5r072B+VVP9K2bWGIlIbcbVHTnnFdfoOm21pG15JgygHMjHhV7/AEoAxLHRisSTakPs1oBxCp+duOOlTaxreneH7FZru5tdFs2xiSdsSy/QdT+NcX8Wfi/Y+Hkey8MyQXuqyjD3COHjhGOxBwW9q+a9e17VNeu1uda1Ce9uFUIHmbOB6ADigD1fxr8axc2k+n+FbKS0jdgTfyOfOcg88dgfrXjd/f3N9KZLueSZ8k5ds4yc1XOSOetNwe1ACE5pO9LSZxg0AHQUwmlJpeACD97HFACZzSdqBgH5skY7GkB4oACeaU8AU3PNL6UAKKeilyqqMsTgCmfWvQ/BHhe3udKg1W5LNKJCUUHgYPBNAGv8PfBxhvUvNWg4ABjQnv716bfzFrby4MhApBU8Vm23nNe/vHby+Mc/oa17gr5TqMADuTzQByMVq7zb2XJz1PNbum2XlyZZOSKs6bZlpVDADcM8tgfia3oIoY5QpUlVH8PrQBXht0EJJXAzx6/hWvBbhuilRjk9yKZbIDExJCjPU/WtiJQVXDZwMGgCrHaRlUG0YzzkdamisIxI5VCDj72efwq0ITuA3FQD271IoIJVTuUDOc0Ac7qdkJC52ZAGMev41wWp2nksrPGUVudp4I+teoXMRkRmJO4cDBwOa57XbMPF8xLbTkZ7GgDy3xDoFvq8LARD7QqnYen4V47qFjcWMzRXETIynByK9+CyxXDkg4z0zmsnx/okWp+H3eJALlCGG09TQB4dnml7U+4iaCdo5AQw4xTBjafWgBM8YIyK7DwR8Qtd8IyoLC5eSzUkm1kY7CfUeh965DHHHak7UAfRGk/GHStbuo11O3/s+ckAuPmVvqa7KR7fUrYOqhhIMoyc5HY5r5FBIbg16J8NvH11o93FYalPJNpsrBF3NxB7j2oA9ZuLGa1kR2UFOwBqpOCXJUbcdVFdbHNDcW0ckUqTwuMo6MCrD1Bqhe6dHIjSw5Vx1GeOlAHMgbkHHzZ6CmoWSQNANpXHzA9Of51I+2JlcMc9evNRTNl1JbA6nB7UAch8R/DVve6c+s6akcU9sha7RePNy33gPXmvKWGO1fRMTGKXzVOARtKk9VPY15d8UvDtlomo2t1p0h+y6hvcRE8xsMZH054oA4bPNPA2nk5FNPv1p+R5fP3s9c9qAJEODV1OVGKz0NX4smNTmgCG5OZm+tQHJI4OB/F/Sp7jmZscimtKrWsUUeQMl5Ae79Mj8KAIx19q9n+F/hyPR9GOs3gD394itbIyg+SmfvYP8RrmvhT4Ut9Ymm1bUJD9k06ZP3BQFZyQTg5r0+ZjKQ7KofGAEG3A9MUAR2yTMpEkjSynJMjYBPPSpNrAFc4fHJFIxKugCtwMdMH8aeiM7gKfvDk45P4UARhWdlB7nnFbljE4RVcFQTgAAYx61PYaSYgkr5APTirC7sMi42dzigBILp4XVPL3qD95MDA7ZzXl3xW+KeoN9o0DR7mSFEZorqVdpEoI+6pH1q/8YfEbaNpEVlZS7L66bLFQDtj7g+hPGK8GJZmJPUnmgBoAUYA4FGOfSpY4WkIVBlvSlmheE/vI2H1FAETYxUbN2pZA20HHBproVCHcDuGcDtQAFjsx60FT5avj5ScfjQI2fhQTk10EHh8veW1vctPBbeSZnlCbiOPTNAHPKAQWOeOB9ajbOeetS3GwSuse7YpIXPX6014ysaOf4s0AMo7UD27UoHGaAEOSAKOeKUnJ4qW3jeadIokZpHYKqgckmgDpfAHhuTXtUYNGXhhAZsEYznvXuaaeIrBY1iChAEGwAcfSsz4deGm0DSn3Em5uCHcsoBTj7tdnYxHGJPuk/exx+FAGXBYSLGNwII54qGa4a3kdJFOOBu45rqJoFGY23KCAd2K53VoVtpFw/mRnoxHNAGtaMn2fzSPlA9vyq5aIVlxtOMc8g4rEtElW1VEfIPOCMYrSsZHLbIdqnGCdvFAGpHDu2sx+U9hj171uCPaeoVgMgVgWcsonKoN5XjIUf5Fbcc4yOhfHzccA+lAD9uM7iSW60khWIFVwpAqNmd5FJI4YHA70zaWuJNx2sxzyMk0AKMsvyqQW7msu8jBBDZHPIraO7ax9OPp71k3o3g5YNtPOBwKAOQvYP9IkKr8vbAqjd2vmWUo7begrYuYf9Jc7jhz+AqqYv3h3HOTjHYUAeA+O7EwampC43LnFcocjPrXpPxctGg1mMhsq0YJ46V5uetACA0q5bgU00qfeH1oADkH3FOCkjgcUkobzTkYzR9e1AHo/wq8a3OnarZ6TfzF9MkPlxqcfu2PTn6mvoBYn899yZCerDH196+OASrAqcEc5HavdvhB4qutctLix1KdWntcGL5AMx47+pzQB2uuWCtB5qAc4+VQBXOKTnKL8p4ziuxugbi0GTtOOABxXHSLJFdkMHUdcMuOKAFC714ySOTUd5p0Gqabd2F0oxPEwjkKglJOx9hVhQse9xvz2JHFMJYzBgd3PTGKAPBNW0250rUbmwvk2XNu/luuc4PX+RFVodnnL5oYp3C4zXpnxT0HzrVfEVsHeWSUx3aKMgYAw5Pv0/CvMSefrQA4DazD0OKnXUEiURmJ2K8ZGKrKOp3fpVeVW8xuR+VAGjN95jWj4Y0W51/V7bTrNB5kp5YnARRyST24zVUwNLJIoZVKI0hz3CjJAr3jwj4Yj8J6HCyTRz6jeIrzSqOFUgEKuefT8aALyWVjptjDZ6VAsNtEFB2jG9scsfc0i4By4yB6etTtGWQAtTXiUKjK33V6e9AEbLvPyAlj+lbmj6eI4vPuY/mXIBYY4qLQ9PM9zveQIQoY/nXSSKYfMw+44KnA6D8aAIZTGyIoUqASTxyfrWVrepW2l6Ne3d0xijjjYg9TnGBx9cVff5nBDEZ5471458XvFd2bu78PIIxbLjzWx8zHggUAeU6hcTXt3LPOzPJIxYknNSWdnJM+FjJ9gKvaVpcl3MqIRk9zXpfgnwW0txveVeAe1AGN4M8E3FzPHPcW2IgcgHvxXqcPhjSWiMdzp1vIuMFSvWt6C3W0tkiTGE4z3pRgEup3fyoA8i8b+AEh0iWTSdOzdCRQqQKScZ54rymLR7+W8MC2kvmqfmRlII5719bQtNu3KfmUDHPNZ1/plo16Lh4gszL8xA5PNAHnHhrwXaTeHYI7mxiW+81md8fw54FUPjPZtoulaUtukcInZkYJ1woBr1GHUNNzJb219btKH2shcBga8r+Pmosdb0y1+Ui2i8wH1J4z+lAHj55/GkY8e1PclnZj1JzVmyQRyR3M0e+BW+6ejn0+lAFLgnjkUDvVvUXWS7eSOFIUY8InQVW7c0AIOCK6/4Y6O2reK7YGESQ2xEzk9Bjpn61yOASM9q9j+A2nuIdRuxk+cyRgeynOaAPZoYVfewt9ue2OajSFYlDy8BTnBq0szQ3BWVxnbzjtzUl3EWiLKVbdx9B+NAFO4uFMYwDlmznGM1iXUay3e3YWQnJzxt+talwxRVCkHYc5bpmqtuhLNMxDGVu35UASeUpkLRnPyjCHoKka1dmUxjZkfPt6VswaZ5O0I6uzHLOe4/wAKljthFMRJICF5GOlAFfR4tpKTISewJwo/xrfe3hVCrICX5I7VWhRXU4ZSe3PWpmIEfzHgDn3oASSPaCI1XCnqR19hUkUY8wHbwB0AqHzGdRs+U7ujGrVvIVZyCpGOvegCORh5JyAFUVh36lLaRgh+Y8bRzWte3Sojgbc4zgnvWDqN7MYBgjLHCbe31oAzUhCruZAzcjLCqCTwfaUi27nDcnrVpJ5Ud0LoQQSfrVazjUI0gI5JBPrQB5Z8ZIljvoQBwY+K8kPGc17d8YYU+z2lxIu5iCAK8TbljketADCeKQ/e9qeykAE96cy/6MGHXcQaAI3bce5+tNzig9aMetACk8Vd0nUp9LvEurV2SRORtOM+1UfSnUAfUPhnVV1bQbK8i6ypzuP3W7j3qfUbFZQrKm5+rZGM15T8IPEbpImjT7BEC0kTk/MGPavZreUtIOAOACx5J/CgDlcAIQ8bA88HtzTSo25xyfatPW7KSFjICCh/vfWqEay7P3jctnBPagBYmWezvrAxb4poXjwwyNxXAJ+hr5/1fTbnSL+Sxv4jFcw4DA+mOD+Ne9uH3sm7cOh28A1ynxj0qK50208QhsXZkW0lTrkbchv0xQB5IgYqxCEgEAkep6CoptyyMGhkyPUYqzG5i3jhlYY+h7Gg6fPP+9Eow3PJNAHpnwgttOnvNcfU4EnkjgiEKv6liD+GOtelJl44wRz0wOg9B+VeefCaxRtPubwqxndzEST8uF5H4816QqMF3AAt7UAKQiyjKsAPQ5p1nCl1Iu1GUEdScgntTrZ0FzGbhD5YIJA6mtLQ7Qz3LSBAIkwQOnfigDY0+yS0t4Qw3uykt7c0twBuIbcQB1HU/WrjsNo+QZ24J6Ec1QvHceY+OOEGaAMXX9YttGsWu7yTbtzjaM89hivm+6aTUdSubu8dpGklLbmPJBPH6V2Xxc8VC81gaZbxeWthKwkb++xAzXKWeoWNzAUu4zHMGG2ROmPcUAeg+DrKyL24CAOfXt716tpllBDbv5S7Xxkc1wfgbSrCSS3uoLgyuFzgKRXpsC+XERH8ucjFAGepVW4Vjk85PtXmWh+JrLT/AIveMtM1jUzEbmTT4rC3lc4LND8wRegyWXP1r0tiYyQV5z1qe0iaclgoIHBNAEdvhXQDJIIBNT3To0i4UkKeVPUjNOEaqTtkCyAgZK4BOfWpI4UL/PyR68ZNAHiNx8Mr678fyXJcx6RLc+ezqcOATnaPel+NHhbVZ9bt57DT7i6hMYQPGu7oOhr2HxFqMWh6adQuoGlgWQLhOq57n2rTN6i+UVAwy7umQcjigD41a2itopoL6GWPUFfG1uAg9CKq3EjGFFDuVBOFPQfSvd/G/wANrO71afUdOO5p3BaAjAUnqc1xOufDHXWvbeHS7dbppiwjVGAOQCcc9OAetAHBaTp9zq2q2mn2MbTXV1IsUSDuxOB9B711nxV07Q9F1e00TQkjkl02AQX12rEm4uM5fgnACk449wc4FdJ4S064+HHhjUfFesWj22vzs9hpFtcIVeN8Ykm2nsoyB+XcV5Ozs7O8jFnJyzMckn1JoAYxGentX0X8MILez8LaR+7liaSJWkzxubJ5+leKeBtJbW/Etrbx273EcZ82VFUnKjqOOlfRmmWUohgVofLK4OCPu4oA6Voop52O0bkXt3p0RDI0UwYg/KC3GPpToIyzMQw3EcsBn/8AVUqRyfZdoCsxJ60AYepWZt5sMS4JHHYVb0GyhkZ5XU4Y4RS2MCnanOnnLathLlsEMR2rRslURLmWNh69/wA6ALUkISEDDtztwo5IqpexqQrNkMBjANX3fYiBME56dOP61n3iSi7UEFZG/wBmgA08xrvdskkjAI4HHrUtzOqS5AIUrnOeD9BWbpxLSTGRN3zY6YqxqClreZSxjjK7V2cFfpQBVu78QyoWkG7PAPJxUttfvJ5mGIbpxWJdBZJkbahOedwzTmlFoSdqHd/DjofpQBpkMXJfJA6nP3jUV0Ykgz5ox0AHas5r1WQB+TgEdqqNdqzkBWZj1zzigCIzB3kZDgHjNRQyJuJUOEjPIz1oFxGqviNtx6k1Na2zfY9zkIJDgZHWgDzj4wX6TfYhGzbdpIGfavI88k9ia9K+MBMeq20WVIEfYYxXme7PbFACsflHNPc4t419SWqLr9KGORzQAhHNS20LTO+0Z2KXb2AqHvU0cpjhlVcfvCOfagCJutA96M8A0vGc0Aa/hG4jtvFGlTT58qO4Ut9K+kLCffK25dq4G0g5Jr5Z54x1r6a+Hxn1Hwnp955aLuhBbaM55I5/KgDobuBLjT9rI7Ntyu7r1rlblAJCoOCpJJbp/wDXrtI49sKlAq4zx171z2t2hinD7eXzyBQBkgxmQSxs7KDx6GrNpaWGoTi21NGktLg7JFI6fSoeQzYXCn2zzQoCso2nIPUDjNAHivizRIdB8YX2m3Pn29lHKTGwXe/lH7pHrVQxaCpIXVdVAHTFsP8A4qvTviX4YudbsZ/EFr5ZksYglymOTGOh/CvEpXAkYZz70Ae3/CJc+H5j289j/Ku8fJVcYxntXC/CZQfDDDDkmd+nfpXdY8nO5Tk+nJFADYBvYcMTnGPeux023EFpCH27ioPoQfQ1j6BAXuTL5ZKRkHJHLcV0E6q8XOScg7cc/SgCWYg24Ybd54UN65qj4qtZNL8OSTNteaON5DjPFa2mW63N7ARnEY8xlI4HPFQfFqRYvhr4klDbWWykCsOoOOMfjigD4v1i6kvNSuriYkySSFmzVHcQeDT5nLOzMSSepqHPGTQB0nhvxLfaXe25jnKxq3K54r6F8GeIoPEGmmQyoJE4bbmvldT2rtfhl4gGia9G07sLZ1ZWXGQSRxmgD6UaEnODvToA1WLUgBlT5QmAVHSs2y1Szv7eKW1kJDcgY5HHerDX0VvaSzzqRGnO1BksPYUASRrAxMpkLbzn2GPSrEbRyQljKjEjjHBHNZ0F5bm2Rl5jfDJj0J7VW1HVrOxjLTpMBjghM0AWtdshqvhzUrBnCm5iaNCeQp7H9K82+F/iK8k1yTw1qr+c8SuISTyNvJGfpW3P8RbK3gmMdrczKmcAx4DmvL9e19m8Vxa9pGny2ZA+ddhwW7/nQB9CxIjOx5yeMHtW34askOoGYIMQqdp9zx/LNcV4V8TDW9PS7ksZERsAZTBJxyfzrtIdVS000Rwki4lzzjOwdPzoA80/aT8TeG/7OXRpLaC/8QLzG4bBsgcEkkdyMfJ+J7Z+cbC9uo5olgI3s4Cjyw3OfTFeqeOPCsGs69qBtRKdWyXKkf6w+vuT61y/guyn0rWvLu9KnN9FIv314jHvQB7T4R03UTawSyMkJ/j2RKhb1yQP0rpXtJiokFwF2tyMVJYKI4YyEkIYZxnOc+ta0MURjV9jxyYH3v6elAGatsHmYiQsqjJ/hz70rSTWqMcgAchupGa1S9vHI3mrksOuOprGmXczcSgZOWJ4HtigDI16KW6uIWaXByPmUVWsYruIktKQuSRjqOfSuhukXCbtpkB429Kzp0Mc+cNuY4OBQBo2k0y26hSGOd3rVlrqZ3QyIpCnA65HvUFuiypiJXBIz8oycD+Va9tAXjD3MchwPk2/eFAGDbXUcd42Xwpb5vU1sah9geMObgKdpIAPaqN3apDuVkQMXHz+3p7mqup2QvpRDHGY4gCAduN3ufWgDnbuaBdQJW4354X1qOR3kkfZ8zY49qlbw7dWNyDJDJL8+7cFACj096nhjla4kW3gdccbnX+lAGIIrqRyrqxxjPBwKlt4ZluGMkZA7HnFdPDBLDGWnYjc2QGOTj2rPmS4Qs4cux4GOgoAwJHbz3XDBR7HrWtM8lrpAmklQIi52kHNNtrW5eYkBmz1J4H4VzHxL8Rw2Hh2ezWRzOcRD1x60AeTeP8AUv7Q1sukgZFXAxXLH9aluHMspZiSajAH40AITnpQeaOlOHGaAG0UueelIOaADsKXqTSjBIB6UEDcQKABc8V9Zfs7xC68C23mg+XsMWD7En+tfJwNfVX7M1yv/CBIHZiBfPGMjODtFAHSXFt5b3MURYlZGTI7ANWVr0aLAm45OSAFz/Our1+LyNQn4bbIu9cDqc81gapF5ttkRuQBQBye628iSGRSZAdwbPNRFWYeYGYxggYPHOKknUea54yDggfzoVHeEyeUxh3hd/YNjofwoAm02YQO0UhDW9x8k0Zyd6nsa47V/gRe6nqVxe6Tq9jFYzuXhSUNuVT2OBiun83yyV3DOc9K7nQrqI6RakuFOzoW6c0AeZfBCCE+DZ7m4dvkmkAVTjJAFdZAv2q6QKdxc4684rjfg5OyeCHjODuupDtx7DrXoui2sjXcTeWAT0/KgDoLdI7eNIkkSN1xyTmnZBaI+Zls8jGM0rNKpIbyxGDghlGTRIxwsm3K4BA4FAG1oEfyS3ByFb5Rls8AnmvOv2jNaaw+HhtUlKy38/lEKfvIDyPp0r0zRT/xJoH29VLY/E14T+1VMwh8MwELhhcSHA6H93j+tAHzw/JPNMA4OetObOc1GSTmgB65Per1rbXJjM0I+Vf4lPSs45BFSRTSKCquQD1waAPTvAXimSCWO3luDHPnILnANexWOqW2oRbXnjdxgMokB5+lfKtvI0cqOPmIORWxp+rXdrPJcwblJbcfmNAH0RdiSCRG3AwABVyfujPSnqJJ3aK5CvERx3ryzw345vLmaOKdFMUeDIWOSRXpfh3xDZ6jK0aIVyvyhiM9aALbeHdO2rM9uQ0bggZyG+oroI4rUBY7eCEIRyoUAn6VSMiRlkYlmY5HNW7QOdjGEIi55HQ0AYVj4j0W6jt7jTtVsJYbq48iExurCSQDOwY6nAzWtq1vLNas9sNs/bn7teI+D/hd4l0W48FXENsY4I7gXGrWpnjPkTJvVZV+bB3I4BC5+6K9+uEdItkYGSCcZ5zQB5F4n1Z9L1oXEjf6QqkOwOMnuK24vsmvaTBfWM0bxEgON4Lo3Ug1xXx1hnstUhuXQBLrIG3oCByK5b4aeK5tD1JbT7MLi2vJkV4887iQMigD6D8PzXJcKm5owv8AEcE4rXN2kactJuAyQD+lSy2k6SJHHGSR908AmqhFwy7WhALEDJx2oAlF8jv5jMU+XoTnBqD7SN6NNKXOD8qHK/nUjWMsk53IqIOhP8VV5tHd4ZJNhDkkARtwPrQBYMxZgjSYU84akliwN7nDdhvDVlXUktrkyhS2fugE4psF49zuYIEUjnJ7f/roA1bS6+zy5zwOqk43fjWvFfvcXLGKTLIv3d4wT9fauUnaXGHUgE5471PZzG3YYTcHHAHUfWgDdkU7c7885O5h1rX0+Ftil3LuVP8AwEelc9Y6xHdWkiFFjVD/ABYyee1bltcNHHkjbvBJ/wAKAF1G2EkIQuoYMM89fwrI8tIbifyCMqO7AAVrvdkZCRghsbjjoO1ZuqafI5BCbY9u7Pr9aAMSaSS5lZzIxUY5z+lWI0SZhDGccfM2cYqwq+VZPD5K5b7uOtY95eR2FrM1yF8qMbnZG+b6UAU/GHiC18PWUii5RWEZ2AsAWOOtfMWsavd6pPJJdzvJvbdhj0rR8Z+IZde1ua5YbY1JWJM5wua53BoACcmk7e9ByKQA+lABilPSk5zipHidEUsMbuRQA2PBbB6Ug4NDAjANGDnjrQAN1HPFApGB70oBoAeor6Z/ZvdI/ASn5i39qyYwcAfIv518zjJwOlfUv7N9vInw9t5DGG36hKw+mwUAeo+IY8yRPwDtYZLY7jjHfrXM3Klt+SNqghstius8Qqxtoyoz82DxyM1y5t33P+7AyTgnmgDir5Fiun2N8ueoPWrFubeTSpoPtAt5WuVkHmfMCAuDWjqmltLlhnIBP7sDmsuytjPuiMKiUnjJ70AQ3UMVmMLfRzo/IKLjbT4ZnEShLwIuOFyOKZExsr4yTWkMxjb/AFcmdrflXQL4ncKPL0LTdnbIP+FAHlnwnYp4RI3HJnk5HpgV7BpdxvkhSPAhjXAfHJ49a8Y+E7hfDGWC7RM2Oa9k0KFo7KGQooJyQrLzQBrhh5oRn3E8kgdB9aJQrBFeZWBGeB0H1oVljUn7OZGJ5YnGPpTJyjwsR8pK8UAdF4dPmaFa/NuBQjI+pr57/aouQde0e2DA+TascdxuPf8AIV9B+FyDoFng5G0j9TXzD+0jcib4iTJ2igjX68UAeRZ5wajIwT+dSSMC2QMVHnBzQADp7igHBqWYxShPJj2Njnnqaib5WI70AWYSoO5yQO3FXIwpaHfMUilOGYDlce1ZRkJwDjipBKMDI4BFAG9DNEjeXbkqxHXP3iOldp4F1GHSdRluNZBji8kBHY4wd3WvMJZkJygwa0otYl/sx7OZfNhJyob+H6UAeuaT4ga98SzPbziS38w+U27IxXrgbylXy3LEKOCeBXyLaa1JZxFLVREzZG9etdHe/EHW7mOzEdw0ctvyGB+9xQB9Mw3YZD5j7mLf3cYrI8XaxDpOh3moNOqmFCVHQu/Zaw/AvieHXfDsF1dyILtTsuB71g/ETT38SRywaTNDMyLnyUlB6deKAPKPFfjfV/E0awarJbyQRuXjVYQpUn3rR+Fej2eq65DJNO6SwOHCL3x/SuV1HRNUsLl4rrT7lCCRnYcH6GvQ/g1ot7DdtqM1pMkJIjRnGA3uPUUAfQNvcF3QuXBHILcr+FR3LBSBvPyrge1Lb28kUyeZGjowGMt+dJJAITvKbi+ASxzt57UAVlupnmXMwweMOMkVKtxLFJhHVoupZhjmud8ea3aeE9BvNau0llgtdm6ODG59zqnGeOC36VubvNszH5W0jn52wf8A69AE/mwyzusoIDnhiuM1Bc2EALNEfmxwAOvPpTZYo1ZmfeeMbgOlXFt4109RENwAzvxz70AY0okhYB5MxjqAMkVPFFBIyh5dykYOOCPrU7NDJHuK9DyuM4H+NQMkUN0BBkHG4x7skA9DigAfRYblGltpGVlYDpkH8K37SzJK77g5VThDyazLS4jaI5OWzg5HBrdtZI5EK+Xhgp+frigCeK1kMKsZQPm4Uj+dBjnYStKQ4QYXv+lKzCKFCVHUgkjOPSo3mRyFlI2gZYDv+FAGTeWc80BuJDtuCcJGvQL61zXjDwxJeeHbuzQtHcTpv46tt5ArufOijhlYxfKOefQelcRruureR3McZCSMuF9MD3oA+UrmAxXMiSAiSMlWB7EGmW8TT3MUMQLSSOEVR1JNdT4ptbH+2J2urxIgykhYR5mT6ZHSqdlq0CPA9pp9rbfZwC02P3hA757mgD1SD4SaNo0Cvrl/JNeSRho448YQ4yc1xtz4H0qCKW5v9XMEYywQKCSM1geK/FNxrd3E4aVY4kCqGf8AWufllaQfMzH6saAL2pmxhm2aepKAkbmOd1Z0sjOx3HNNPSpIImkYhVzQBEfvClB6+tW0068bkQPg96WW2igTMjgyEY2jnBoApHtUsce7O1u1MYrn5RSo+0nFAEgUDgk5FfY/wBs1tfhTozf89903PqTj+lfGo6e3qa+2/goMfCrw1gY/0QfzNAHR+IJlisDubBZgBjqa5uWbe2QWUEkj3HvWz4p+b7KmCeWbj2x/jWMNgDMq46+/6UAQhSxyrALzkY4rAMcaeI4/Lfhj6dTj9K2r9gkLkYXg/MB1Heub0UpJqocYwpypb6UAXNX04G63QFnduSi8/WtPS9O1VNPgVdOLALwXVcn9aVNkkd0JV3llIIYYwT6Vztzrljps72d1qlpbzQna0TzbSvsRmgDzf4Mq91oT2yKQBKWZ+K93tw9vaQjGVQYJB614D8BblIrnUI5XAUQxuiE99x3EV783l+XEykEnnANAE4aQsGA8vf1B5PtTbpnW3cn7zLwoxj605JAJMMwQYBJIyarTKHjClhtcck8UAWvC+r+Vo8sRwz2/OSeOW6V8xfG+eS58c3k0pz5igj6V7xp0Ww3kS/KJFOQOv3q8N+NtssGu2jLkh4iMk5yRwaAPNSabgk4HWnHrRuCj5evrQA6WF4FBbqewqFs596czk4DHrTCeOKAA+9GcDApPxoxQAuTgU5ZGDA9cHpTO+OSfQCtjS/Dt/qEJnSF0twM+Yw4NAGYz7pCQuAT0HanEtu5ODUt5bC1do2bLA9ajt0SSULJII16ljQBYtL66tA32aZ493Xa2M11Pw5Ooya8JLR3zJG6swPUd64xiPmweOgr2LwRqOl23gp7SPy01JYpHE3dckdaAKEPioTS6odRkaSSzYBFJypycVn6v4s8SQ6hZW97G9jGzI0SDgBCw5H4VzuqvDZPPZWd3b3SrJ53nqvLseoJ7gelQa74m1PXr5LvU5Y5Zo0WNMIFVFUADA7dKAPr22aX7LbyNhg0YYNkEfWq0kksrny2CsQAQcY61wHgH4l6Ld6fZafqFzFYzwwhWlmY4kIH8zXoNm9nfxRzWU8NxC/IMbZGKAOZ+Inhh/FnhC/0R7n7I115Y8/yxJt2yK+duRnO3HXvWn4c07VYNLkTW7+DUrh5iUmjtvs6quAAu3c3OcnOe/tXQtBbNLlpAVU/KAelNPkgAM5A3ccd6AGR253YI3dz6E066ldFZEVTt7ipZHTorjHfnpVeSWPGEdSM8n0oAjCExjBCkDJJAyTUPlCO4yA0pcYJAGeKWcqE3SE5U8YPUfWlWZTMTbzAbuGI5IoApIxtmkTh0ZsnPUVu6ed7h8hVde5rJQLIsxKgyBsZHeqkzTwSJ5O0DHOTjaBQB1F5cR26eVziQ8jqPrVaCZ52KQJkKOVyPzOea8+8e+J7i08PTXlpOHAkC5AAx78V4XeeOdekumkTUZFJ7rxmgD6g1q+kMUls/y4444xXn3jTS9UGhn+xY3llJ5CYyQeteSWnxB8RW4Km9WZWI3ecgckfU19A+DdTg8Q6VaTWayW8Tplw2eD359KAPnw+CdWe2uLvUcWUcYLfvOS35VlXL6cNLW3tIZTc7gWlkI5/KvqLxr4Kj1jw/cRQXkiSlSxCchuOBXyhqFpJZXkkE42yRsVNAEYjIBPb3qA5qaeYsqjI+X0qAnPegBSAo65zUyXciLhML71W79acvTmgDVtdf1C2GyObMZ5KkA5qjJ+/d5OjHkioBy2OlOOUdlBB7ZFADTnNL0NOQbiBnntQwKnmgBVJOF7k4FfdPwutjZ/Dzw/AQAUtEHFfD+lQfadStYFBJklVQB1NfdvhBlj8PWFuWw0NuisDxjigCl4hlEmpAchYUxnIwSayjLtk3sqF8YXbmklHnXly5mjRGld03HduG49qVhEHB80qz5HAz+VAGfrUjLaSh1xnOOfasXQZFt5shVLHovrWh4lIS0CgsWLHn14qr4dt4ZZg7svy+g5FAHRRqssMpZcMcEHtXx344ukvfF2rXETmRHnYhjzntX2GJQWK4Hl8jJbB6V8U6pg6nd46ec+P++jQB3nwu12LQdege5i3wXcX2ckDJVj90j8a+nEnzBCyp+6AHHqa+OYJpLeNJ4W2SwgSRsOzDkGvrbT2u7e00+O9kADW6SKQRg7lBJ/M0AarORKQYVcnAOTjNRhpPKRpI8HjLEfypn79Zx5jxuoXnB5NNf94gRiwbAxzwAO1AGVC4/tKcbCx8vg575ryz49WzS2elXiQkCLekj+5ORXqhGzUU28lhjOeOtc78TrGK98BayAzD7LGZ844ypxj9aAPmVutMyMdDT2HTFM9aAHkK2AMrT9kWSS5I9MVAKTJx1oAfO6vJmNNi9hTMmjtTe/WgDo/Bl9Baa3ZmeASbpkAPpz+terfEv4g21hG2m2en7rmSLKzHCiI57LjmvIfC9rG2qWtzNKESKVXC92IPSovE+o3Gp63cz3TZbeQB6DNAGdcSSTzPLISXdixPvTO/SnfL5Zzkk0wdaAHKcKc9K9Csxa6X8NHuZo8ajeSFEJ6hc8fhXng989a09V1S5vo7aCaTdFbrtjA6AUAUcnzCe5qRTCYCDG/m5+8DxTbVPMlwTgYJpnQkA8ZoAnjBznGK9v8A2e9M1q6mvZoopV08ooR5CQpOeSK8RVuB+VfbHwl006V8ONChbPnfZUL4Hc5P9aANax0SKPi8w5zkLnv9a0ZdNs5oyjQJ9QOR+NQ3CTSTjLbPTnt71LBIoO3zC0iAjB6H3oA5Lxh4fmSzkmsDiOMbioP6msLSLoyWY+QkIv7wnjNerEBgQwBB4IPevKtYgTR9fuLSZiILkg5UHoTxmgDRtA1wokCeXF2z3rVENs5yLcB2XaXzyajSIxhFRwFT5QD0xVpoWaRS5+UryFoAxZrdoVaW2VmZDkrjpXH/ABB8Ry+HtBup7uF2kvYzDEgPTPcnt9K9ORGFu6AsW75wO1eA/tFyXEFvo8EjkpMWcAnng0AcBoOuwHT73SLqKU/bidsu7O1uqjH1rlri3kt5jFMhVkOCKakrRSpIhwykMD71Y1S+a6k+0M5aR1+fjoaAO68JfC7WNSns7m8W3FhKFlH7wZdT7V9B2/2bwdZ772EW2kwRhVdeQPT8zXlOgeOX8E+B9IPkC7a4w+Zj90egNYPxR+KknizSU0mxikt7NirzBushHIH0BoA9g1D4ieHdKsftbXDfvVLxxxjezex9K+YfFGqS+IdeubxYmU3EpZIRyVz2461m+dIByx9BnnAqKKRo5kkVyrK2dw6igBjIySFXUqw4IPUUYrqND06y8Ualci7vfsMoQFWOArHvnNZ2vaBd6NcKkjJNE4LLJEcqRnFAGP8AhU62kzWrXKxkwKdpYdjVYtz1q3a31zbwSwRSEQy/fXAINAFcdRkUoJGeKRm+ajOTQAoJDAjqKklYyNubqetRg8808cZ596AOn+GVnPdeN9JeCEyJbzrNJ7KOtfV0960OjGLB8+4xj2Ge9eO/BPREtfDQ1ZiVuLmZkXPoOlemwSS3V+HZxttxtXpz9aANKAkIiGFSAuOn3uasEDDZgYDngHOP8armd+hIGRkD156UhmJZGaWSPBOUbB/IigDO8RxPJbBUjEp3ch+QBisnSLyWznT7UhK5xxwMV0GpkeXlJMyPlTjr0qjBFbjbHdSbQvUtzjjvigCLxNqEUXhLXbnZ8kNs7kE43H+6D6mvj+6INxIcYyxOPrXvvxq1M2GjJpNndHF6yyMgH3lXr/OvAbrP2h89c0AarqMBCuAVwRX1j8O3l8S/CjQbmRRJfRRsj7I1BIVmAH5AV8nysCQQcgjr616v+zzr0uneNYtMa4mFtqSsFTf+7SRVLbiPcDH40Ae0Ih2FipVAFAG3kccnPeqzTqkIL7iTj5FHIrpde0cg/abEMEYDKp/D7gVxuslolKq5kQgYAPf60AUTftPeHIVQhwCoz3rT1G2S/wBMktrkBkmUoy47H19a5qWWNHYOTuC8bPWui0lkn04kscqhKrn5ifSgD5f8VaRNoevXunzKwaGQhSy4LL2NY2Ote0fHXSIxa6dqEEG+5Dsl1Mi5+XHy5P1rxl/0oAjpAOOcZpygc5NNPU0AIfpSk/NnGOO1GBtzSYzQA+OUo6MOqEEVc1jy5JYZ4s/vk3OCO+cVUniEfl7ZA+5Qxx/CfSnTkmGAE5AU4H40AQ9qQdaO1KuM80ALjilHJoQAhjTRxQBZsXMU4kUAleRkZFRkhmZiMEknAFLCfvrg5I64pFHGc0AdT8ONLOs+ONJtPKMkPmiSYbc/ux1OPyr7kgiSGCKGMYWNQFA44AwK+aP2d/CTSypr7JKZi5hTP3Anc19N43KM49aAGMoL5CAnHU0vljkjgkYyB0pYwwX5yCc9RTqAAcCuS8YWBlvoZxEWRoypbbkBgcjP+e1dbUdzAlzA8MoyjjBoA5WB/tNpGFjDEAAnHQjrU0JIY5YqeRwM1zl+0ui30W2WWMnPyt91j3p154r0jR7qOW6uZcSAPIVXcMDqBQBta1qdrpWjXN9fSstvAu+Ryvavlf4s+NF8aaxbzW8JisrVCkCsm1jnqTVXxh421jxFe3sd7qlzPp7TP5UDHCqm47ePpiuSmYbQAMA0ARsR/wDWra8I6bHquptbTsEi27icVih1UD5QTnvS291JBNutgyydVI60AfYGk2WiQ+D0t9Ws7SSCJEWFpolIU44wTXGeLfBegeJGit7KWG2nVdwmtkUlfYjuK8r1bxbcan4Yh0wXTBlCyOQ23e49a4+01C802+S5tLmWC4j+66OcigDX8ReEtV0S/mgltZpYVOFnCcMPWuckV42KupVvQ129z41u9S04C8u5PtIBBP8Ae964+e8luTm5bzGz1brQBXOA/HI961dN1i7tIXgjMbxOuCsiBgPpnpWU7BmzgD6UqnHegC9/aTZZXt7YqeCBEAfzqnIysxZRgHtSOhAB+8epxzTD7UAKSCc4xQKVQGNG0BTkneCMY6YoAfgHtitPw7oV74h1JbHTIHlkI3SMo/1aZ5Y1lt90EnAr274D6I8WnalfyxPDcXJWKJnO3dFjJx+NAHfaTZx6NodnaRAyi2iWPJUAsR3x61b0qeGCT5yMsOMLzVa+kijjEYbhCAD15qKy2ySDcznA79c0AdPE4uom2pgEYGFAPXvUswRXZliJGCpVhjbWRbkI+9cjA2lnOBj2rb8Paf8A2nO73Bb7NFkbkbAdqAJdH06XUnMj7BbZIZwgBJHaum8mwhAQQQ4J24CA5+tV2lijVbWwRlUdkXArO1XW9L8PWE+oardCIJwyMwOMDj5aAPmr9oW5jl+Jd2kDKY47WFdq9EbByMdjXmDac0zGQNgNzjFanirV5Nf8R6lqtwd73U7SLkYwpPAA7AVWhYCJRwOOlADLoKJWG3AHQelaHhrV20HWrTU44Ema2Jby3JAYEYPT2rPuB85JqNW5welAH2p4P8TtdaZavewPHFLGssT8YVCMjdWH4pxI808IEse4bdgwoGfevNfg5q0+o6Rc2moXTPHZyIkRdzkKQePoK7qaWW5YwqR5GVKlzhSM9QO9AGXdILiCKTYdyqd2Bjv61Jo2ovZXShx+5LADdjH1Pet1I1kjeOY+YuflQDlvwrC1bT2s7gXCgMv8IU7yDnoR2oA9I1zQBfoDBBE+84cSAAYx2B/rXxp420WbQPFGpadcD5opSc7cAgnIx+dfbPhPVxrWixXJXbKpMcinsw61wfxp+HFr4m0281eBnTU7eEuuOQwUdPyFAHyERwQBk1GT6VYKnuCPY8YqPHNADWJ2qMAYqzbxrAnmzgZ42p61AFy2M4HrSz4aTEecAAUAM/1jqoHU4FSTvhhGAMLxmnQrGjKzHc+eAD0NVnJLsW+9nmgAII7fjSg4OQKTkjPvSgEEUATJg2knHOetQfWnqSEYHJFNI4oAkQ4Ugd6uaRp1zq1/DaWcEk0kjhSEXOATyfypml6fdapfRWdjEZLiQ4VR0HufavqP4QfD2PQNK82Rt105Vp2DcsR2A9KAPTvCGlpo3hrTrCMLthhVRtXGeO/vUOo+Jba0nMMcbzOvUKKXUdWgsJnvL2cRWyLtRTxubsB7muYu4DFptrq7tMfNAbAYjknjNAGhqPiiYuqRo0AYcZHP1rJN9M2399K3OAcnr61l2t7LdzTvO4kkDdWOMVM9zJFtAwwbOSB8q/jQB1MPia7UkSwROq8lgSK0LHxTZXUqwlZEn7qRwPxNcN5ol+Ub8q2cLxmok8N6vqMjy25fcnIZ22556UAdB49K31vHKg3fZpDwvJIP/wCqvM9a04eIWNpAojmcfui+Qu70/GvSfDd1Bc+bYXoFvfxkoTniUj+tQ614TmW6hmsJY45O4kOB9RQB8c3kckF5cQyjEkUrI49CCQahcnaK9n8d/DxLq+vZoFMGok5B35jkb+leRarpl7pV0bbUbd4ZeoDdCPUUAUST3qW2na3Evl4y67eR0FRlT+tIwIIB4NACjOOKVzvC54I4zSDhaSgBy8E8jFMbg077uRTWoAT604ZIwKAvODSYNAD0cpyKlaQTkswCt6gVBj0pR6UAOYFTg4p27MSjHzA9aYRk9a2fCvh+98S6ollYrgZ/eSfwxr6mgDX+GehvrXiuyaS3Z7K2bzZHK/JkcgH1yRX0hc3vlKxaFRu+4sahQoqt4a0m10LQ7axtCq28I+8Ryx9WqlqV0st3IzN8wG1R0GPYUAVJX3KMRnGRw386nsTKJNyDCKvLHofapbDTJriNGZtgY43k8AVfXTXgDqxiZSAeTznPUDvQBraHBPfeWlusYbcCzMCQFzyK7e+kgtkQSzLDHg4QD730rzzR76ewkZonZOzFhgYzVu+vDK/nXlwWC5KkNkD6elAG7d621srx2UKrEM/vJSck98AV4n8eb9T4YskZz9ouLobgRkyRBTz9M4rup9RaUSStMFhGd0nYe5NfOfxG14654muZIZi9jFiOBFcsoA6kfU80AcyzZY1Xku5o3Ko2FHTipM89ap3H+uf60Ab14u2RlPUVT6VZvpvMuJGHQniqhNAHReCNY/sjxDaTyXEkNqX2zlOcoevHevdLG/t5Zo3gkHlsQyyD5sj2FfNKtg17H8MtTfVNNFlb2wEljHGrPkfNuYgEUAesKIGkSQvLJxg7+hGeoFWD5D+Yi7GjIOARuwPcVgW7TWz4u4QgJ2/M+cfka1ba5kY7IookPK/Jzn86AJ9Kni8O6/8AaHmnGnThgwVSVB4wSPzruptSt0t1uvNEttMBs29CO9cSIJ5ptkgDDBGH6dO1T+Hb99MjbRr6Mm1mcrbzjkJu7MD2zQBwPx0+HtpqGkxa54SsJp71ZRHNb2kZYsp/i2j0x+tfOdzDJDM8U0bxyocMjjDKfQivvXT7NrCSIO4YnKkgda82+MPwiPi++TVNDmtrPUNpE4kU4mwOOnegD5OI52jNMbhjjIrc8QeHNV8PzmLVrR7dtxUMSCGIrGYEnNAEeccjqKknC7gcckZpB8rA9e9LksWyPwoAipykBuh6UpWp7O2nu7pILSJpZmHCKMmgCBe9XNI0q81e8jt9PgeZ3cLlVyq/U9q9E8G/BrX/ABEnmytbWkKyBZFkyWA6np7V9M+DPB1j4Xso44liZ0TbuCAYFAHFfCn4bWOhI0jW8hlkUGSWYct7A+lehalrui6PE0U91EGXgwxnc/0wOfzrm9f8dzR3s1rodvFOEyjTO3Ab2HfFee2sDh5JHjL3ErEvI3JYk5NAHdaBdnxV4tWXUoS1paxF7aAp8qNkcn1Nd9MILyDypY5CjEDBjYd/pxXmnhyO50m+W5t0hMhUo4ZmAZTzj68Cu5sPEEc3lpcwtDK5AyCCv1z6UAcN4wt107W90OVjVMfd6556d/rWUdVsTH804VejA+texXdpbXSn7TEkg2kZYdAfesKx8JaFYh7m3sI2fBYeZ8wyKAMfwbZi+vTczQSNbqmYyy/Ix/rXXW1tMQXvJdoJ+WGPhFHYepqrPcXU88K28B8oDOFbA/yKr6hr1tp0rWYRrmdF3Oqnhc9iTQBjfEfSM2kF9ZWxLRviURDnae+B/OuOutTv/MWNb64UFcmMNiuxvfE13PC0YhSFCMYGScVzF5eSR3g3w+aAuQVUD8DQBlziaS3yrSMe7d6z9Z0TTtdtlj1e0MrKpUShCGj/AN0129i4uLFv3R2uM4wBg+lVrdpkkkjNsjkD7rOOPfrQB8y+LdAl0XUrsW8Fw+lpJiOd1yMHoCfWudbJbJr6x1S0e4jIWKF4GbJt2AKn615N4q+GF3dX011oUUMKOC7WhJyD/sn0oA8l6H2pOoq1cWc1vdNbXEZinRtrI3UGopInRsMuKAI07kjPammnt0ApMZFAEkYDRuQMlQOPX6VGM4p8bMkisv8ADU7PvwSoz7UAQx4wQODTkj4Jb8qtW1jcXMuLZDIx7Cux8P8Aw21XWH/0iSO2TPzJgl8eoxxQBzXhnQbrxBq1tZ2cUhikcJJMqErGPc9q+lPCfh/SvDemLY2AdM/NPIUwXPuav6T4bj0fTYrdFjVVUAlF2k4HU1Tk1CRzJa2UaSsTtaQZOPagB2t6rbzJFDaBmbO0kt1pNJ0tpZWkvkIZfuJjgCr2nWRtSsjpE79OF4GauPHI5ZEjzk527sZ+lACHyggBVeoAAHH0NPUwlFR/N4AOF7c9vao5p5EhVoo8OrAEjBAqpLJeTyZCYGM88fyoArahcRMvlwEMpJ3Z6g5qvAquyq7Mq8//AFzU8NqIY2ldVDgliecDntUeoXsMKrIxRmY5UdBntQBzvxE8R2egaDcQMrLcXSPBEmM5JXBz6YByK+chwqjPQAV1nxL1l9V8U3aiWOS2t38uIxklW4+9z+VckTzQAq9aqzKTKxAJ59KsA1IHYDAxigB2eTzSE4FI5IYj0pmaAHZ6c1reGdQlsNZtnju2topJFjnbd8vlk8k/QVik04MAQefegD6B0i7inRpF1KO4tgCBIqbgwzwQa07W6YQnF04dGJHy4715l8OPETQW0theXC+RbqHtxK4GAW5jUdySc16NDcfaUYILyJueCdvHcdKANiPVLt7oBmK9fnJ4YY7Va+0R3Ng8NzcHex4ZXII5zWA0rxodwuXjz/C4H9OaQOgXCibd1LNIOPwoA9O8NeIpUljstXuEdGT9zckbd2MDBPr712oIIBByD3rwO11RkKoZUaLPXeCSPSup0LxlLp58ts3dvjCxM43r9D6UAP8Aip4Z0/UovNvLdhG0hZiWOC2Oo9K8juvhvoVzAotJJ7SQnGTKZP519IaZrdhrFmVkKIzcPDIwJFcrqnhSGOWRrGWby8D5WkByfrQB4MPhXCzY/twBcjlogDinD4UQLMwfXoxGDwQgy30FerJZvErLJAykn++MYFPSJY3BRYigHIZwO9AHmcXw50ONfLaaa7lBxuDlc/UV3nw++H2kWV2bzzPstsq8u7AMx9Ax5FastwyxfuxtCnPDDH5VI15dtKHljaQdPvgUAdrBqmjaLamDTisg3ZIRiSx9STXPav4huL+J43mSG3cldkZIJ+prKZ3kY+aOpyAzD+VOEolhAYEc9G9R3oAx7Gzglmm2sYggyT61dtNMiSJ5YbsFs5Ebd6uNLGpDF4z13fMMn6UxJY5GLIoAx0ZgpPvQBLI9z8u0IzDr83T6UsLQlESZ51PQ5X+ncVGqRpKshV89cb9wFPLKTtIyW/vSAZoA29O1UWFxuF089sy7DFISAPcDtXWK9tLo8jxXAS1ZGYyZGEHf8ua87iVk3r8rKPu7mDAVHf6/LY+E73S1tRJJNuRSrfKFfr/WgBdb1pZtSi0vwzqzpbKA1zdJIWOQfuqe34VHBFa23mObncztkyM2Wc/WqOkoun2YEaR4YAH5gefrVuP5mYyKhIHyqzjNAE0t4rN+5JbGcn0NRS28d1Inm+Y4UYwj7f1FNuCY0G6IH0+b/OafZng71dDjp0oAltlgtYGhEzJGSfkZiefrUSW0IL+ZKoynDZ5PtT+ZAS6vwem7NI0BYkhbUtt5LSgGgCK5mghVFjlbYDhiBkfnTt1vOoMczOV7r/LNNlLwK4WA7g3DRyAiqkk6o4cpO7nnhwAKAOd1zQNMvb4zXlvHKQfvp8rfia53xD8NrC+uFfR7uSNdgbD/ADAnvzXpVpJbXtwoubWcIxAO9tx/SvRtF0nT0tIkihHlou1QTkH6UAfJVx8PZYkPleZcN0yvAzXLaroV1pspjnhcEegJr7pudE0yZf31rFgfhVC48PaJFAGls450JACucigD4dXTbjcAsE7E+kZNd14O+GV74ihjk3yxFj9zy+evfPSvrK2azsoymn2cUIUYOFCj9OtW9PknnRpJSAjfdAI/woA8r0L4OW+j6XcSWkgXUXjby0kO9A3bLdcV6FoOiW2k6Qn2iKKKZU3ykNuVTjnBPatLVNTtNKtjLeTKgwSqk/M+OwHevOfE3iO81jMVs72ViAd3zDMg9/8ACgCv4l1VdV1H7Jp925t1bmaJc54pljHDYQMiZPUmTO0/U4rD/tWKzj2wAhxwCBntVVr26kgaWSTyweAoPX8KAOmm1eFQFimXeOhVic1VOoL5hee7EZ77jnH+FYaznYgVQxI5OcEfhSkSOxzjCjpjNAG4l7YEKftY34/hc8/hVd9UypihcsFA+YE5xn1rNiG2FfNVY9x4ZyBURufLYKzs+OMbxg0AWpbyVo2BmJA4UFj19DXB/EjXZdPtVtoj++uEZVkDH5B3P1rotY1OOw0+5u5BdNDENz7HB4z06cV4x4j1SXWNSluJGl8rcRCkjbjGnYZ7n3oAyccUnehiBxSDrQA4VHJIQ5AJxUi96txqCi9OlAFebiV/rTCenNDnLE+tJ2oAO9JkCjvTeDQBPHKUkjdDhkYMrehHINes+DtVl1jSmmvr5J7zzGMwztZeflOPf2ryEcjnt0xV3Sb+bTL+G8tGVZ4myCV3AjuCO49qAPfraaUSgeZC6nhFGenqe1WLdXELjzl3c9AOfzpPDt9pfiS2jnsHfy2ZkIaJUcMACflz0q1LYXCtIkWHiXkN5Q+b6H1oAp5WNQvyhj3KgChJGRiRJtGP4QuBUsgSRolaLcM4ywyagu0WIHyTEvY+YP6UATRXUm5Qk4Z854IBNWl17UbUFVu2EbYwvXmslfLQjfBljyGCBRWlYajbx71lhUjjDLGDigB76tIH3SXGWYglTjnNWFv7KU/PL82P4sACmrBYSalJfDYXkiSLY8YwNpJz9Tmrb20M8i+ZbW24LkFYwAefSgB8FxZtCxjmXbk/NxxT45LUOpEwBxkDJqM2Vo4ZVtwCpPzKMAU6W1gVlCQSZA4IUUASRz2zu48/593TjjiiSCF8Sp5hYHBZTz+RqqbKENvYSRshz9wHP1qyhdljQggAk5UYBoAdHGWZuGx2LBaWK2aISq0oUueASpIHtSFlRCNnAJ+8ME1Esu5GIiXA7tGPloAfKsqSLtkQADkE9alheWSKNmmiO7sQOKpXEUsrryoC9SEByalZVjgA2FWUDO4YBP0oAlS1aNwVIl5zgOBj86sHQkn065v5neNI24G9SAO+azypYEy+UueNyqDn8KytRvjbIbe3IOTg8YB+tAGtC1oyxx+e3X/lmBwfxq7IUCuT5mAP9YQK5y11JYAq3CxCTrlUBxWhDeRTRbnkdyeyLjNAE90IzCkzZYr90OeT+FTQFEQFxs3AEENnNUZNRtARnfhT/HEM/nTobq3lmzGYzgc7uD+AoAvJcRrGw80AE9CDTmuWdiIjGQVwcqMgVDHKvlsSV68BhikaePZgqqsF5wgyaAGTSm1iklkO854VO9R6bNG8TSu5ibuDg8fjVoNFIAMBj9BxShLTDeZHHyMAFRQBUmFtNIWEj7vZwPyrotD16ey2I0gMCj/Vsy1iPaWOCJIADkbcKD1pFtLM7WaIKTyAVGaAO/j8R6ZfoEmkaAnrll4/EE1qD7AsC5mhZAMhmcfnXlb6bbszMiFD3wopDYadFGd5LOOu6MDNAHc3HijQdMk2QM07uMkQ4OP++iK5/VfG9/OQNP8AKs4+fmba7dfTp0rmNQaxjkCQw5BHUjPNYpl2sQwyg6YjA70Aa2o6pPfXLS3NxLdSgEBm2jA74HQfhVGSZ5gf3kwUH+LbwKaCxbAiHzZwNuaUJNkqY1C/3iooAjk2KylGZ8c7jtBpQJmJMal2HTdjinALGxzEjt2JWmPJOiMSNy/3BGOKALUgKRqbiRnf0AXj8qr73ZmKK2B0AIBJ9anjt5bjCrC491XgVdstKEkzpI2HQcZX+dAGM1syFZJJTlmz1BP5VLbWQmceSX55BOAB+daGsaromg2wlvWj3RsBtChnPv8ASvMfH3juObT1sNFEkRuBuneRcOF7KPQ/0oA57xx4mnv7yextZpVso2aN1OP3jA8njtXItJxwajJ9Kb1oAdyTTxTAacDxQA9asKSFHNVgamU5AoAiIxSHpQTmkoAQmm0ppDQAZpQab0ooA0dL1O4sbgSQTPGOfunGCe9d14f+J2pWcQtr50vYSeWlGXx7elea9OnSrdhcwxBku4PPt2JJUcMGxgEH+lAH0Rp+u+HvEKW0FpJHG7HJRz5ZJ9AD1Na11o5hiBtmIUf3lP8AOvmy3sZ2urOLT5UuJp8bArbCjehY4ANdBpfiLxD4WvC0yXny5DLKTIh/HkUAewNHeedtZEKY++Dn9KimmRRsKMzDHbjP1rnbX4waW9vH5+mXCzj7xjK7Tx71q6d478O6kubucwOcBUkXv9RQBY/cMQeUcEdR1qZJREzGK7KuerJVyODSb+NH09oJVIGX8zn64zU0ujhF+78/UYFAFFNQvVOxpFOTw2PyzUz6jeCXcyxMSuMYqM6TdgPhSUPUZpj6ReBuIDjpkNQAr6pd7DlIo0B5+Q5NNGrSYGza7E8hR2pjaXfYYCFjz1z2pW0y73B4rZ0bHtQBINXuOQYOB0Gw/wA6Rdbuyq5KJnqM0hstR8vaYDjHJyKamn3qg/uiCfYUASvqNzMMBiB/u1UknvH4d3YE8ADIqVrK7UgrFIx9iKljtNRIwIio9CRQBWEt4GZFDAdScYqtFbTSAs4xznhsk1ptp2pOeEXHuaF0m/A5TH0oAzTG20fIwxweMCnJHOz43tntjnitI6Xejqj1C2mXgbJhdvocUAVjaNuG6YA+/wDKlMLM3ALYGQc8Vbh0iWSRS6mJRySzU660pxtaCbzFA+6jA4oAz1c7DteRDnoVNTIZ9uZJnIxgjGaT7Bcop2RyY/3hTza3xjVvs7SDHKhsZoAZNFIYciVxzgH7n86rsksR3HccjnDZq42lXTpn7K8TbsbSxYGhNIv2lw0YUgYJzzQBUWSSJwA8ilvfpUkksqZC3bdP7hq6NLu1G3YzenFR/wBmXgYAW5UkdSaAI7dJpV3vcOSP4i/X8KkkhjZVzKWYkZJBNPXTLjy8mIEZ5GTxViDR5ZYTtTb9DQBnG3tklkHmzOZG3YAPyew9qD5AUKrIQO8i5bNdA2hRAReYdrd2LYqBzpNjGTO0aqpySXHr1oAzFmc7hC+Tzk7cURQXM4+6FHPA6mqeqePvCloGUGSZlbHlwjk/ieKzH+L+hRkpb6PdPyeSw3dPagDroNKkmZWlLKB29anEFnpwMl3JFGpP3nbaB9a851j4ryzQk6TpM8J7PKCcce3FebavrV9qNxJJfXEjMxyVLHH5dKAPcfEvj7RNMtdljdC5us/6uFeB/wACrzbW/iTrd7PIYbp7OBl27IcDI964KSUbcIoX1NRlhvJdWIx0PegC498X3ys252bOGyc+9UC3JpKSgBSaKSloAUU4UynrwKAHqKsIPlHNQrVhPuCgCqaTmlIGaKAGmkNONNNACGk5xQaSgBwJ6UA02lFADw7bdueK29M8U6tpsUkMNws0LjHl3CCRQPYHpWHRQBbuLtLku8kCLMxzmMbFH/ARVjTY9Pk4vb2eF+22IMv481lk0UAdZY2rxMsthrECkYI+bBrdt9b8S2xHlaxC+P7xDCvNT9TRk9i350Aeqjxb4tHA1Czx/wBclp3/AAl3jI/dvLVv+2QrykOw6M351Kl1Ohysrg+xoA9PPjPxtED+/tz/ANsAaqy+P/GKg75Yf/AcVwces6hGMJeTKPrUg17UsfNdyN9cUAdi3xH8UIfmkh/78Cm/8LR8Rj7zwH6wiuQGt3Ocv5cn+8uaU6wzKQ1nZn38v/69AHZL8VNbHVbb/v2KRviv4hH+re1H/bAGuCuLkS4xDEn+4uKZHcPEQY2KmgDv/wDhbPiv+B7Yf9ugph+Kvi5hxLAPpagVx0WualET5d5Kv0x/hT5Nf1OQYkvZWHvj/CgDrP8AhaviwfeuofxtxT1+LPigdbm2P1tlrhpb6eb/AFsrN9arswJyeaAO01b4k+IdRtHt5rmBY3+95cIU/nVHw1421jQrmWS0uVYSgB1lUOCAe2elc2jovWND9asC8RSP9Etjj1Q/40Ad9P8AFjV3jIjjtFc87vLBqJ/i94pIQLLYgr/ds1rgZZkkz+4iTP8AcGMUWt3LaOXtXMTEYyvXFAHoX/C4vF//AD1s/wDwDWmP8YPFjYBlsxjjP2Na4w6/qhGDezY/D/CmPrWov/rLuRh74/woA7cfF3xM4+ae1yBj/j2Apj/FnxMVws9qF6Y+zCuAkneTJc5PfI60q3DpjYxFAHfQ/FXxYZMxzW7sP+nQGtax8c/EDU2SK2jtvm+6Taoo/PNebLrWoxrtS7kVfQYqtLeXEoy80hP+9igD1nVNP8Z30ofVNZ0+BcdBIFx+ArmNQ02wihJv/EjSzL1SOMOPzzXEGWQnmRz9WNMyfUmgDUuTaJNiGV54x1Drsz+VOTVY7YkWVnFFz1c+YfzNZQOKQHmgDXu/EWpXMPkvMFiznai7R0rJJY9TkmgAk8Ak+goONnOd36YoAeyNGsUm+Nt3IXqR9RSTSNLIXc/MaYaSgBaTn1o9KKAFoopKAAU8cU3vS0ASKaa0koYhTxQlTrGCATQBEaU9KD1NIc0AJSUUUANI5oxSmkoAKUUlGaAHUhpKDQAE0A9qSkzigBSaM0A+vNIeD7UALn1opMiigBaSiigBaKSigBaKTBOOD+VBB9D+VABjml7Ug5OBnNLtYj7poAKSl2t/dNADf3TQAlLQVPdSKb34oAWl7UlFAC96KT86KAFopKAfTNAC96D0pPwNL2oAM80Cjv705EZxkAhe7HoOaAGU9E3fecIuDyaWZFjkZA4kKkgsn3T6EHvTM0AKGwOB83r3pKSgUAFLSUtACdMUtJRQAvaiiigApRSUooAetWkB2CqyVZUcDmgCDHJpD9KcTyaQ+1ADCOaTmnYPWkxQA3FGKWigBKMUCloASilNNzQAGm0uaKAEoFLikoAuWc0CyxrewmWDeC+xtsm0dlbt+VdNpFp4W1W9MDPe6ZxlHmnDhvXJAGK42lzQB2svh/QZDIll4lUFWxtljI3H1pU8CPcOq23iHRW3Dgy3Cxj8STXGec/2cw5Hllt5G0ZzjHXrTAFyBnHuQKAO+Hwv1Rhldb8KknsNWizUkfwq108xXvh+Q/7GqRH+tefhGKswVdqjJPFIkjKMo7L9DigD0v8A4Vh4yL7Y309iOfkvYzVPWPh341sLYy3NqZYhjmGRZOv0rhlvrpfuXU6/SVv8auQa/q9uFEOp3agdB5rEfzoA0rLwnrdxcPv0bU7lE+95cZTH5ir8nha5jGJPC+uggZPz/wD2NZaeM/ESNuTV7pTjHDYqQeOvEw6axc/iaALg8OyYA/4RrXdx75/+xqM6CwYg+HdaBHUb/wD7GmQ/ELxTCwaPWZwR04B/pT5PiL4rkJL6xKSep2L/AIUASxeHJWbH/CNa6x6jDf8A2NTf8IrdFlCeFPEH03H/AOJqkfiF4qIA/tm4/AAf0pv/AAsDxXvDf23dZ6DmgDXj8GXzbh/wiPiEnt+8x/7LVqLwFfycDwlrq/79yq/+y1zcvjzxTKCH1y8Of9vFUpfE+uy48zV748f89m/xoA6DUPAuuLc+TaaNeW4LY/eyhwPyAqVPhd4jbIxYLjqJZ1jI/OuSbWtULZbUbwn/AK7N/jVeXUbyVsy3k7H3lP8AjQB3Ufws1lnxLqnhy39d+pRjFXY/hfLEB5/i7w3Hx/yzv0b+teaQRTXc3lxkySH+839TSiJY5QtyCBzkJgn/AAoA9El8EaRaFvtfiiykOOTDOCDWe+h+GkR5X1C5aBBkyA8N7D1PtXEkqk26EkAfd3AZoaR2BBY7SdxHbPrigDckutCgaX7Np1xM44jeeYFT7lcViSzPIqqx+VM7VHRQTkgfjUZPNJQAuKKKWgBKKWigBKKDQKACkp1JzQAUlOooAQU7IJoC5pdhoAcnNW0HyDmqsYxVxMbBnrQBUxzyKByKKKADB9KQ/SiigBCD6U0g0UUAFFFFABSEHOCOaKKAEIox7UUUAJijB9KKKADBo2n0oooAMe1GDRRQAbfanLxztHHrRRQBZkuY5ViV7VP3aFcqduT6moGRdilWJYjkEYANFFAEex89AaXacdMUUUAG3ketBU0UUAJtNG0noOaKKADa3daUq3oKKKAJrXyo5ke5hM8Y6x7tmfxFSXV15xULBDGigqqqnOPc9z70UUAVcHGAOKTaR2oooAUKT2pdp44oooAQ8Hmk9eaKKAF4xRkUUUAGRQOelFFABg0UUUAFFFFABipFAoooAmSInkClZCOAKKKABExnipRjFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) scan of a patient with acute pulmonary histoplasmosis shows compression of the right middle lobe bronchus (arrow) by a lymph node (N), causing collapse and consolidation of the right middle lobe. The CT scan also shows central lucency in a subcarinal lymph node (L) and lucency within the right middle lobe infiltrate (L). These lucent areas are caused by caseous necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Wheat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11794=[""].join("\n");
var outline_f11_33_11794=null;
var title_f11_33_11795="DEB milia";
var content_f11_33_11795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Recessive dystrophic epidermolysis bullosa (EB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions, crusts, atrophic scarring, and milia formation in recessive dystrophic EB",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <font color=\"black\">",
"      Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"     </font>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11795=[""].join("\n");
var outline_f11_33_11795=null;
var title_f11_33_11796="Five finger rotation from occiput posterior";
var content_f11_33_11796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Five finger manual rotation from occiput posterior",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 683px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The operator places four fingers behind the posterior parietal bone with the palm up and the thumb over the anterior parietal bone. The right hand is used for left OP position and the left hand is used for right OP position. The head is grasped with the tips of the fingers and thumb.",
"    <br>",
"     (B-F) During a contraction, the patient is encouraged to push and the operator attempts to flex and rotate the fetal head to the OA postion.",
"     <div class=\"footnotes\">",
"      OP: occiput posterior; OA: occiput anterior.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11796=[""].join("\n");
var outline_f11_33_11796=null;
var title_f11_33_11797="Deep neck space anatomy";
var content_f11_33_11797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Deep neck spaces and fascial layers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11797=[""].join("\n");
var outline_f11_33_11797=null;
var title_f11_33_11798="Cystic hygroma CXR II";
var content_f11_33_11798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55203%7EPULM%2F52563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55203%7EPULM%2F52563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma involving right axilla and mediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph demonstrates a large right-sided mediastinal mass displacing the trachea to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma involving right axilla and mediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan demonstrates a heterogeneous mass in the right axilla and right hemithorax, displacing the thymus to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11798=[""].join("\n");
var outline_f11_33_11798=null;
var title_f11_33_11799="Reconstructive materials used in surgery: Classification and host response";
var content_f11_33_11799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reconstructive materials used in surgery: Classification and host response",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/33/11799/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11799/contributors\">",
"     Emanuel C Trabuco, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11799/contributors\">",
"     John B Gebhart, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/33/11799/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11799/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11799/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/33/11799/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11799/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/33/11799/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review will discuss the classification and histologic behavior of reconstructive materials used in surgery. The use of prosthetic material for the surgical management of specific conditions are reviewed in individual topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USE OF RECONSTRUCTIVE MATERIALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hernia repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prosthetic material dramatically reduces the incidence of recurrence associated with inguinal and femoral hernia repair. Polypropylene and polytetrafluoroethylene (PTFE) are the most common materials used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29000?source=see_link\">",
"     \"Overview of treatment for inguinal and femoral hernias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pelvic organ prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic organ prolapse (POP) and urinary incontinence are common, comorbid disorders in women, and can greatly impact quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TYPES OF RECONSTRUCTIVE MATERIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four kinds of surgical reconstructive materials differ by source: synthetic mesh, autografts, allografts, and xenografts. Advantages and disadvantages of the different material types are found in the table (",
"    <a class=\"graphic graphic_table graphicRef72868 \" href=\"UTD.htm?23/42/24236\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Synthetic materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic materials are available as both absorbable (eg, polygalactin 910 [Vicryl&reg;], polyglycolic acid [Dexon&reg;]) and nonabsorbable mesh (eg, polypropylene [Marlex&reg;, Prolene&reg;], and expanded polytetrafluoroethylene [ePTFE, Gortex&reg;]). Compared with biologic grafts, advantages of synthetic materials include: greater availability (does not require harvesting), lack of risk of donor-to-host infectious disease transmission, and cost-effectiveness. However, infectious and erosion complications, especially with transvaginal surgery, have prompted a search for alternative materials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/2\">",
"     2",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H10\">",
"     'Host response'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autografts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autograft materials are harvested from the patient who is undergoing the procedure. Fascia lata and rectus fascia, the most commonly used autografts, have been used for decades and yield predictable results [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/3\">",
"     3",
"    </a>",
"    ]. A clear advantage of autografts is that the host response is rarely problematic. However, use of autografts is limited by morbidity associated with harvesting the tissue (eg, pain, bleeding, infection, hernia formation), as well as inconsistent size, quantity, and quality of tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/4\">",
"     4",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H10\">",
"     'Host response'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Allografts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allografts are processed cadaveric fascia lata or acellular extracts of collagen harvested from the dermis of human donors (",
"    <a class=\"graphic graphic_table graphicRef63852 \" href=\"UTD.htm?22/48/23308\">",
"     table 2",
"    </a>",
"    ). The material is rendered non-immunogenic by washing processes, which are designed to remove cellular debris without permanently damaging the connective tissue scaffold.",
"   </p>",
"   <p>",
"    Although tissue banks in North America are accredited through the National Association of Tissue Banks, evidence-based comparisons among allografts distributed by different companies are difficult because the harvesting, processing, and preservation of these materials are varied and proprietary. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Allograft processing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Human donors of allografts are screened for blood-borne pathogens; those with risk factors or who test positive for HIV, syphilis, HTLV, or hepatitis B or C are excluded. There have been no reported cases of donor-related viral infection associated with the use of allografts.",
"   </p>",
"   <p>",
"    Use of this class of materials eliminates the morbidity associated with autologous fascia harvest. However, allografts have consistently under performed compared to autologous fascia and synthetic materials. Furthermore, supply shortages have occurred during periods of increased demand given the limited donor pool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Xenografts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xenografts are acellular extracts of collagen with or without additional extracellular matrix components that are harvested from non-human sources (",
"    <a class=\"graphic graphic_table graphicRef73182 \" href=\"UTD.htm?35/52/36684\">",
"     table 3",
"    </a>",
"    ). They differ in the source species (bovine or porcine), site of harvest (pericardium, dermis, or small intestine submucosa), and by whether or not chemical crosslinking is used in the processing of the material [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bovine-derived xenografts pose a theoretical risk of infection with bovine spongiform encephalopathy.",
"   </p>",
"   <p>",
"    It is not clear whether architectural differences due to harvest site (eg, dermis with high elastin content versus intestinal submucosa with no elastin content) affects if in vivo performance.",
"   </p>",
"   <p>",
"    Some patients may object to use of porcine or bovine implants due to religious or cultural issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HOST RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic behavior to a class of material depends upon the physical and structural properties of the prosthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Host response to reconstructive materials is described by varying terminology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/6\">",
"     6",
"    </a>",
"    ], as an example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incorporation: graft infiltration by host cells, allowing neovascularization and collagen deposition throughout the material",
"     </li>",
"     <li>",
"      Encapsulation: collagen and connective tissue deposit at the periphery of the material, rather than infiltration of graft by host cells",
"     </li>",
"     <li>",
"      Mixed response: incorporation occurs at graft pores and encapsulation occurs around the remaining material",
"     </li>",
"     <li>",
"      Resorption: material is replaced by host neoconnective tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Theoretically, materials which undergo encapsulation or mixed response are at increased risk of infection and erosion. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinically, prosthetic material related complications are manifested in at least three different ways: exposure (usually relatively asymptomatic), infection (often a proxy for an exposed, symptomatic prosthetic), or, more commonly, erosion (exposed material, symptomatic). It is rare to have an infected, unexposed material. In some locations such as the vagina, it is difficult to differentiate between infection and colonization. Furthermore, it is unclear whether these clinical manifestations are due to host response or technical aspects of material use (eg, thickness of vaginal flaps).",
"   </p>",
"   <p>",
"    The key factor(s) for host response to each type of material are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Synthetic mesh: pore size and weave",
"     </li>",
"     <li>",
"      Autografts: autologous tissue, host response is rarely problematic",
"     </li>",
"     <li>",
"      Allografts: key factor(s) have not been elucidated",
"     </li>",
"     <li>",
"      Xenografts: removal of host cellular components and chemically crosslinking",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Synthetic materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Host response to synthetic prosthetic materials depends on several factors: absorbability, pore size (space between fibrils), weave (mono- or multifilament), and weight (density).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Absorbable versus nonabsorbable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both absorbable and nonabsorbable materials cause initial and chronic inflammatory tissue responses after they are implanted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/7\">",
"     7",
"    </a>",
"    ]. The quantity and quality of local inflammation depend directly on the specific material used.",
"   </p>",
"   <p>",
"    The implantation of absorbable material (eg, polygalactin 910 [Vicryl&reg;] or polyglycolic acid [Dexon&trade;]) elicits a chronic foreign body reaction and promotes fibroblast activity. After complete absorption (30 days for polygalactin 910; 90 days for polyglycolic acid), the prosthetic material is replaced by a collagen-rich connective tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/8\">",
"     8",
"    </a>",
"    ]. Absorbable materials are less likely to become infected than nonabsorbable materials, and are less harmful to viscera [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/9\">",
"     9",
"    </a>",
"    ]. One disadvantage to absorbable implants, based on animal studies, is that the resultant scar tissue weakens after the material is absorbed, and therefore may not provide the necessary long-term repair strength [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonabsorbable prosthetic materials (eg, polypropylene [Prolene&reg;, Marlex&reg;]) are associated with more connective tissue reaction than absorbable materials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, repair strength is increased due to the continuing presence of the implant and greater scar formation.",
"   </p>",
"   <p>",
"    Partially absorbable materials have been developed, with the aim of decreasing the amount of permanent foreign material while maintaining mechanical resistance. These materials are composites of absorbable and nonabsorbable materials (eg, polypropylene with polygalactin [Vypro&reg;] or with poliglecaprone-25 [Ultrapro&reg;]) and are lightweight; few reports are available regarding clinical performance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H15\">",
"     'Weight'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pore size and weave",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pore size influences cellular infiltration, risk of infection, and mesh density and flexibility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Macropores (&gt;75 microns; 1 mm = 1000 microns) allow for host cell colonization with collagen deposition and angiogenesis, although this has only been reported in animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition, in vivo evidence suggests that the large pore allows unrestricted immune cell access and minimizes the risk of infection.",
"   </p>",
"   <p>",
"    Micropores (&lt;10 microns) result in restriction of fibroblast and immune cell colonization to the material surface. Therefore, collagen and connective tissue deposition occurs at the periphery, rather than infiltration by host cells, according to animal data. This process is called encapsulation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, microporous materials are at increased risk of becoming infected, as large immune cells (macrophages and natural killer cells, mean diameter 9 to 20 microns) cannot infiltrate the interstices (space between fibers) to phagocytose bacteria (&lt;1 micron) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesh weight, or density, is another descriptor for synthetic materials (",
"    <a class=\"graphic graphic_figure graphicRef78709 \" href=\"UTD.htm?35/20/36168\">",
"     figure 1",
"    </a>",
"    ). Generally speaking, the weight is a measure of how much material is needed to produce a given amount of the material.",
"   </p>",
"   <p>",
"    Weight and elasticity are determined by pore size. Meshes with larger pores generally have a lower weight and are more elastic compared with those that have smaller pores. The larger the pores, the less material content and the more flexible the elicited scar [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/18\">",
"     18",
"    </a>",
"    ]. It has been postulated that light-weight materials may be less prone to infection or erosion than heavy-weight materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonabsorbable synthetic materials are generally described by type, a classification based on pore size and weave (",
"    <a class=\"graphic graphic_figure graphicRef78709 \" href=\"UTD.htm?35/20/36168\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/19\">",
"     19",
"    </a>",
"    ]. There are four types (",
"    <a class=\"graphic graphic_figure graphicRef78709 \" href=\"UTD.htm?35/20/36168\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I &mdash; Macroporous (&gt;75 microns) , monofilament polypropylene (eg, Prolene&reg;, Marlex&reg;). Type I meshes are further subdivided into heavy-, mid- and light-weight materials.",
"     </li>",
"     <li>",
"      Type II &mdash; Microporous (&lt;10 microns), eg, expanded polytetrafluoroethylene (Gortex&reg;).",
"     </li>",
"     <li>",
"      Type III &mdash; Macroporous (&gt;75 microns) grafts with either microporous components or multifilament fiber structure, eg, polyethylene [Mersilene&reg;]. Histologic behavior is similar to Type II materials. This category includes some polypropylene materials, eg, ObTape&reg; (heat bonded, heat welded polypropylene with microporous components) and IVS Tunneler&trade; (multifilament polypropylene). Both materials have been associated with increased rates of infections and erosion [",
"      <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/20\">",
"       20",
"      </a>",
"      ]; OBTape&reg; has been removed from the market and IVS Tunneler&trade; is not being marketed.",
"     </li>",
"     <li>",
"      Type IV &mdash; Submicroscopic pore size (eg, polypropylene sheet [Cellgard&reg;]). These are not commonly used in gynecologic surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Allograft processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allograft processing is intended to render a graft non-immunogenic. As mentioned above, the methods used by companies to process human tissue to produce allografts vary and details are not publicly disclosed (",
"    <a class=\"graphic graphic_table graphicRef63852 \" href=\"UTD.htm?22/48/23308\">",
"     table 2",
"    </a>",
"    ), thereby interfering with evidence-based comparisons among allografts.",
"   </p>",
"   <p>",
"    There are at least four major steps in allograft processing:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Harvesting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Harvesting of fascia lata and dermis is done aseptically from cadavers. For dermis products, the epidermis is mechanically or chemically separated from the underlying dermis; the collagen matrix is then extracted from the dermis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Host cell removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;After harvesting, the material is made acellular by washing it in a solution to extract cellular components. These processes render the allograft non-immunogenic by eliminating cell surface proteins (eg, human histocompatibility antigen, HLA) and sugar moieties. The solvents must remove cellular debris without permanently denaturing the protein scaffold.",
"   </p>",
"   <p>",
"    Despite assertions by manufacturers, it appears that the cellular extraction process is imperfect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/21\">",
"     21",
"    </a>",
"    ]. In one study, the HLA type of allograft donors could still be identified (using the polymerase chain reaction) in freeze-dried and Tutoplast&reg; processed grafts; Repliform&reg; interfered with the assay in the study and its antigenicity could not be determined. These data suggest that not all contaminating DNA had been extracted. However, this finding does not signify that the grafts were immunogenic. Host rejection is mediated by host lymphocyte detection of cell surface proteins and sugar moieties, not by DNA or other intracellular components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Preservation and sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The collagen and extracellular matrix are preserved via lyophilization (freeze-dried under vacuum) or solvent dehydration. In some tissue banks, the graft is then sterilized (usually with gamma irradiation).",
"   </p>",
"   <p>",
"    The processes employed for these steps appear to affect the final graft strength. As an example, the rate of lyophilization alters the size of ice crystal formation (the more ice crystals formed, the weaker the final product) and the terminal sterilization temperature influences the degree of free radical formation.",
"   </p>",
"   <p>",
"    Both lyophilization and sterilization affect the final integrity of the material and, theoretically, graft performance. However, the effect of preimplantation biomechanical characteristics of a graft on in vivo behavior is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/6,22-26\">",
"     6,22-26",
"    </a>",
"    ]. No data on postimplantation biomechanical testing exist for allografts; it appears that preimplantation mechanical testing does not predict in vivo behavior of xenografts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In fact, the few studies which have compared different allografts by preimplantation strength are not consistent with reports of clinical performance. As an example, one study reported that the preimplantation maximum load to failure (minimum force needed to tear the tissue) and stiffness were significantly higher for solvent dehydrated compared with freeze-dried fascia lata [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/22\">",
"     22",
"    </a>",
"    ]. Nevertheless, solvent dehydrated allografts have consistently been reported to result in early failure after pubovaginal sling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], sacrocolpopexy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/25\">",
"     25",
"    </a>",
"    ], and vaginal reinforced repairs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/26\">",
"     26",
"    </a>",
"    ]. Similarly, the only study which evaluated vaginal repair with a freeze-dried graft reported a high failure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Xenograft processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to allografts, xenografts processing includes harvesting, host cell removal, preservation and sterilization. These processes are generally proprietary, and thus comparisons among different grafts are difficult. In our experience, some patients have had increased tissue reaction with xenografts, raising concerns about how well the processes remove cellular debris. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Allograft processing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, xenografts undergo chemical crosslinking, which is one of the key determinants of host response to xenografts (",
"    <a class=\"graphic graphic_table graphicRef73182 \" href=\"UTD.htm?35/52/36684\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Crosslinking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-crosslinked xenografts (eg, Surgisis&reg;, Xenform&reg;) are purported to serve as biologic scaffolding for fibroblast and angioblast ingrowth; they are replaced by host connective tissue at varying rates, depending on material thickness, method of freezing, and site of implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, materials which are crosslinked (eg, Pelvicol&reg;) are functionally nonporous. As a result, host cellular infiltration does not occur and the material is surrounded by a connective tissue envelop (ie, encapsulation, similar to synthetic type II materials) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If crosslinked materials are perforated prior to implantation (eg, Pelvisoft&reg; and Fortagen&reg;), they undergo a mixed response with incorporation at the perforations and encapsulation in the remainder of the material (similar to what is observed for type III synthetic materials) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although crosslinking is performed to permanently stabilize the material, crosslinked graft resorption over time is an area of concern. According to the manufacturer report only, the process of resorption would be different for crosslinked and non crosslinked grafts.",
"   </p>",
"   <p>",
"    It is not known whether eventual graft loss affects the structural integrity of the repair. Furthermore, it also remains to be elucidated if resorption occurs in all patients implanted with a crosslinked graft, or only in a subset of patients that reject the graft. This is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small histopathologic study evaluated women who had undergone placement of a midurethral sling using a crosslinked porcine dermal collagen implant (Pelvicol&reg;) and who required sling revision due to recurrent stress urinary incontinence or urinary retention [",
"      <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/28\">",
"       28",
"      </a>",
"      ]. Time from graft placement to biopsy ranged from 15 to 67 months. Although the graft remained encapsulated in the early biopsy specimens, there was a progressive increase in the immunologic response at the graft-host interface at 21 weeks. Histiocyte and multinucleated giant cell infiltration of the graft was detected by 42 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/28\">",
"       28",
"      </a>",
"      ]. No residual graft was found in the 58- and 67-week samples, suggesting that the materials were resorbed in the interim [",
"      <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/5,28\">",
"       5,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, women who had a Pelvicol reinforced posterior repair were evaluated upon reoperation one year postoperatively; no residual Pelvicol was found [",
"      <a class=\"abstract\" href=\"UTD.htm?11/33/11799/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical treatment of a variety of conditions requiring reconstruction (eg, hernia, prolapse) are followed by high recurrence rates. The interposition of many reconstructive materials remains investigational. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are four categories of reconstructive surgical materials: synthetic material, autografts, allografts, xenografts (",
"      <a class=\"graphic graphic_table graphicRef72868 \" href=\"UTD.htm?23/42/24236\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types of reconstructive materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Host response to a class of material depends upon the physical and structural properties of the prosthesis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Host response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Synthetic material pore size determines host response, including risk of infection, as well as graft elasticity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Host response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allograft processing is intended to render a prosthesis nonimmunogenic. Processing techniques vary by manufacturer and information is not publicly disclosed, thus limiting evidence-based comparison of allografts. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Allograft processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemical crosslinking is a key determinant of host response to xenografts. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Xenograft processing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/1\">",
"      Helstr&ouml;m L, Nilsson B. Impact of vaginal surgery on sexuality and quality of life in women with urinary incontinence or genital descensus. Acta Obstet Gynecol Scand 2005; 84:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/2\">",
"      Huebner M, Hsu Y, Fenner DE. The use of graft materials in vaginal pelvic floor surgery. Int J Gynaecol Obstet 2006; 92:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/3\">",
"      Albo ME, Richter HE, Brubaker L, et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med 2007; 356:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/4\">",
"      Walter AJ, Hentz JG, Magrina JF, Cornella JL. Harvesting autologous fascia lata for pelvic reconstructive surgery: techniques and morbidity. Am J Obstet Gynecol 2001; 185:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/5\">",
"      Trabuco EC, Klingele CJ, Gebhart JB. Xenograft use in reconstructive pelvic surgery: a review of the literature. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/6\">",
"      Trabuco EC, Zobitz ME, Klingele CJ, Gebhart JB. Effect of host response (incorporation, encapsulation, mixed incorporation and encapsulation, or resorption) on the tensile strength of graft-reinforced repair in the rat ventral hernia model. Am J Obstet Gynecol 2007; 197:638.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/7\">",
"      Klinge U, Klosterhalfen B, M&uuml;ller M, Schumpelick V. Foreign body reaction to meshes used for the repair of abdominal wall hernias. Eur J Surg 1999; 165:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/8\">",
"      Klinge U, Schumpelick V, Klosterhalfen B. Functional assessment and tissue response of short- and long-term absorbable surgical meshes. Biomaterials 2001; 22:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/9\">",
"      Chen CC, Ridgeway B, Paraiso MF. Biologic grafts and synthetic meshes in pelvic reconstructive surgery. Clin Obstet Gynecol 2007; 50:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/10\">",
"      Barbolt TA. Biology of polypropylene/polyglactin 910 grafts. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17 Suppl 1:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/11\">",
"      Tyrell J, Silberman H, Chandrasoma P, et al. Absorbable versus permanent mesh in abdominal operations. Surg Gynecol Obstet 1989; 168:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/12\">",
"      Bell&oacute;n JM, Rodr&iacute;guez M, Garc&iacute;a-Honduvilla N, et al. Partially absorbable meshes for hernia repair offer advantages over nonabsorbable meshes. Am J Surg 2007; 194:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/13\">",
"      Achtari C, Hiscock R, O'Reilly BA, et al. Risk factors for mesh erosion after transvaginal surgery using polypropylene (Atrium) or composite polypropylene/polyglactin 910 (Vypro II) mesh. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/14\">",
"      Iglesia CB, Fenner DE, Brubaker L. The use of mesh in gynecologic surgery. Int Urogynecol J Pelvic Floor Dysfunct 1997; 8:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/15\">",
"      Falagas ME, Velakoulis S, Iavazzo C, Athanasiou S. Mesh-related infections after pelvic organ prolapse repair surgery. Eur J Obstet Gynecol Reprod Biol 2007; 134:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/16\">",
"      White, RA. The effect of porosity and biomaterial on the healing and long-term mechanical properties of vascular prostheses. ASAIO J 1988; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/17\">",
"      Bobyn JD, Wilson GJ, MacGregor DC, et al. Effect of pore size on the peel strength of attachment of fibrous tissue to porous-surfaced implants. J Biomed Mater Res 1982; 16:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/18\">",
"      Cobb WS, Burns JM, Peindl RD, et al. Textile analysis of heavy weight, mid-weight, and light weight polypropylene mesh in a porcine ventral hernia model. J Surg Res 2006; 136:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/19\">",
"      Amid, PK. Classification of biomaterials and their related complications in abdominal wall hernia surgery. Hernia 1997; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/20\">",
"      Baessler K, Hewson AD, Tunn R, et al. Severe mesh complications following intravaginal slingplasty. Obstet Gynecol 2005; 106:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/21\">",
"      Fitzgerald MP, Mollenhauer J, Brubaker L. The antigenicity of fascia lata allografts. BJU Int 2000; 86:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/22\">",
"      Lemer ML, Chaikin DC, Blaivas JG. Tissue strength analysis of autologous and cadaveric allografts for the pubovaginal sling. Neurourol Urodyn 1999; 18:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/23\">",
"      Huang YH, Lin AT, Chen KK, et al. High failure rate using allograft fascia lata in pubovaginal sling surgery for female stress urinary incontinence. Urology 2001; 58:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/24\">",
"      McBride AW, Ellerkmann RM, Bent AE, Melick CF. Comparison of long-term outcomes of autologous fascia lata slings with Suspend Tutoplast fascia lata allograft slings for stress incontinence. Am J Obstet Gynecol 2005; 192:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/25\">",
"      Culligan PJ, Blackwell L, Goldsmith LJ, et al. A randomized controlled trial comparing fascia lata and synthetic mesh for sacral colpopexy. Obstet Gynecol 2005; 106:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/26\">",
"      Gandhi S, Goldberg RP, Kwon C, et al. A prospective randomized trial using solvent dehydrated fascia lata for the prevention of recurrent anterior vaginal wall prolapse. Am J Obstet Gynecol 2005; 192:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/27\">",
"      Ward RM, Sung VW, Clemons JL, Myers DL. Vaginal paravaginal repair with an AlloDerm graft: Long-term outcomes. Am J Obstet Gynecol 2007; 197:670.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/28\">",
"      Gandhi S, Kubba LM, Abramov Y, et al. Histopathologic changes of porcine dermis xenografts for transvaginal suburethral slings. Am J Obstet Gynecol 2005; 192:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11799/abstract/29\">",
"      Altman D, Zetterstr&ouml;m J, L&oacute;pez A, et al. Functional and anatomic outcome after transvaginal rectocele repair using collagen mesh: a prospective study. Dis Colon Rectum 2005; 48:1233.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2879 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11799=[""].join("\n");
var outline_f11_33_11799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USE OF RECONSTRUCTIVE MATERIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hernia repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pelvic organ prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TYPES OF RECONSTRUCTIVE MATERIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Synthetic materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autografts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Allografts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Xenografts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HOST RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Synthetic materials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Absorbable versus nonabsorbable",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pore size and weave",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Weight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Allograft processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Harvesting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Host cell removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Preservation and sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Xenograft processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Crosslinking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2879\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2879|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/20/36168\" title=\"figure 1\">",
"      Classification of synthetic materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2879|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/42/24236\" title=\"table 1\">",
"      Comparison of reconstructive materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/48/23308\" title=\"table 2\">",
"      Allografts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/52/36684\" title=\"table 3\">",
"      Xenografts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29000?source=related_link\">",
"      Overview of treatment for inguinal and femoral hernias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_33_11800="Ifosfamide: Pediatric drug information";
var content_f11_33_11800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ifosfamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"    see \"Ifosfamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/46/19173?source=see_link\">",
"    see \"Ifosfamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ifex",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ifex",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"      see \"Ifosfamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols; details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     To prevent bladder toxicity, combination  therapy with mesna (urinary protectant) and hydration, in adults: At least 2 L/day of oral or I.V. fluid; specific protocols should be consulted for hydration recommendation in pediatric patients; some centers have used 2 times maintenance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Ewing sarcoma:",
"     </b>",
"     Limited data available; dosing regimens and combinations variable: Children and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     IE regimen: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days in combination with mesna and etoposide every 3 weeks for 12 cycles; or may alternate with VAC (vincristine, doxorubicin, and cyclophosphamide) every 3 weeks for a total of 17 courses (Grier, 2003; Miser, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ICE regimen: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3-4 weeks for up to 12 cycles in combination with carboplatin, etoposide, and mesna; or may follow with 2 courses of CAV (cyclophosphamide, doxorubicin, and vincristine) (Milano, 2006; van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     VAIA regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, 22, 23, 43, and 44 for 4 courses in combination with vincristine, doxorubicin, dactinomycin, and mesna (Paulussen, 2001)",
"     <b>",
"      or",
"     </b>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 3 weeks for 14 courses in combination with vincristine, doxorubicin and dactinomycin (Paulussen, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     VIDE regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 1-3 hours for 3 days every 3 weeks for 6 courses in combination with vincristine, doxorubicin, etoposide, and mesna (Juergens, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Lymphoma, Hodgkin (HL) and Non-Hodgkin&rsquo;s (NHL), recurrent/refractory:",
"     </b>",
"     Limited data available; dosing regimens and combinations variable: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     IE regimen: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days alternating in combination with etoposide and mesna; alternate at 3-week intervals with DECAL [dexamethasone, etoposide, cisplatin, cytarabine (high-dose ara-C)], and L-asparaginase for 4 cycles (Kobrinsky, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ICE regimen: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for 6 courses in combination with etoposide, carboplatin, and mesna (Cairo, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     MIED regimen: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours on days 2-4 in combination with high dose methotrexate, etoposide and 	dexamethasone (and mesna); patients with NHL also received intrathecal methotrexate, hydrocortisone, and cytarabine (Sandlund, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Griffin, 2009:",
"     </i>",
"     3000  mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours on days 3-5 in combination with rituximab and ICE (carboplatin, etoposide, and mensa) every 23 days for up to 3 courses has been used in NHL patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Osteosarcoma:",
"     </b>",
"     Limited data available; dosing regimens and combinations variable:  Children and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     IE regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 3 hours for 4 days every 3-4 weeks in combination with etoposide and mesna has been used in children and adolescents 7-19 years of age (Gentet, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ICE regimen:  1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for up to 12 cycles in combination with carboplatin, etoposide, and mesna (van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Bacci, 2003:",
"     </i>",
"     3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days (total dose: 15 g/m",
"     <sup>",
"      2",
"     </sup>",
"     ) during weeks 4 and 10 (preop) and during weeks 16, 25, and 34 (postop) in combination with cisplatin, doxorubicin, methotrexate (high-dose), and mesna has been used in patients 6-39 years (median: 18.1 years) with newly diagnosed high-grade osteosarcoma of the extremity with metastases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Basaran, 2007:",
"     </i>",
"     Adolescents: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 3 days (days 2, 3, and 4) every 3 weeks for 3 cycles (preop) and every 4 weeks for 3 cycles (postop) in combination with cisplatin, epirubicin, and mesna has been used in patients 15-41 years (median: 22 years) (Basaran, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Le Deley, 2007:",
"     </i>",
"     3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 3 hours for 4 days during weeks 4 and 9 (three additional postop courses were administered in good responders) in combination with methotrexate (high-dose), etoposide, and mesna has been used in patients 5-19 years (median: 13.3 years) (Le Deley, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Testicular cancer:",
"     </b>",
"     I.V.: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days in combination with other chemotherapy agents and mesna every 3 weeks or after hematologic recovery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustments in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: The following adjustments have been recommended: (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: 1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     followed by hemodialysis 6-8 hours later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT): No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Manufacturer&rsquo;s labeling: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); ifosfamide (and metabolites) are excreted renally and may accumulate in patients with renal dysfunction. Dose reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     The following adjustments have been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Hemodialysis: No supplemental dose needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt; 60 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Administer 70% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustments in hepatic impairment:",
"     </b>",
"     Adults:  There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, ifosfamide is extensively metabolized in the liver to both active and inactive metabolites; use with caution. The following adjustments have been recommended (Floyd, 2006):  Bilirubin &gt;3 mg/dL: Administer 25% of dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 3 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifex: 1 g, 3 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 50 mg/mL (20 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Reconstitute powder with SWI or bacteriostatic SWI  to a concentration of 50 mg/mL. Further dilute with  D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or lactated Ringer&rsquo;s to a final concentration not to exceed 80 mg/mL (manufacturer recommends 0.6-20 mg/mL). Administer as a slow I.V. intermittent infusion or continuous infusion; infusion times may vary by protocol; usually over at least 30 minutes; in most pediatric trials, usual infusion time was 2 hours or administer as a 24-hour infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F181834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, caspofungin, doripenem, doxorubicin liposome, etoposide phosphate, filgrastim, fludarabine, gallium nitrate, gemcitabine, granisetron, linezolid, melphalan, mesna, ondansetron, oxaliplatin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, propofol, sargramostim, sodium bicarbonate, teniposide, thiotepa, topotecan, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Epirubicin, mesna.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Mesna with epirubicin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); avoid temperatures &gt;30&deg;C (86&deg;F). Reconstituted solutions and diluted solutions for administration may be stored  for 24 hours under refrigeration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for injection: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Solutions diluted for administration are stable for 24 hours under refrigeration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of germ cell testicular cancer in combination with other antineoplastic agents (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     Should be used in combination with mesna for prophylaxis of hemorrhagic cystitis; has also been used in the treatment of Hodgkin and non-Hodgkin's lymphoma, Ewing sarcoma, osteosarcoma, and soft tissue sarcomas",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ifosfamide may be confused with cyclophosphamide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F181833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS toxicity or encephalopathy, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea/vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, liver dysfunction, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria (reduced with mesna), renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute respiratory distress syndrome, acute tubular necrosis, agranulocytosis, alkaline phosphatase increased, allergic reaction, alveolitis (allergic), amenorrhea, aminoaciduria, amnesia, anaphylactic reaction, angina, angioedema, anuria, arrhythmia, arthralgia, asterixis, atrial ectopy, atrial fibrillation/flutter, azoospermia, bladder irritation, bleeding, blurred vision, bone marrow failure, bradycardia, bradyphrenia, bronchospasm, bundle branch block, BUN increased, capillary leak syndrome, cardiac arrest, cardiogenic shock, cardiomyopathy, cardiotoxicity, catatonia, cecitis, chest pain, cholestasis, coagulopathy, colitis, conjunctivitis, creatinine clearance decreased/increased, creatinine increased, cylindruria, cytolytic hepatitis, delirium, delusion, dermatitis, diarrhea, DIC, DVT, dysesthesia, dyspnea, dysuria, echolalia, edema, ejection fraction decreased, enterocolitis, enuresis, enzymuria, erythema, extrapyramidal disorder, facial swelling, Fanconi syndrome, fatigue, gait disturbance, GGT increased, GI hemorrhage, glycosuria, gonadotropin increased, granulocytopenia, growth retardation (children), hemolytic anemia, hemolytic uremic syndrome, hemorrhagic cystitis, hepatic failure, hepatic sinusoidal obstruction syndrome (SOS; formerly veno-occlusive disease [VOD]), hepatitis fulminant, hepatitis (viral), hepatorenal syndrome, herpes zoster, hyperglycemia, hyper-/hypotension, hypersensitivity reactions, hypocalcemia, hypokalemia, hyponatremia, hypophosphatemia, hypoxia, ileus, immunosuppression, infertility, infusion site reactions (erythema, inflammation, pain, pruritus, swelling, tenderness), interstitial lung disease, jaundice, LDH increased, leukoencephalopathy, lymphopenia, malaise, mania, mental status change, methemoglobinemia, MI, mucosal inflammation/ulceration, multiorgan failure, mutism, myocardial hemorrhage, myocarditis, nephrogenic diabetes insipidus, neuralgia, neutropenia, oligospermia, oliguria, osteomalacia (adults), ovarian failure, ovulation disorder, palmar-plantar erythrodysesthesia syndrome, pancreatitis, pancytopenia, panic attack, paranoia, paresthesia, pericardial effusion, pericarditis, peripheral neuropathy, petechiae, phosphaturia, pleural effusion,",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia, pneumonia, pneumonitis, pollakiuria, polydipsia, polyneuropathy, polyuria, portal vein thrombosis, premature atrial contractions, premature menopause, progressive multifocal leukoencephalopathy, proteinuria, pruritus, pulmonary edema, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, QRS complex abnormal, radiation recall dermatitis, rash (including macular and papular), renal failure, renal parenchymal damage, renal tubular acidosis, respiratory failure, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, rickets, salivation, secondary malignancy, seizure, sepsis, septic shock, SIADH, skin necrosis, spermatogenesis impaired, status epilepticus, sterility, Stevens-Johnson syndrome, stomatitis, ST segment abnormal, supraventricular extrasystoles, tachycardia, tinnitus, toxic epidermal necrolysis, tubulointerstitial nephritis, tumor lysis syndrome, T-wave inversion, uremia, urticaria, vasculitis, ventricular extrasystoles/fibrillation/tachycardia, ventricular failure, vertigo, visual impairment, wound healing impairment",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ifosfamide or any component; urinary outflow obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function, bone marrow suppression, and prior radiation therapy; risk increased for toxicity development. Ifosfamide may interfere with wound healing.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Severe bone marrow suppression may occur (dose-limiting toxicity) and lead to fatal infections",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor blood counts before and after each cycle; leukopenia, neutropenia, thrombocytopenia, and anemia are associated with ifosfamide; myelosuppression is dose dependent, increased with single high doses (compared to fractionated doses) and increased withrenal dysfunction. Severe myelosuppression may occur when administered in combination with other chemotherapy agents or radiation therapy. Use with caution in patients with compromised bone marrow reserve; unless clinically necessary, avoid administering to patients with WBC &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Antimicrobial prophylaxis may be necessary in some neutropenic patients; administer antibiotics and/or antifungal agents for neutropenic fever. May cause significant suppression of the immune responses; may lead to serious infection, sepsis or septic shock; reported infections have included bacterial, viral, fungal, and parasitic; latent infections may be reactivated. Use with caution with other immunosuppressants or in patients with infection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ifosfamide may cause CNS toxicity which may be severe, resulting in encephalopathy and death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor for CNS toxicity; discontinue for encephalopathy. Symptoms of CNS toxicity may include somnolence, confusion, dizziness, disorientation, hallucinations, cranial nerve dysfunction, blurred vision, psychotic behavior, extrapyramidal symptoms, incontinence, seizures, and/or coma and have been observed within a few hours to a few days after initial dose, and generally resolves within 2-3 days of  treatment discontinuation (although may persist longer); maintain supportive care until complete resolution. Risk factors may include hypoalbuminemia, renal dysfunction, and prior history of ifosfamide-induced encephalopathy. Concomitant centrally acting medications may result in additive CNS effects. CNS effects may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Peripheral neuropathy has been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hemorrhagic cystitis may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; concomitant mesna reduces the risk of hemorrhagic cystitis. Hydration (at least 2 L/day in adults), dose fractionation, and/or mesna administration will reduce the incidence of hematuria and protect against hemorrhagic cystitis. Obtain urinalysis prior to each dose; if microscopic hematuria is detected, withhold until complete resolution. Exclude or correct urinary tract obstructions prior to treatment. Use with caution (if at all) in patients with active urinary tract infection, Hemorrhagic cystitis is dose-dependent and is increased with high single doses (compared with fractionated doses); past or concomitant bladder radiation or busulfan treatment may increase the risk for hemorrhagic cystitis. Ifosfamide may cause severe nephrotoxicity, resulting in renal failure",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; acute and chronic renal failure, as well as renal parenchymal and tubular necrosis (including acute), have been reported; tubular damage may be delayed and may persist. Renal manifestations include decreased glomerular rate, increased creatinine, proteinuria, enzymuria, cylindruria, aminoaciduria, phosphaturia, and glycosuria. Syndrome of inappropriate antidiuretic hormone (SIADH), renal rickets, and Fanconi syndrome have been reported. Evaluate renal function prior to and during treatment; monitor urine for erythrocytes and signs of urotoxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cardiotoxicity, possibly fatal, has been reported with ifosfamide use; manifestations include arrhythmias, ST-segment or T-wave changes, cardiomyopathy, pericardial effusion, pericarditis, and epicardial fibrosis. The risk for cardiotoxicity is dose-dependent; concomitant cardiotoxic agents (eg, anthracyclines), irradiation of the cardiac region, and renal impairment may also increase the risk. Interstitial pneumonitis, pulmonary fibrosis, and pulmonary toxicity leading to respiratory failure have been reported; monitor for signs and symptoms of pulmonary toxicity. Hepatic sinusoidal obstruction syndrome (SOS), formerly called veno-occlusive disease (VOD), has been reported with ifosfamide-containing regimens. Secondary malignancies may occur; the risk for myelodysplastic syndrome (which may progress to acute leukemia) is increased with treatment. Ifosfamide can cause fetal harm; advise women of childbearing potential to avoid becoming pregnant and men to avoid fathering a child for 6 months post-treatment. Anaphylactic/anaphylactoid reactions have been associated with ifosfamide; cross-sensitivity with similar agents may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (major), CYP2B6 (minor), CYP2C19 (major), CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: May enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk of hemorrhagic cystitis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inducers (Strong): May increase the metabolism of CYP2A6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inhibitors (Moderate): May decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inhibitors (Strong): May decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ifosfamide may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4811888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxic and teratogenic effects have been observed in animal reproduction studies. Fetal growth retardation and neonatal anemia have been reported with exposure to ifosfamide-containing regimens during human pregnancy. Male and female fertility may be affected (dose and duration dependent). Ifosfamide interferes with oogenesis and spermatogenesis; amenorrhea, azoospermia, and sterility have been reported and may be irreversible. Avoid pregnancy during treatment; male patients should not father a child for at least 6 months after completion of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (prior to each dose), urine output, urinalysis (prior to each dose), liver  and renal function tests, serum electrolytes, CNS changes, signs and symptoms of pulmonary toxicity, signs and symptoms of hemorrhagic cystitis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures; inhibits protein synthesis and DNA synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetics are dose-dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Approximates total body water; unchanged ifosfamide penetrates CNS but not in therapeutic concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Neglible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic to active metabolites isofosforamide mustard, 4-hydroxy-ifosfamide, acrolein, and inactive dichloroethylated and carboxy metabolites; acrolein is the agent implicated in development of hemorrhagic cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Low dose (1600-2400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High dose (3800-5000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): ~15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Low dose (1600-2400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Urine (12% to 18% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High dose (5000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Urine (70% to 86%; 61% as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/46/19173?source=see_link\">",
"      see \"Ifosfamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This drug can only be administered by infusion. Report immediately any swelling, redness, or pain at infusion site. Maintain adequate hydration, unless instructed to restrict fluid intake, for at least 3 days prior to infusion and each day of therapy. Susceptibility to infection increased. May cause loss of hair (reversible, although regrowth hair may be different color or texture), fertility or amenorrhea, nausea or vomiting, headache, or mouth sores. Report any difficulty or pain with urination, chest pain, rapid heartbeat, palpitations, CNS changes (eg, hallucinations, confusion, somnolence), unusual rash, persistent nausea or vomiting, swelling of extremities, respiratory difficulty, unusual fatigue, or opportunistic infection (eg, fever, chills, easy bruising, or unusual bleeding). Contraceptive measures are recommended during therapy.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bacci G, Briccoli A, Rocca M, et al, \"Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities With Metastases at Presentation: Recent Experience at the Rizzoli Institute in 57 Patients Treated With Cisplatin, Doxorubicin, and a High Dose of Methotrexate and Ifosfamide,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2003, 14(7):1126-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/12853357/pubmed\" id=\"12853357\" target=\"_blank\">",
"        12853357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Basaran M, Bavbek ES, Saglam S, et al, \"A Phase II Study of Cisplatin, Ifosfamide and Epirubicin Combination Chemotherapy in Adults With Nonmetastatic and Extremity Osteosarcomas,\"",
"      <i>",
"       Oncology",
"      </i>",
"      , 2007, 72(3-4):255-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/18185020/pubmed\" id=\"18185020\" target=\"_blank\">",
"        18185020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cairo MS, Davenport V, Bessmertny O, et al, \"Phase I/II Dose Escalation Study of Recombinant Human Interleukin-11 Following Ifosfamide, Carboplatin and Etoposide in Children, Adolescents and Young Adults With Solid Tumours or Lymphoma: A Clinical, Haematological and Biological Study,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 128(1):49-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/15606549/pubmed\" id=\"15606549\" target=\"_blank\">",
"        15606549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gentet JC, Brunat-Mentigny M, Demaille MC, et al, \"Ifosfamide and Etoposide in Childhood Osteosarcoma. A Phase II Study of the French Society of Paediatric Oncology,\"",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1997, 33(2):232-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/9135494/pubmed\" id=\"9135494\" target=\"_blank\">",
"        9135494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al, \"Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/12594313/pubmed\" id=\"12594313\" target=\"_blank\">",
"        12594313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griffin TC, Weitzman S, Weinstein H, et al, \"A Study of Rituximab and Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children With Recurrent/Refractory B-Cell (CD20+) Non-Hodgkin Lymphoma and Mature B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 52(2):177-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/18816698/pubmed\" id=\"18816698\" target=\"_blank\">",
"        18816698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juergens C, Weston C, Lewis I, et al, \"Safety Assessment of Intensive Induction With Vincristine, Ifosfamide, Doxorubicin, and Etoposide (VIDE) in the Treatment of Ewing Tumors in the EURO-E.W.I.N.G. 99 Clinical Trial,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2006, 47(1):22-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/16572419/pubmed\" id=\"16572419\" target=\"_blank\">",
"        16572419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kobrinsky NL, Sposto R, Shah NR, et al, \"Outcomes of Treatment of Children and Adolescents With Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease With Dexamethasone, Etoposide, Cisplatin, Cytarabine, and l-Asparaginase, Maintenance Chemotherapy, and Transplantation: Children's Cancer Group Study CCG-5912,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(9):2390-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/11331317/pubmed\" id=\"11331317\" target=\"_blank\">",
"        11331317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le Deley MC, Guinebreti&egrave;re JM, Gentet JC, et al, \"SFOP OS94: A Randomised Trial Comparing Preoperative High-Dose Methotrexate Plus Doxorubicin to High-Dose Methotrexate Plus Etoposide and Ifosfamide in Osteosarcoma Patients,\"",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2007, 43(4):752-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/17267204/pubmed\" id=\"17267204\" target=\"_blank\">",
"        17267204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milano GM, Cozza R, Ilari I, et al, \"High Histologic and Overall Response to Dose Intensification of Ifosfamide, Carboplatin, and Etoposide With Cyclophosphamide, Doxorubicin, and Vincristine in Patients With High-Risk Ewing Sarcoma Family Tumors: The Bambino Ges&ugrave; Children's Hospital Experience,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(8):1838-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/16532434/pubmed\" id=\"16532434\" target=\"_blank\">",
"        16532434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miser JS, Kinsella TJ, Triche TJ, et al, \"Ifosfamide With Mesna Uroprotection and Etoposide: An Effective Regimen in the Treatment of Recurrent Sarcomas and Other Tumors of Children and Young Adults,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1987, 5(8):1191-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/3114435/pubmed\" id=\"3114435\" target=\"_blank\">",
"        3114435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oberlin O, Fawaz O, Rey A, et al, \"Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5350-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/19826134/pubmed\" id=\"19826134\" target=\"_blank\">",
"        19826134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paulussen M, Ahrens S, Dunst J, et al, \"Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing's Sarcoma Study CESS 86,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(6):1818-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/11251014/pubmed\" id=\"11251014\" target=\"_blank\">",
"        11251014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paulussen M, Craft AW, Lewis I, et al, \"Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment - Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(27):4385-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/18802150/pubmed\" id=\"18802150\" target=\"_blank\">",
"        18802150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandlund JT, Pui CH, Mahmoud H, et al, \"Efficacy of High-Dose Methotrexate, Ifosfamide, Etoposide and Dexamethasone Salvage Therapy for Recurrent or Refractory Childhood Malignant Lymphoma,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2011, 22(2):468-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/20624787/pubmed\" id=\"20624787\" target=\"_blank\">",
"        20624787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Winkle P, Angiolillo A, Krailo M, et al, \"Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children's Cancer Group (CCG) Experience,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 44(4):338-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11800/abstract-text/15503297/pubmed\" id=\"15503297\" target=\"_blank\">",
"        15503297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13373 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11800=[""].join("\n");
var outline_f11_33_11800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708917\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181779\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181780\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047814\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047806\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181758\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181743\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047818\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181834\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047809\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047817\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136825\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181833\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047821\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047805\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047804\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181823\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181752\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181754\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4811888\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047813\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047803\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047820\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047811\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13373\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13373|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=related_link\">",
"      Ifosfamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/46/19173?source=related_link\">",
"      Ifosfamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_33_11801="Topical chemical burns";
var content_f11_33_11801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Topical chemical burns",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Sangeeta Kaushik, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Steven Bird, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/33/11801/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/33/11801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical burns, which are often work-related [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/1\">",
"     1",
"    </a>",
"    ], are unique injuries that require individualized treatment and management depending upon the causative agent. They account for 4 percent of admissions to burn units in developed countries and up to 14 percent in underdeveloped countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of chemicals are manufactured for household, agricultural, industrial, and military use, with an estimated 60,000 new chemicals produced each year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/3\">",
"     3",
"    </a>",
"    ]. For management of toxic exposures, it is helpful to organize these chemicals into general categories, keeping in mind that some have overlapping properties or incompletely understood pathophysiology.",
"   </p>",
"   <p>",
"    The evaluation and treatment of common topical chemical burns will be reviewed here with a focus on the basic principles of management. Thermal burns, chemical ingestions, chemical eye injuries, and agents used for chemical warfare are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40551?source=see_link\">",
"     \"Caustic esophageal injury in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4473?source=see_link\">",
"     \"Caustic esophageal injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=see_link\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potency and concentration of the toxic agent and the duration of contact primarily determine the degree of tissue destruction. Therefore, it is critical that treatment be started immediately. In the great majority of cases, the management of topical chemical burns consists of the following general steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ensure protection of rescuers and health care workers from exposure.",
"     </li>",
"     <li>",
"      Remove the patient from the area of exposure.",
"     </li>",
"     <li>",
"      Remove all clothing and jewelry.",
"     </li>",
"     <li>",
"      Brush any dry chemicals off the patient; any suitable instrument may be used (eg, dry brush, towel).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most important component of active therapy is irrigation of all wounds and areas of exposure thoroughly with copious amounts of water. Irrigation is begun at the site of contamination and the eyes and face, if they are involved or adjacent to the exposed area. Some experts suggest cleaning the exposed area with a mild soap following irrigation.",
"   </p>",
"   <p>",
"    There are a small number of exceptions to this approach. Among the few chemical toxins that should NOT be irrigated immediately with water are dry lime, phenols, concentrated hydrochloric acid (ie, muriatic acid), sulfuric acid, and elemental metals (eg, sodium, potassium, calcium oxide, magnesium, phosphorous). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Chemicals NOT treated with immediate water irrigation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients entering the medical system via emergency medical services (EMS) or other first responder systems (eg, fire department) are often decontaminated, including water irrigation, using portable decontamination units prior to entering the hospital. Decontamination may also be performed by hospital-based decontamination teams. Plans for the decontamination of patients exposed to hazardous substances are generally determined by the hospital's disaster planning committee and local and state emergency management departments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Protection of providers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating irrigation for patients with chemical burns, first responders and clinicians must don appropriate protective gear to prevent contamination or injury. The clothing and equipment needed to protect an individual from a chemical or biological threat depends upon the type of threat and the duration of exposure. In the United States (US), the Occupational Safety and Health Administration (OSHA) classification system is often used to describe the levels of personal protection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Level A: Maximal protection includes encapsulation boots and gloves and a self-contained breathing apparatus (SCBA).",
"     </li>",
"     <li>",
"      Level B: Non-encapsulating splash protective suit that is not airtight but provides full respiratory protection and SCBA.",
"     </li>",
"     <li>",
"      Level C: Splash suit and full or half-face respirator.",
"     </li>",
"     <li>",
"      Level D: Work clothes, boots, safety goggles, and gloves; no respiratory protection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Available equipment varies considerably among EMS systems and hospitals. For most hospital decontaminations of an unknown substance, OSHA believes the following protection is adequate for those working in the decontamination zone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Powered air-purifying respirator (PAPR) that provides a protection factor of 1000 combined with a 99.97 percent high-efficiency particulate air",
"      <span class=\"nowrap\">",
"       (HEPA)/organic",
"      </span>",
"      <span class=\"nowrap\">",
"       vapor/acid",
"      </span>",
"      gas respirator cartridges.",
"     </li>",
"     <li>",
"      Double layer protective gloves.",
"     </li>",
"     <li>",
"      Chemical resistant suit; suit openings are sealed with tape.",
"     </li>",
"     <li>",
"      Head covering with eye and face protection (if not part of respirator).",
"     </li>",
"     <li>",
"      Chemical protective boots.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A parent or other adult holding or helping a child who is being treated with decontamination should also don protective equipment appropriate for the agent involved and clinical circumstance. For those providing post-decontamination care, protection comparable to that used for infection control should be used (ie, gown, glove, mask).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Removal of chemical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete removal of the toxic chemical is essential. Tissue damage continues for as long as the chemical remains in contact with skin. Furthermore, destruction of the epidermis allows substances to reach the dermis, which is more permeable to chemical toxins and may permit systemic absorption. To ensure thorough decontamination, remove all clothing (including footwear and jewelry), brush off all dry agents, and begin irrigation with copious amounts of water immediately at the scene of exposure. Water irrigation is continued upon arrival at the emergency department (ED).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Irrigation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Basic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copious irrigation with water dilutes and removes the large majority of chemicals (a common mnemonic is: \"the solution to the pollution is dilution\"). A small number of chemicals should NOT be irrigated with water and these are discussed immediately below.",
"   </p>",
"   <p>",
"    When initiated in the field, water irrigation reduces burn severity and the length of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/7\">",
"     7",
"    </a>",
"    ]. Immediate water irrigation also represents the essential first aid for chemical burns of the skin and eye, reducing the risk for prolonged conjunctivitis and corneal ulceration.",
"   </p>",
"   <p>",
"    Moderately warm water in high volumes but at low pressures should be used for irrigation. High pressure irrigation should be avoided as it can splash chemicals on to unexposed areas and drive them deeper into tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/8\">",
"     8",
"    </a>",
"    ]. During cold weather, warmer water is needed to prevent hypothermia. Either a shower or a hose can be used.",
"   </p>",
"   <p>",
"    Irrigation should begin at the site of contamination and the eyes and face, if they are involved or adjacent to the exposed area. Decontamination of the face prevents further inhalation or ingestion of any toxin.",
"   </p>",
"   <p>",
"    Once imminent threats to human health and life are addressed, reasonable efforts to contain and mitigate environmental damage should be made. The effluent from decontamination is dilute following copious irrigation and generally does not pose an environmental threat. Many decontamination units include equipment to manage irrigation runoff, which can be collected and disposed of in an environmentally safe manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Skin irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence to guide the method and duration of water irrigation is lacking. For acid burns of the skin, we suggest continuous water irrigation until the pH of any exposed tissue becomes neutral. For alkali burns of the skin, we suggest the same approach, but a much longer period of irrigation is necessary. Two hours or more of continuous irrigation may be required before the pH of tissue exposed to a strong alkali returns to neutral. It is best to measure the pH approximately 10 to 15 minutes after stopping irrigation to ensure the measurement accurately reflects the presence of any residual chemical rather than the water used for irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutralization of alkali burns using a weak acid, such as 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    (household vinegar), may be a useful treatment, but further research is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Eye exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eye contact with acids or alkalis requires emergent evaluation and treatment to prevent permanent vision loss. Burn severity depends upon the agent involved, duration of exposure, and depth of penetration (",
"    <a class=\"graphic graphic_table graphicRef56411 \" href=\"UTD.htm?27/59/28604\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Alkaline substances usually cause more severe damage than acids because they saponify phospholipid membranes. This action leads to rapid epithelial cell death and caustic penetration into the eye. Concentrated ammonia can inflict severe injury to anterior ocular structures after less than one minute of exposure, and lye can cause deep eye injury within three to five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/10\">",
"     10",
"    </a>",
"    ]. Acid burns cause coagulation necrosis that may result in extensive corneal scarring and ulceration, possibly resulting in vision loss.",
"   </p>",
"   <p>",
"    Patients with chemical eye burns present with decreased vision, moderate to severe eye pain, blepharospasm (inability to open the eyelids), conjunctival redness, and photophobia. In severe cases of alkali exposure, the eye may appear white due to ischemia of the conjunctiva and scleral vessels (",
"    <a class=\"graphic graphic_picture graphicRef67858 \" href=\"UTD.htm?34/12/35023\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many solvents penetrate the cornea or eye only to a limited extent and irrigation longer than 15 to 30 minutes may not be necessary. However, with any significant ocular exposure to alkali or acid, ophthalmologists generally recommend continuous irrigation until a neutral pH is achieved in the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. Water or isotonic saline may be used. Irrigation initiated at the scene is continued at the emergency department.",
"   </p>",
"   <p>",
"    Once at the hospital, prolonged irrigation is best performed using intravenous tubing and a polymethylmethacrylate scleral lens (ie, Morgan&reg; lens) (",
"    <a class=\"graphic graphic_figure graphicRef51399 \" href=\"UTD.htm?28/19/28989\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74905 \" href=\"UTD.htm?25/57/26513\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63134 \" href=\"UTD.htm?39/43/40638\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53892 \" href=\"UTD.htm?20/54/21346\">",
"     picture 4",
"    </a>",
"    ). If a Morgan&reg; lens is not available, it is important to keep the eyelids retracted for maximal exposure of the conjunctiva and cornea. Irrigation should be less forceful if a concomitant globe rupture is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link\">",
"     \"Open globe injuries: Emergent evaluation and initial management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is often necessary to apply topical analgesics to an eye that has sustained a chemical injury to permit irrigation and examination.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/57/2963?source=see_link\">",
"     Proparacaine",
"    </a>",
"    (one to two drops of 0.5 percent) may be used; repeat doses may be needed. Intravenous analgesics should be used to supplement topical treatment as necessary.",
"   </p>",
"   <p>",
"    A \"normal\" eye pH depends upon the method of measurement. Typically a pH of 6.5 to 7.5 is considered normal, particularly if using pH paper. Urine dipsticks, which contain litmus paper, can be used safely to measure the ocular pH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/16\">",
"     16",
"    </a>",
"    ]. If only one eye is affected, the uninvolved eye should be used to determine the normal pH. Measurements of pH are generally taken at the fornix (region between the conjunctiva and the lower eyelid).",
"   </p>",
"   <p>",
"    Initial irrigation is performed continuously for 30 minutes before assessing pH. Thereafter, pH is reassessed every 15 to 30 minutes until it is in the neutral range. Occasionally, more than two hours may be required to achieve a neutral pH at the eye surface. The pH should be remeasured at 5 and 30 minutes after the completion of irrigation to confirm that a neutral pH has been maintained. If these measurements are abnormal, irrigation is performed for another 30 minutes and the process is continued until a neutral pH is achieved.",
"   </p>",
"   <p>",
"    Weak acids do not readily penetrate into the anterior chamber. Therefore, prolonged irrigation is not generally necessary. However, with alkali burns, irrigation should be continued for two to three hours regardless of the eye surface pH in order to normalize the pH of the anterior chamber. Once irrigation is complete, a broad spectrum topical antibiotic (eg, fluoroquinolone) should be applied to the eye following any alkali or other severe exposure. Immediate ophthalmologic consultation is mandatory for significant eye exposures. Severe burns occasionally require prolonged continuous irrigation, which may exceed 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemicals NOT treated with immediate water irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate water irrigation is contraindicated for a few chemicals because it causes a harmful exothermic (heat-producing) reaction or releases hazardous byproducts. Such chemicals include dry lime, phenol, muriatic acid (hydrochloric acid), concentrated sulfuric acid (52 to 100 percent), and metals such as elemental potassium and sodium (",
"    <a class=\"graphic graphic_table graphicRef70216 \" href=\"UTD.htm?32/14/33004\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dry lime",
"      </strong>",
"      should be brushed off the skin prior to irrigation. It contains calcium oxide, which reacts with water to form calcium hydroxide, a strong alkali. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Alkali'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      If water irrigation is begun inadvertently, it is important to stop as soon as the presence of dry lime is recognized and to brush off any remaining particles prior to restarting water irrigation. Intravenous pain medication is likely to be needed in such instances.",
"     </li>",
"     <li>",
"      <strong>",
"       Elemental metals",
"      </strong>",
"      and certain reactive metal compounds combust or release hazardous byproducts when exposed to water. Examples include: sodium, potassium, magnesium, phosphorous,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , cesium, and titanium tetrachloride. All fragments of such materials should be carefully removed with dry forceps and placed in a nonaqueous solution (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      ). Once this is done, the affected area should be covered with mineral oil (or a comparable nonaqueous solution) to prevent further exposure to air and moisture. The mineral oil may be wiped off and reapplied to ensure that any remaining metal fragments are removed. Surgical debridement may be necessary if fragments are embedded in the skin.",
"     </li>",
"     <li>",
"      <strong>",
"       Phenol",
"      </strong>",
"      is not readily soluble in water. Removal of phenol requires that it be wiped off the skin by sponges soaked in 50 percent polyethylene glycol (PEG). Decontamination may be started with large amounts of water until PEG is obtained. It is important to use copious amounts of water because dilute solutions of phenol are more rapidly absorbed through the skin. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Phenol (carbolic acid) and derivatives'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Muriatic acid",
"      </strong>",
"      is the name formerly given to an industrial strength, impure form of hydrochloric acid (&gt;35 percent) used in heavy-duty masonry cleaning, removal of mineral deposits, and reduction of pH in swimming pools. Sulfuric acid and muriatic acid produce extreme heat when combined with water. Whenever possible, patients contaminated with these agents should be treated with soap prior to irrigation. Any basic soap may be used. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Sulfuric acid",
"      </strong>",
"      is sold in highly concentrated (52 to 100 percent) solutions and is used to clear clogged drains. Dermal exposure can produce full thickness burns [",
"      <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/17\">",
"       17",
"      </a>",
"      ]. Sulfuric acid and muriatic acid produce extreme heat when combined with water. Whenever possible, these agents should be treated with soap or lime prior to irrigation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antidotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidotes do NOT play a major role in the treatment of most chemical burns. Water irrigation is of primary importance and should not to be delayed while an antidote is sought. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Irrigation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are a few toxic substances that require antidotal treatment. As an example, hydrofluoric acid burns cause intense pain and tissue destruction, as well as electrolyte abnormalities that may precipitate cardiac arrest. Calcium salts are the mainstay of treatment of hydrofluoric acid burns; the dose and route depend upon the clinical situation. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Hydrofluoric acid'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    White phosphorus is found in military explosives and fireworks. In the past, some toxicologists recommended treating white phosphorus burns with 1 or 2 percent copper sulfate solution along with copious water irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the copper solution can be toxic, and we do NOT recommend its use. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'White phosphorus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Burn assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical burns can be difficult to assess and burns that appear superficial may be associated with severe deep tissue injury. As a result, the extent of injury is often underestimated, leading to insufficient irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/18\">",
"     18",
"    </a>",
"    ]. To avoid such mistakes, we recommend that clinicians err on the side of treating with copious water irrigation. Frequent reexamination of the patient and all wounds should be performed with any chemical burn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic chemicals absorbed through the skin can cause systemic toxicity, and inhaled chemical vapors can cause both systemic toxicity and lung injury. Management of such exposures can be complex and we recommend that clinicians consult with a medical toxicologist or poison control center. (See",
"    <a class=\"local\" href=\"#H5572634\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of thermal burns from chemical exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical burns differ from thermal burns in that they continue to cause damage as long as some active component of the chemical remains in the wound [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/2\">",
"     2",
"    </a>",
"    ]. Chemical burns heal slowly and generally require a hospitalization period that is 30 percent longer than a thermal burn of comparable surface area and depth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other than the importance of immediate decontamination, including extensive water irrigation, the principles of management for chemical burns are similar to those for thermal injuries. These include rapid airway assessment and stabilization as indicated, fluid resuscitation, tetanus prophylaxis, and analgesia. Like thermal burns, chemical burns to a large body surface area can lead to significant fluid shifts requiring treatment with aggressive intravenous fluid resuscitation. Topical antibiotics should be applied to all nonsuperficial burns. The management of thermal burns is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SPECIFIC AGENTS AND TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inorganic and organic acids denature the skin's proteins, ultimately causing coagulation necrosis. The agent involved often determines the color of the coagulum. As examples, nitric acid causes a yellow eschar, while sulfuric acid causes a black or brown eschar. Initial treatment in the majority of cases consists of extensive irrigation with water. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Irrigation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hydrofluoric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrofluoric acid (HF) is a highly corrosive inorganic acid with numerous applications. It is widely used in glass etching, electronic industries, and cleaning solutions. When hydrofluoric acid contacts skin, it causes both local injury and a potentially fatal systemic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/19\">",
"     19",
"    </a>",
"    ]. Solutions with concentrations of 15 percent or greater cause symptoms immediately, while less concentrated solutions may take hours but remain capable of causing severe injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HF penetrates quickly through the epidermal layer into the dermis and deeper. Fluoride ions complex with calcium and magnesium, which can lead to hypocalcemia and hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. These electrolyte abnormalities and the direct cardiotoxic effects of fluoride ions contribute to the development of cardiac arrhythmias, which are the primary cause of death in HF burns [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Hypocalcemia may stimulate an efflux of potassium ions from cells resulting in hyperkalemia, and predisposing to cardiotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. QTc interval prolongation, due to hypokalemia, hypomagnesemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypocalcemia may be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H14#H14\">",
"     \"Acquired long QT syndrome\", section on 'Hypokalemia, hypomagnesemia, and hypocalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ophthalmic injury from topical HF exposure can be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/27\">",
"     27",
"    </a>",
"    ], and inhalation of HF vapor can cause severe pulmonary injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Management of hydrofluoric acid burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic hydrofluoric acid (HF) burns are treated with copious water irrigation and calcium. Calcium ions complex free fluoride ions to prevent further toxicity, and also help to correct cellular and systemic hypocalcemia. Initial treatment consists of applying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    gel (2.5 percent) to burned areas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commercially available calcium gel may be used or it can be made by mixing 3.5 grams of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    powder with approximately 140 g (5 oz) of water soluble surgical lubricant. The gel is massaged into the skin for 30 to 60 minutes. Topical calcium gel treatment may be repeated as necessary. The patient or clinician performing the massage should wear two pairs of surgical gloves.",
"   </p>",
"   <p>",
"    Many HF injuries occur on the hands and upper extremities. To treat hand burns, the gel can be put in a surgical glove, which is then placed on the patient's hand and used as a dressing over the burn. Inactivation of free fluoride ions by the calcium results in pain relief.",
"   </p>",
"   <p>",
"    If pain persists following a topical exposure despite initial treatment, 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    (0.5 mL per square cm of wound area) may be injected intradermally directly into and around the affected areas. Injection directly into digits is NOT recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/1\">",
"     1",
"    </a>",
"    ]. Resolution of pain suggests that treatment is successful, and generally occurs soon after injection.",
"   </p>",
"   <p>",
"    If within approximately one hour local pain is not adequately controlled by topical application or direct injection, calcium can be given via an artery or vein. Intraarterial injection of 10 to 15 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    in 40 mL of Ringer's lactate may be given via an arterial line in the affected extremity over three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/20\">",
"     20",
"    </a>",
"    ]. Arterial placement must be definitively confirmed (eg, arterial tracing on a pressure monitor) before injecting calcium gluconate, which is caustic to soft tissue. Alternatively, a mixture of 10 to 15 mL of 10 percent calcium gluconate and 3000 to 5000 IU of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be added to 40 mL of Ringer's lactate and instilled intravenously using a Bier block [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/1,18,20,31\">",
"     1,18,20,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immediate treatment using intraarterial injection or a Bier block may be necessary in the setting of large burns or burns involving concentrated hydrofluoric acid. This is best done in consultation with a medical toxicologist or a comparable expert. (See",
"    <a class=\"local\" href=\"#H5572634\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Systemic toxicity from hydrofluoric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;HF burns can lead to systemic toxicity resulting in severe electrolyte abnormalities, particularly hypocalcemia and hyperkalemia. Intravenous (IV) access, serum electrolyte concentrations, an electrocardiogram, and cardiac monitoring should be obtained in patients exposed to HF.",
"   </p>",
"   <p>",
"    Inhalational exposures may be severe and the airway of any patient with such an exposure should be rapidly assessed and managed as indicated. Patients with inhalation injuries are treated with oxygen and nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    (4 mL of 2.5 to 5 percent).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    is best avoided if rapid sequence intubation must be performed in the setting of HF exposure due to the possibility of hyperkalemia.",
"   </p>",
"   <p>",
"    If systemic toxicity is suspected (due to QTc prolongation, cardiac arrhythmia, or obvious systemic illness), calcium is administered intravenously.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     Calcium gluconate",
"    </a>",
"    can be given as 1000 mg (10 mL of a 10 percent solution) infused slowly over two to three minutes; several repeat doses may be necessary if profound hypocalcemia is present. In cases of systemic toxicity, we also give magnesium replacement (4 g IV over 20 minutes).",
"   </p>",
"   <p>",
"    There is a case report of severe fluoride intoxication from hydrofluoric acid exposure resulting in severe burns and recurrent ventricular fibrillation successfully treated with emergency hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/32\">",
"     32",
"    </a>",
"    ]. Hemodialysis is generally not considered standard treatment for HF acid toxicity. However, fluoride ions are renally excreted and therefore hemodialysis may be of benefit in the setting of renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Phenol (carbolic acid) and derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenol is a colorless or white solid but is often sold in liquid form. It has a strong sweet odor and is widely used in disinfectants and in the production of resins and plastics. It is readily absorbed through the skin and across the lungs when its vapor form is inhaled. Severe dermal burns from phenol can cause severe systemic toxicity and death.",
"   </p>",
"   <p>",
"    Phenol is only moderately soluble in water and swabbing merely spreads the chemical, increasing the area of absorption and thereby toxicity. The solvent polyethylene glycol (PEG) is used to remove phenol from the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/18\">",
"     18",
"    </a>",
"    ]. PEG can generally be found in hospital pharmacies or areas where phenol is used. After swabbing thoroughly with a 50 percent PEG 400 solution, exposed areas are then irrigated with copious amounts of water. Isopropanol or glycerol may be substituted if PEG is unavailable.",
"   </p>",
"   <p>",
"    The toxicity of phenol depends upon the free plasma concentration. Systemic toxicity most often manifests as central nervous system or cardiac abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/33\">",
"     33",
"    </a>",
"    ]. CNS dysfunction can manifest as agitation, seizures, or coma, while cardiac dysfunction generally manifests as hypotension or dysrhythmia. Phenol also demyelinates peripheral nerves and causes lysis of erythrocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     White phosphorus",
"    </span>",
"    &nbsp;&mdash;&nbsp;White phosphorus is a solid element that spontaneously ignites in air forming phosphorus pentoxide. White phosphorus is used as an incendiary agent in weapons and fireworks. Oxidation may produce yellow flame, while the production of white smoke indicates ongoing formation of phosphoric acid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/34\">",
"     34",
"    </a>",
"    ]. The corrosive action of phosphoric acids and the heat from their chemical reactions contribute to tissue damage.",
"   </p>",
"   <p>",
"    White phosphorus produces a combined chemical and thermal burn. Particles of white phosphorus that become embedded in wounds can continue to oxidize, causing tissue damage, until debrided, treated, or consumed. Systemic toxicity can lead to severe hypocalcemia or hypophosphatemia and hepatic necrosis. There is no reliable method to predict which patients will develop severe metabolic abnormalities. Death can occur from burns covering a total body surface area of only 10 to 15 percent. Serum calcium and phosphorus levels should be monitored for 48 to 72 hours while caring for these patients.",
"   </p>",
"   <p>",
"    Following the removal of all clothing, the initial management of white phosphorus injuries consists of copious water irrigation. White phosphorus particles embedded in wounds must be kept wet; particles will reignite if allowed to dry. Wounds should be covered with saline-soaked gauze to prevent drying. Immediate surgical debridement is often necessary and repeated debridements may be needed to remove all phosphorus particles.",
"   </p>",
"   <p>",
"    Animal studies demonstrate that vigorous water irrigation of white phosphorus wounds is superior to topical treatment with water soaked dressings, 3 percent copper sulfate solution, copper sulfate emulsion, or intralesional superoxide dismutase injection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Copper sulfate solution is no longer considered an antidote for white phosphorus burns and is potentially dangerous: it is readily absorbed via the wound and can cause acute renal failure, cardiovascular collapse, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/35\">",
"     35",
"    </a>",
"    ]. We recommend that copper sulfate NOT be used in the treatment of white phosphorous exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Alkali",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkali agents dissolve proteins and collagen resulting in the formation of soluble protein complexes and causing extensive tissue damage. The soluble protein complexes allow the alkali agent to penetrate deeper into tissues creating further damage and making irrigation more difficult. Alkali burns are notable for their degree of edema and fluid loss. Anhydrous ammonia and cement are among the more common causes of alkali burns. Initial treatment in the majority of cases consists of extensive irrigation with water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Anhydrous ammonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anhydrous ammonia is a colorless, pungent gas used extensively as a fertilizer and in the manufacturing of synthetic fibers and methamphetamine. The compound is usually stored as a pressurized liquid at -33&ordm; Celsius (-28&ordm; Fahrenheit). Exposures therefore often cause a combination of cold injury and alkali burn [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/36\">",
"     36",
"    </a>",
"    ]. Injuries to eyes and lungs are common. Symptom severity and tissue damage from dermal exposure are related to the concentration of hydroxyl ions. Severe anhydrous ammonia burns result in black, leathery tissue, while less severe burns are grey-yellow and softer.",
"   </p>",
"   <p>",
"    Anhydrous ammonia is extremely soluble in water and immediate treatment consists of copious water irrigation, once all clothing has been removed. Repeat irrigation should be performed every four to six hours for the first 24 hours. Eye exposures are treated with topical analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/57/2963?source=see_link\">",
"     proparacaine",
"    </a>",
"    one to two drops of 0.5 percent) and copious water irrigation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Eye exposure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Acute contact with high concentrations of ammonia damages the lung parenchyma via collagen degradation and other means and can produce laryngospasm and glottic edema. Mild pulmonary insults produce coughing, laryngitis, pharyngitis, or tracheobronchitis. Severe pulmonary injury results in pulmonary edema and bronchiectasis. We recommend early intubation for patients with significant facial or pharyngeal burns or signs of upper airway injury (eg, dyspnea, stridor, hoarseness, hemoptysis). There is no specific treatment for inhalation injury.",
"   </p>",
"   <p>",
"    Anhydrous ammonia is a key ingredient for illicit methamphetamine production in makeshift laboratories. Producers of illicit methamphetamine often steal anhydrous ammonia from storage areas (eg, farms, industrial refrigeration systems, railroad tanker cars). During thefts, exposure can occur when valves of storage containers are left open while ammonia is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"     \"Methamphetamine intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cement burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wet cement is a poorly recognized and under-reported cause of alkali burns. A cement mixture has an initial pH of 10 to 12 that may rise as high as 14 as hydrolysis occurs and the cement sets.",
"   </p>",
"   <p>",
"    Cement burn injuries occur most often on the lower legs and knees [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/38\">",
"     38",
"    </a>",
"    ]. Presenting symptoms generally occur several hours after exposure and include burning sensations, erythema, pain, and vesicle formation. Twelve to 48 hours later, partial to full thickness burns become evident [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/39\">",
"     39",
"    </a>",
"    ]. Treatment consists of copious water irrigation.",
"   </p>",
"   <p>",
"    Cement burns can be prevented by wearing appropriate skin protection. Many patients are unaware of the potential hazards of cement and fail to take preventive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Automobile airbag burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports document burns resulting from automobile airbag deployment. Airbags may occasionally perforate and release sodium azide or sodium hydroxide resulting in alkali chemical burns [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, damaged, deployed airbags may cause both chemical and thermal injury. Clinicians may underestimate the degree of injury from such wounds, which may require aggressive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/42\">",
"     42",
"    </a>",
"    ]. When treating patients with burns following airbag deployment, clinicians should ask the patient and paramedics whether the airbag was perforated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hydrocarbons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocarbons are ubiquitous. They can be found in a wide range of kitchen cleaning products, chemical solvents, and automobile products. Contact with gasoline and other hydrocarbons may cause dermatitis, itching, and inflammation. Significant burns and systemic toxicity may occur, especially in the setting of trauma, such as industrial or motor vehicle accidents.",
"   </p>",
"   <p>",
"    Hydrocarbons cause cell membrane injury and dissolution of lipids, which results in skin necrosis with prolonged exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/43\">",
"     43",
"    </a>",
"    ]. Most burns are superficial or partial thickness. However prolonged exposure may cause full thickness burns. Once skin damage has occurred, hydrocarbons are readily absorbed. This can result in systemic toxicity, including severe pulmonary, neurologic, renal, cardiovascular, and gastrointestinal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of dermal exposure consists of removal from the scene and decontamination, including copious water irrigation. The management of systemic hydrocarbon toxicity is beyond the scope of this review and should be undertaken with the assistance of a toxicologist. (See",
"    <a class=\"local\" href=\"#H5572634\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Tar and asphalt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tar is obtained from bituminous coal; asphalt is produced from crude petroleum. Both are used for paving and roofing. For construction use, both substances must be heated to high temperatures (approximately 140&ordm;C for paving; approximately 245&ordm;C for roofing). Thermal burns occur when heated tar or asphalt comes into contact with skin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/45\">",
"     45",
"    </a>",
"    ]. However, both tar and asphalt cool rapidly.",
"   </p>",
"   <p>",
"    Treatment at the scene of injury consists of accelerating cooling by immediately applying cold water. In the emergency department, tar and asphalt can be removed by applying any of several organic solvents. Solvents that have been used successfully include: polymyxin-neomycin-bacitracin (ie, Neosporin) ointment, which has the added benefit of infection prophylaxis, polyoxyethylene sorbitan, petrolatum, sunflower oil, olive oil, butter, and baby oil [",
"    <a class=\"abstract\" href=\"UTD.htm?11/33/11801/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several hourly reapplications of the solvent may be necessary to remove the tar or asphalt. For minor exposures without complications, this may be done as an outpatient with follow-up the next day. Once the wound is clean, thermal burns are treated in standard fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5572634\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of chemical exposures can be complex and we recommend clinicians consult with a medical toxicologist or poison control center about specific exposures. The United States (US) Poison Control Network can be accessed by calling 1-800-222-1222. The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The US Department of Transportation publishes an Emergency Response Guidebook to help first responders managing a chemical spill or exposure to identify specific agents, protect themselves, and protect the general public during the initial response (",
"    <a class=\"external\" href=\"file://www.phmsa.dot.gov/hazmat/library/erg\">",
"     www.phmsa.dot.gov/hazmat/library/erg",
"    </a>",
"    ). The handbook includes concise descriptions and tables for the initial management of many toxic chemicals.",
"   </p>",
"   <p>",
"    The US Department of Labor Occupational Safety and Health Administration publishes a handbook for hospital-based clinicians likely to provide initial care for those exposed to hazardous substances (",
"    <a class=\"external\" href=\"file://www.osha.gov/dts/osta/bestpractices/html/hospital_firstreceivers.html\">",
"     www.osha.gov/dts/osta/bestpractices/html/hospital_firstreceivers.html#appa2132",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/31/30193?source=see_link\">",
"       \"Patient information: Chemical eye injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The potency and concentration of the toxic agent and the duration of contact primarily determine the degree of tissue destruction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General approach'",
"      </a>",
"      above.) In the great majority of cases, the management of topical chemical burns consists of the following general steps:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ensure protection of rescuers and health care workers from exposure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Protection of providers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Remove the patient from the area of exposure.",
"     </li>",
"     <li>",
"      Remove all clothing and jewelry.",
"     </li>",
"     <li>",
"      Brush any dry chemicals off the patient; any suitable instrument may be used (eg, dry brush, towel).",
"     </li>",
"     <li>",
"      Irrigate exposed tissue with copious amounts of water. The details of skin and eye irrigation are discussed in the text. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Irrigation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete removal of the toxic chemical is essential. Tissue damage continues for as long as the chemical remains in contact with skin. Furthermore, destruction of the epidermis allows substances to reach the dermis, which is more permeable to chemical toxins and may permit systemic absorption.",
"     </li>",
"     <li>",
"      A small number of chemicals should NOT be treated with immediate water irrigation. These include dry lime, phenol, concentrated hydrochloric acid (muriatic acid), concentrated sulfuric acid (52 to 100 percent), and metals such as elemental potassium and sodium (",
"      <a class=\"graphic graphic_table graphicRef70216 \" href=\"UTD.htm?32/14/33004\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chemicals NOT treated with immediate water irrigation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemical burns can be difficult to assess and burns that appear superficial may be associated with severe deep tissue injury. As a result, the extent of injury is often underestimated, leading to insufficient irrigation. We recommend that clinicians err on the side of treating with copious water irrigation. Frequent reexamination of the patient and all wounds is crucial. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Burn assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other than the importance of immediate decontamination, the principles of management for chemical burns are similar to those for thermal injuries. These include rapid airway assessment and stabilization as indicated, fluid resuscitation, tetanus prophylaxis, topical antibiotics, and analgesia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"       \"Emergency care of moderate and severe thermal burns in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antidotes do NOT play a major role in the treatment of most chemical burns. Hydrofluoric acid is an important exception. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management of hydrofluoric acid burns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxic chemicals absorbed through the skin can cause systemic toxicity, and inhaled chemical vapors can cause both systemic toxicity and lung injury. Management of such exposures can be complex and we recommend that clinicians consult with a medical toxicologist or poison control center. (See",
"      <a class=\"local\" href=\"#H5572634\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alkali burns cause greater tissue destruction than comparable acid burns. The management of common chemical burns is described in the text. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Specific agents and treatments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1993086\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/1\">",
"      Pruitt VM. Work-related burns. Clin Occup Environ Med 2006; 5:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/2\">",
"      Eldad A, Weinberg A, Breiterman S, et al. Early nonsurgical removal of chemically injured tissue enhances wound healing in partial thickness burns. Burns 1998; 24:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/3\">",
"      Edlich RF, Farinholt HM, Winters KL, et al. Modern concepts of treatment and prevention of chemical injuries. J Long Term Eff Med Implants 2005; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     Chemical protective clothing; OSHA Technical Manual. www.osha.gov/dts/osta/otm/otm_viii/otm_viii_1.html (Accessed on January 06, 2009).",
"    </li>",
"    <li>",
"     Respiratory protection; OSHA Technical Manual. file://www.osha.gov/dts/osta/otm/otm_viii/otm_viii_2.html (Accessed on January 06, 2009).",
"    </li>",
"    <li>",
"     Conclusions regarding personal protective equipment; OSHA Best Practices for Hospital-based First Receivers of Victims from Mass Casualty Incidents Involving the Release of Hazardous Substances. www.osha.gov/dts/osta/bestpractices/html/hospital_firstreceivers.html#t3 (Accessed on January 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/7\">",
"      Leonard LG, Scheulen JJ, Munster AM. Chemical burns: effect of prompt first aid. J Trauma 1982; 22:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/8\">",
"      Harchelroad, F, Rottinghaus, D.  Chemical Burns. Emergency Medicine Reports 2008; 29:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/9\">",
"      Andrews K, Mowlavi A, Milner SM. The treatment of alkaline burns of the skin by neutralization. Plast Reconstr Surg 2003; 111:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/10\">",
"      Spector J, Fernandez WG. Chemical, thermal, and biological ocular exposures. Emerg Med Clin North Am 2008; 26:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/11\">",
"      Duffy B. Managing chemical eye injuries. Emerg Nurse 2008; 16:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/12\">",
"      Ikeda N, Hayasaka S, Hayasaka Y, Watanabe K. Alkali burns of the eye: effect of immediate copious irrigation with tap water on their severity. Ophthalmologica 2006; 220:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/13\">",
"      Fish R, Davidson RS. Management of ocular thermal and chemical injuries, including amniotic membrane therapy. Curr Opin Ophthalmol 2010; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/14\">",
"      Naradzay J, Barish RA. Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/15\">",
"      Knoop K, Trott A. Ophthalmologic procedures in the emergency department--Part I: Immediate sight-saving procedures. Acad Emerg Med 1994; 1:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/16\">",
"      Saari KM, Leinonen J, Aine E. Management of chemical eye injuries with prolonged irrigation. Acta Ophthalmol Suppl 1984; 161:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/17\">",
"      Bond SJ, Schnier GC, Sundine MJ, et al. Cutaneous burns caused by sulfuric acid drain cleaner. J Trauma 1998; 44:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/18\">",
"      Cartotto RC, Peters WJ, Neligan PC, et al. Chemical burns. Can J Surg 1996; 39:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/19\">",
"      Bartlett D. Dermal exposure to hydrofluoric acid causing significant systemic toxicity. J Emerg Nurs 2004; 30:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/20\">",
"      Wedler V, Guggenheim M, Moron M, et al. Extensive hydrofluoric acid injuries: a serious problem. J Trauma 2005; 58:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/21\">",
"      Dalamaga M, Karmaniolas K, Nikolaidou A, Papadavid E. Hypocalcemia, hypomagnesemia, and hypokalemia following hydrofluoric acid chemical injury. J Burn Care Res 2008; 29:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/22\">",
"      Sanz-Gall&eacute;n P, Nogu&eacute; S, Munn&eacute; P, Faraldo A. Hypocalcaemia and hypomagnesaemia due to hydrofluoric acid. Occup Med (Lond) 2001; 51:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/23\">",
"      Yamaura K, Kao B, Iimori E, et al. Recurrent ventricular tachyarrhythmias associated with QT prolongation following hydrofluoric acid burns. J Toxicol Clin Toxicol 1997; 35:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/24\">",
"      Bordelon BM, Saffle JR, Morris SE. Systemic fluoride toxicity in a child with hydrofluoric acid burns: case report. J Trauma 1993; 34:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/25\">",
"      McIvor ME, Cummings CE, Mower MM, et al. Sudden cardiac death from acute fluoride intoxication: the role of potassium. Ann Emerg Med 1987; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/26\">",
"      Baltazar RF, Mower MM, Reider R, et al. Acute fluoride poisoning leading to fatal hyperkalemia. Chest 1980; 78:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/27\">",
"      McCulley JP, Whiting DW, Petitt MG, Lauber SE. Hydrofluoric acid burns of the eye. J Occup Med 1983; 25:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/28\">",
"      Wing JS, Brender JD, Sanderson LM, et al. Acute health effects in a community after a release of hydrofluoric acid. Arch Environ Health 1991; 46:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/29\">",
"      Roblin I, Urban M, Flicoteau D, et al. Topical treatment of experimental hydrofluoric acid skin burns by 2.5% calcium gluconate. J Burn Care Res 2006; 27:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/30\">",
"      H&ouml;jer J, Personne M, Hult&eacute;n P, Ludwigs U. Topical treatments for hydrofluoric acid burns: a blind controlled experimental study. J Toxicol Clin Toxicol 2002; 40:861.",
"     </a>",
"    </li>",
"    <li>",
"     Su, Mark. Hydorfluoric acid and fluorides. In: Goldfrank's Toxicologic Emergencies, 8th edition, McGraw-Hill, New York 2006. p.1417.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/32\">",
"      Bj&ouml;rnhagen V, H&ouml;jer J, Karlson-Stiber C, et al. Hydrofluoric acid-induced burns and life-threatening systemic poisoning--favorable outcome after hemodialysis. J Toxicol Clin Toxicol 2003; 41:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/33\">",
"      Spiller HA, Quadrani-Kushner DA, Cleveland P. A five year evaluation of acute exposures to phenol disinfectant (26%). J Toxicol Clin Toxicol 1993; 31:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/34\">",
"      Barillo DJ, Cancio LC, Goodwin CW. Treatment of white phosphorus and other chemical burn injuries at one burn center over a 51-year period. Burns 2004; 30:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/35\">",
"      Barqouni L, Abu Shaaban N, Elessi K. Interventions for treating phosphorus burns. Cochrane Database Syst Rev 2012; 3:CD008805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/36\">",
"      Amshel CE, Fealk MH, Phillips BJ, Caruso DM. Anhydrous ammonia burns case report and review of the literature. Burns 2000; 26:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Anhydrous ammonia thefts and releases associated with illicit methamphetamine production--16 states, January 2000-June 2004. MMWR Morb Mortal Wkly Rep 2005; 54:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/38\">",
"      Poupon M, Caye N, Duteille F, Pannier M. Cement burns: retrospective study of 18 cases and review of the literature. Burns 2005; 31:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/39\">",
"      Spoo J, Elsner P. Cement burns: a review 1960-2000. Contact Dermatitis 2001; 45:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/40\">",
"      Lewis PM, Ennis O, Kashif A, Dickson WA. Wet cement remains a poorly recognised cause of full-thickness skin burns. Injury 2004; 35:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/41\">",
"      Suhr M, Kreusch T. Burn injuries resulting from (accidental) airbag inflation. J Craniomaxillofac Surg 2004; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/42\">",
"      Vitello W, Kim M, Johnson RM, Miller S. Full-thickness burn to the hand from an automobile airbag. J Burn Care Rehabil 1999; 20:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/43\">",
"      Hansbrough JF, Zapata-Sirvent R, Dominic W, et al. Hydrocarbon contact injuries. J Trauma 1985; 25:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/44\">",
"      Schneider MS, Mani MM, Masters FW. Gasoline-induced contact burns. J Burn Care Rehabil 1991; 12:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/45\">",
"      Baruchin AM, Schraf S, Rosenberg L, Sagi AA. Hot bitumen burns: 92 hospitalized patients. Burns 1997; 23:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/46\">",
"      T&uuml;reg&uuml;n M, Ozt&uuml;rk S, Selmanpako��lu N. Sunflower oil in the treatment of hot tar burns. Burns 1997; 23:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/47\">",
"      Tiernan E, Harris A. Butter in the initial treatment of hot tar burns. Burns 1993; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/48\">",
"      Juma A. Bitumen burns and the use of baby oil. Burns 1994; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/33/11801/abstract/49\">",
"      Bozkurt A, O'Dey D, Pallua N. Treatment of hot bitumen-contact-burn injuries. Burns 2008; 34:1053.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 345 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11801=[""].join("\n");
var outline_f11_33_11801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Protection of providers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Removal of chemical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Irrigation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Basic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Skin irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Eye exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemicals NOT treated with immediate water irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antidotes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Burn assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of thermal burns from chemical exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SPECIFIC AGENTS AND TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hydrofluoric acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Management of hydrofluoric acid burns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Systemic toxicity from hydrofluoric acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Phenol (carbolic acid) and derivatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - White phosphorus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Alkali",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Anhydrous ammonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cement burns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Automobile airbag burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hydrocarbons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Tar and asphalt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5572634\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1993086\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/345|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/19/28989\" title=\"figure 1\">",
"      Morgan lens close up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/345|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/12/35023\" title=\"picture 1\">",
"      Corneal alkali burn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/57/26513\" title=\"picture 2\">",
"      Morgan lens insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/43/40638\" title=\"picture 3\">",
"      Morgan lens flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/54/21346\" title=\"picture 4\">",
"      Morgan lens removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/59/28604\" title=\"table 1\">",
"      Chemicals associated with ocular burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/14/33004\" title=\"table 2\">",
"      Chemicals requiring specific decontamination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40551?source=related_link\">",
"      Caustic esophageal injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4473?source=related_link\">",
"      Caustic esophageal injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/31/30193?source=related_link\">",
"      Patient information: Chemical eye injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_33_11802="Risperidone: Drug information";
var content_f11_33_11802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Risperidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/27/21942?source=see_link\">",
"    see \"Risperidone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/5/32857?source=see_link\">",
"    see \"Risperidone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      RisperDAL&reg;;",
"     </li>",
"     <li>",
"      RisperDAL&reg; Consta&reg;;",
"     </li>",
"     <li>",
"      RisperDAL&reg; M-Tab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Risperidone&reg;;",
"     </li>",
"     <li>",
"      Ava-Risperidone;",
"     </li>",
"     <li>",
"      CO Risperidone;",
"     </li>",
"     <li>",
"      Dom-Risperidone;",
"     </li>",
"     <li>",
"      JAMP-Risperidone;",
"     </li>",
"     <li>",
"      Mint-Risperidon;",
"     </li>",
"     <li>",
"      Mylan-Risperidone;",
"     </li>",
"     <li>",
"      Novo-Risperidone;",
"     </li>",
"     <li>",
"      PHL-Risperidone;",
"     </li>",
"     <li>",
"      PMS-Risperidone;",
"     </li>",
"     <li>",
"      PMS-Risperidone ODT;",
"     </li>",
"     <li>",
"      PRO-Risperidone;",
"     </li>",
"     <li>",
"      RAN&trade;-Risperidone;",
"     </li>",
"     <li>",
"      ratio-Risperidone;",
"     </li>",
"     <li>",
"      Risperdal&reg;;",
"     </li>",
"     <li>",
"      Risperdal&reg; Consta&reg;;",
"     </li>",
"     <li>",
"      Risperdal&reg; M-Tab&reg;;",
"     </li>",
"     <li>",
"      Riva-Risperidone;",
"     </li>",
"     <li>",
"      Sandoz-Risperidone;",
"     </li>",
"     <li>",
"      Teva-Risperidone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimanic Agent;",
"     </li>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     When reinitiating treatment after discontinuation, the initial titration schedule should be followed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bipolar mania:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Recommended starting dose: 2-3 mg once daily; if needed, adjust dose by 1 mg daily in intervals &ge;24 hours; dosing range: 1-6 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: No dosing recommendation available for treatment &gt;3 weeks duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bipolar I maintenance:",
"     </b>",
"     <i>",
"      I.M. (Risperdal&reg; Consta&reg;):",
"     </i>",
"     25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5-50 mg); maximum dose: 50 mg every 2 weeks. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, demonstrated poor tolerability to other psychotropic medications).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral risperidone (or other antipsychotic) should be administered with the initial injection of Risperdal&reg; Consta&reg; and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site. When switching from depot administration to a short-acting formulation, administer short-acting agent in place of the next regularly-scheduled depot injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 2 mg daily in 1-2 divided doses; may be increased by 1-2 mg daily at intervals &ge;24 hours to a recommended dosage range of 4-8 mg daily; may be given as a single daily dose once maintenance dose is achieved; daily dosages &gt;6 mg do not appear to confer any additional benefit, and the incidence of extrapyramidal symptoms is higher than with lower doses. Further dose adjustments should be made in increments/decrements of 1-2 mg daily on a weekly basis. Dose range studied in clinical trials: 4-16 mg daily. Maintenance: Recommended dosage range: 2-8 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (Risperdal&reg; Consta&reg;):",
"     </i>",
"     Initial: 25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5-50 mg); maximum dose: 50 mg every 2 weeks. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, demonstrated poor tolerability to other psychotropic medications).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral risperidone (or other antipsychotic) should be administered with the initial injection of Risperdal&reg; Consta&reg; and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site. When switching from depot administration to a short-acting formulation, administer short-acting agent in place of the next regularly-scheduled depot injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Post-traumatic stress disorder (PTSD) (unlabeled use):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     0.5-8 mg daily (Bandelow, 2008; Benedek, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tourette's syndrome (unlabeled use):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 0.25 mg once daily for 2 days, then 0.25 mg twice daily for 3 days, then 0.5 mg twice daily for 2 days; titrate slowly thereafter in increments/decrements &le;0.5 mg twice daily and at intervals &ge;3 days; maximum dose: 6 mg daily (Dion, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F218683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/5/32857?source=see_link\">",
"      see \"Risperidone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     When reinitiating treatment after discontinuation, the initial titration schedule should be followed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Autism:",
"     </b>",
"     Children &ge;5 years and Adolescents:",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;15 kg: Use with caution; specific dosing recommendations not available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 to &lt;20 kg: Initial: 0.25 mg daily; may increase dose to 0.5 mg daily after &ge;4 days, maintain dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose by 0.25 mg daily in &ge;2-week intervals. Doses ranging from 0.5-3 mg daily have been evaluated; however, therapeutic effect reached plateau at 1 mg daily in clinical trials. Following clinical response, consider gradually lowering dose. May be administered once daily or in divided doses twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;20 kg: Initial: 0.5 mg daily; may increase dose to 1 mg daily after &ge;4 days, maintain dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose by 0.5 mg daily in &ge;2-week intervals. Doses ranging from 0.5-3 mg daily have been evaluated; however, therapeutic effect reached plateau at 2.5 mg daily (3 mg daily in children &gt;45 kg) in clinical trials. Following clinical response, consider gradually lowering dose. May be administered once daily or in divided doses twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bipolar mania:",
"     </b>",
"     Children and Adolescents 10-17 years:",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 0.5 mg once daily; dose may be adjusted in increments of 0.5-1 mg daily at intervals &ge;24 hours to a dose of 1-2.5 mg daily. Doses ranging from 0.5-6 mg daily have been evaluated; however doses &gt;2.5 mg daily do not confer additional benefit and are associated with increased adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: No dosing recommendation available for treatment &gt;3 weeks duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Adolescents 13-17 years:",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 0.5 mg once daily; dose may be adjusted in increments of 0.5-1 mg daily at intervals &ge;24 hours to a dose of 3 mg daily. Doses ranging from 1-6 mg daily have been evaluated, however, doses &gt;3 mg daily do not confer additional benefit and are associated with increased adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tourette's syndrome (unlabeled use):",
"     </b>",
"     Adolescents:",
"     <i>",
"      Oral:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Initial: 0.5 mg twice daily; titration should progress slowly in increments of no more than 0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should occur at intervals of &ge;1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Additional monitoring of renal function and orthostatic blood pressure may be warranted. If once-a-day dosing in the elderly or debilitated patient is considered, a twice daily regimen should be used to titrate to the target dose, and this dose should be maintained for 2-3 days prior to attempts to switch to a once-daily regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Psychosis/agitation related to Alzheimer&rsquo;s dementia  (unlabeled use): Initial: 0.25-1 mg daily; if necessary, gradually increase as tolerated not to exceed 1.5-2 mg daily; doses &gt;1 mg daily are associated with higher rates of extrapyramidal symptoms (Rabins, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. (Risperdal&reg; Consta&reg;): 25 mg every 2 weeks; a lower initial dose of 12.5 mg may be appropriate in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral risperidone (or other antipsychotic) should be administered with the initial injection of Risperdal&reg; Consta&reg; and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site. When switching from depot administration to a short-acting formulation, administer short-acting agent in place of the next regularly-scheduled depot injection.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F218665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Starting dose of 0.5 mg twice daily; titration should progress slowly in increments of no more than 0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should occur at intervals of &ge;1 week. Clearance of the active moiety is decreased by 60% in patients with moderate-to-severe renal disease (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute) compared to healthy subjects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.M.: Initiate with",
"     <b>",
"      oral",
"     </b>",
"     dosing (0.5 mg twice daily for 1 week then 2 mg daily for 1 week); if tolerated, begin 25 mg",
"     <b>",
"      I.M.",
"     </b>",
"     every 2 weeks; continue oral dosing for 3 weeks after the first I.M. injection. An initial I.M. dose of 12.5 mg may also be considered.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F218666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Child-Pugh class C: Starting dose of 0.5 mg twice daily; titration should progress slowly in increments of no more than 0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should occur at intervals of &ge;1 week. The mean free fraction of risperidone in plasma was increased by 35% in patients with hepatic impairment compared to healthy subjects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.M.: Initiate with",
"     <b>",
"      oral",
"     </b>",
"     dosing (0.5 mg twice daily for 1 week then 2 mg daily for 1 week); if tolerated, begin 25 mg",
"     <b>",
"      I.M.",
"     </b>",
"     every 2 weeks; continue oral dosing for 3 weeks after the first I.M. injection. An initial I.M. dose of 12.5 mg may also be considered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, microspheres for reconstitution, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; Consta&reg;: 12.5 mg, 25 mg, 37.5 mg, 50 mg [contains polylactide-co-glycolide; supplied in a dose-pack containing vial with active ingredient in microsphere formulation, prefilled syringe with diluent, needle-free vial access device, and 2 safety needles (a 21 G UTW  1-inch and a 20 G TW 2-inch)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 1 mg/mL (30 mL) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 0.25 mg, 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 1 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg;: 2 mg, 3 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 0.5 mg [contains phenylalanine 0.14 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 1 mg [contains phenylalanine 0.28 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 2 mg [contains phenylalanine 0.42 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 3 mg [contains phenylalanine 0.63 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RisperDAL&reg; M-Tab&reg;: 4 mg [contains phenylalanine 0.84 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F218635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral solution can be administered directly from the provided pipette or may be mixed with water, coffee, orange juice, or low-fat milk, but is",
"     <b>",
"      not compatible",
"     </b>",
"     with cola or tea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In children or adolescents experiencing somnolence, half the daily dose may be administered twice daily",
"     <b>",
"      or",
"     </b>",
"     the once-daily dose may be administered at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Risperdal&reg; M-Tab&reg; should not be removed from blister pack until administered. Do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet. Using dry hands, place immediately on tongue. Tablet will dissolve within seconds, and may be swallowed with or without liquid. Do not split or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Risperdal&reg; Consta&reg; should be administered into either the deltoid muscle or the upper outer quadrant of the gluteal area. Avoid inadvertent injection into vasculature. Injection should alternate between the two arms or buttocks. Do not combine two different dosage strengths into one single administration. Do not substitute any components of the dose-pack; administer with needle provided (1-inch needle for deltoid administration or 2-inch needle for gluteal administration).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of schizophrenia; treatment of acute mania or mixed episodes associated with bipolar I disorder (as monotherapy in children or adults, or in combination with lithium or valproate in adults); treatment of irritability/aggression associated with autistic disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Treatment of schizophrenia; maintenance treatment of bipolar I disorder in adults as monotherapy or in combination with lithium or valproate",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F218700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Tourette's syndrome; psychosis/agitation related to Alzheimer&rsquo;s dementia; post-traumatic stress disorder (PTSD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       RisperiDONE may be confused with reserpine, rOPINIRole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       RisperDAL&reg; may be confused with lisinopril, reserpine, Restoril&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sedation (children 12% to 63%; adults 5% to 11%), parkinsonism (children: 28% to 62%; adults 8% to 25%), somnolence (adults 5% to 41%; children 4% to 11%), insomnia (&le;32%), fatigue (children 18% to 31%; adults 1% to 9%), headache (12% to 21%), anxiety (&le;8% to 16%), dizziness (3% to 16%), fever (children 16%; adults 1% to 2%), akathisia (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased (children 4% to 44%; adults 4%), weight gain (&ge;7% kg increase from baseline: children 8% to 33%; adults 4% to 21%), vomiting (children 10% to 20%; adults &lt;4%), constipation (5% to 17%), nausea (5% to 16%), abdominal pain (children 6% to 16%; adults &lt;4%), drooling (children 12%; adults &lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary incontinence (children 5% to 22%; adults &lt;4%), enuresis (children 16%; adults &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (adults &le;24%; children &le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (children 19%; adults &le;4%), cough (children &le;17%; adults &le;4%), rhinorrhea (children 12%; adults &lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrioventricular block first degree (&lt;4%), bradycardia (&lt;4%), bundle branch block (&lt;4%), chest pain (&lt;4%), ECG changes (&lt;4%), facial edema (&lt;4%), hypotension (&lt;4%), orthostatic hypotension (&lt;4%), palpitation (&lt;4%), QT prolongation (&lt;4%), tachycardia (adults &lt;4%; children &lt;1%), hypertension (&le;3%), peripheral edema (&le;3%), syncope (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Gait disturbance (4%), pain (1% to 4%), attention span decreased (&le;4%), agitation (&lt;4%), akinesia (&lt;4%), coordination impaired (&lt;4%), depression (&lt;4%), malaise (&lt;4%), nervousness (&lt;4%), postural dizziness (&lt;4%), seizure (&lt;4%), sleep disturbances (&lt;4%), sluggishness (&lt;4%), vertigo (&lt;4%), lethargy (2%), hypoesthesia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&lt;4% to 8%), eczema (&lt;4%), pruritus (&lt;4%), dry skin (&le;3%), acne (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menorrhea (&le;4%), breast discomfort (&lt;4%), ejaculation disorder/delayed (&lt;4%), erectile dysfunction (&lt;4%), galactorrhea (&lt;4%), gynecomastia (&lt;4%), hyperglycemia (&lt;4%), hyperprolactinemia (&lt;4%), libido decreased (&lt;4%), menstrual irregularities (&lt;4%), sexual dysfunction (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (3% to 10%), xerostomia (&le;7% to 10%), salivation increased (1% to 10%), diarrhea (&lt;4% to 8%), appetite decreased (&le;6%), anorexia (&lt;1% to &lt;4%), weight loss (&le;4%), gastritis (&lt;4%), gastroenteritis (&lt;4%), toothache (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis (&lt;4%), glucosuria (&lt;4%), urinary tract infection (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (&lt;4%), neutropenia (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (&lt;4%), AST increased (&lt;4%), GGT increased (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess (&lt;4%); injection site induration, pain, reaction, swelling (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dystonia (2% to 6%), limb pain (2% to 6%), dyskinesia (adults &le;6%; children &lt;1%), arthralgia (2% to 4%), back pain (&le;4%), buttock pain (&lt;4%), dysarthria (&lt;4%), hypokinesia (&lt;4%), musculoskeletal chest pain (&lt;4%), myalgia (&lt;4%), neck pain (&lt;4%), paresthesia (&lt;4%), posture abnormal (&lt;4%), tardive dyskinesia (&lt;4%), weakness (&lt;4%), creatine phosphokinase increased (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (2% to 7%), conjunctivitis (&lt;4%), visual acuity reduced (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache (&le;4%), otitis media (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (&le;6% to 10%), pharyngolaryngeal pain (3% to 10%), rhinitis (&lt;4% to 9%), respiratory infection (&le;6% to 8%), bronchitis (&lt;4%), dyspnea (&lt;4%), pharyngitis (&lt;4%), pneumonia (&lt;4%), sinusitis (&lt;4%), epistaxis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Thirst (children &le;7%; adults &lt;1%), flu-like syndrome (&lt;4%), hypersensitivity (&lt;4%), infection (&lt;4%), viral infection (&lt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acarodermatitis, agranulocytosis, allergic reaction, alopecia, anaphylactic reaction, angioedema, antidiuretic hormone disorder, apnea, aspiration, atrial fibrillation, cerebral ischemia, cerebrovascular accident, cholestatic hepatitis, cholesterol increased, cholinergic syndrome, coma, cyst formation, delirium, diabetes mellitus, diabetic coma, diabetic ketoacidosis, diverticulitis, esophageal dysmotility, eye infection, eye swelling, fecal incontinence, fecaloma, glaucoma, granulocytopenia, hematoma, hemorrhage, hepatic failure, hepatocellular damage, hyperkeratosis, hypertonia, hypertriglyceridemia, hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hypothermia, intestinal obstruction, leukocytosis, leukopenia, leukorrhea, lower respiratory tract infection, lymphadenopathy, mania, migraine, myocardial infarction, myocarditis, necrosis, neuroleptic malignant syndrome (NMS), nystagmus, ocular hyperemia, pancreatitis, Pelger-Hu&euml;t anomaly, pituitary adenomas, precocious puberty, premature atrial contractions, priapism, pulmonary embolism, RBC disorders, renal insufficiency, retinal artery occlusion, retrograde ejaculation, rhabdomyolysis, skin ulceration, ST depression, stroke, superficial phlebitis, synostosis, temperature regulation impairment, thrombocytopenia, thrombophlebitis, thrombotic thrombocytopenic purpura, tongue paralysis, torticollis, transient ischemic attack, urinary retention, ventricular extrasystoles, ventricular tachycardia, water intoxication, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to risperidone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Use caution with history of conduction abnormalities. Relative to other neuroleptics, risperidone has a low risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, risperidone has a low potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of risperidone for the unapproved use in elderly patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyslipidemia: Has been reported with atypical antipsychotics; risk profile may differ between agents. Discrepant results have been reported in clinical trials, regarding lipid changes associated with risperidone (American Diabetes Association, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (eg, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Risperidone is associated with greater increases in prolactin levels as compared to other antipsychotic agents; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukopenia: Neutropenia has been reported with antipsychotic use, including fatal cases of agranulocytosis. Pre-existing myelosuppression (disease or drug-induced) increases risk and these patients should have frequent CBC monitoring; decreased blood counts in absence of other causative factors should prompt discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect (eg, concurrent medication use which may predispose to hypotension/bradycardia or presence of hypovolemia) or in those who would not tolerate transient hypotensive episodes. Use caution with history of cerebrovascular or cardiovascular disease (MI, heart failure, or ischemic disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Rare cases of priapism have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be low to moderately sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction or ischemic heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Risperidone is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; dosage reduction is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal disease; dosage reduction is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reyes syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:\",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vehicle used in injectable (polylactide-co-glycolide microspheres): Has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of RisperiDONE. Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: RisperiDONE may enhance the adverse/toxic effect of Paliperidone.  Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of RisperiDONE.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Limit or avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Oral solution is not compatible with beverages containing tannin or pectinate (cola or tea). Management: Administer oral solution with water, coffee, orange juice, or low-fat milk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may increase CNS depression. Management: Avoid kava kava, gotu kola, valerian, and St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2888768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     An increased risk of teratogenic effects was not observed in animal reproduction studies; however, an increase in pup mortality was observed following peri-postnatal exposure. In human studies, risperidone and its metabolite cross the placenta (Newport, 2007). An increased risk of teratogenic effects has not been observed following maternal use of risperidone (limited data) (Coppola, 2007).  Agenesis of the corpus callosum has been noted in one case report of an infant exposed",
"     <i>",
"      in utero",
"     </i>",
"     . Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization. When using Risperdal&reg; Consta&reg;, patients should notify healthcare provider if they become or intend to become pregnant during therapy or within 12 weeks of last injection. Risperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Healthcare providers are encouraged to enroll women 18-45 years of age exposed to risperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F218642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Risperidone and its metabolite are excreted in breast milk; it is recommended that women not breast-feed during therapy or for 12 weeks after the last injection if using Risperdal&reg; Consta&reg;.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (RisperDAL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (30 mL): $260.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (RisperiDONE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (30 mL): $152.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (RisperDAL Consta Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (1): $171.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $343.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (1): $515.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $687.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (RisperDAL M-TAB Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (28): $214.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (28): $250.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (28): $406.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (28): $513.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (28): $689.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (RisperiDONE M-TAB Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (28): $131.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (28): $154.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (28): $250.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (28): $316.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (28): $424.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (RisperiDONE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (30): $134.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (30): $147.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (28): $154.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (28): $250.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (28): $316.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (28): $424.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (RisperDAL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $667.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $732.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $778.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $1300.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $1527.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (60): $1231.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (RisperiDONE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (60): $234.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (60): $256.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (60): $273.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $456.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (60): $536.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (60): $719.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; fasting lipid profile and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually); CBC; BMI, personal/family history of obesity, waist circumference; blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms; orthostatic blood pressure changes for 3-5 days after starting or increasing dose. Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anxilet (TW);",
"     </li>",
"     <li>",
"      Aspidon (PH);",
"     </li>",
"     <li>",
"      Ispidon (PE);",
"     </li>",
"     <li>",
"      Neorisp (BG);",
"     </li>",
"     <li>",
"      Neripros (ID);",
"     </li>",
"     <li>",
"      Noprenia (ID);",
"     </li>",
"     <li>",
"      Persidal-2 (ID);",
"     </li>",
"     <li>",
"      Renuvie (PH);",
"     </li>",
"     <li>",
"      Ridal (SG);",
"     </li>",
"     <li>",
"      Rileptid (HK);",
"     </li>",
"     <li>",
"      Riper (TW);",
"     </li>",
"     <li>",
"      Riperidon (KP);",
"     </li>",
"     <li>",
"      Risdin (PH);",
"     </li>",
"     <li>",
"      Risdon (TW);",
"     </li>",
"     <li>",
"      Risfree (KP);",
"     </li>",
"     <li>",
"      Risoperin (KP);",
"     </li>",
"     <li>",
"      Rispa (AU);",
"     </li>",
"     <li>",
"      Risperdal (AE, AR, AT, AU, BD, BE, BF, BH, BJ, BO, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, NZ, OM, PE, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Risperdal Const (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Risperdal Consta (AU, CH, CL, DE, DO, GB, HK, ID, IE, IL, KP, MY, NZ, PE, PH, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Risperdal Quicklet (BB, BM, BS, BZ, DE, DO, GB, GY, HK, IE, IL, JM, NL, NZ, PH, PR, SG, SR, TH, TT);",
"     </li>",
"     <li>",
"      Risperdalconsta LP (FR);",
"     </li>",
"     <li>",
"      Risperidex (IL);",
"     </li>",
"     <li>",
"      Risperigamma (HK);",
"     </li>",
"     <li>",
"      Rispid (IN);",
"     </li>",
"     <li>",
"      Rispolept (RU);",
"     </li>",
"     <li>",
"      Rispolet (EE, PL);",
"     </li>",
"     <li>",
"      Rispolux (CR, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Rispond (IL, PH);",
"     </li>",
"     <li>",
"      Rispons (HK);",
"     </li>",
"     <li>",
"      Rixadone (AU);",
"     </li>",
"     <li>",
"      Sequinan (AR);",
"     </li>",
"     <li>",
"      Torendo (BG);",
"     </li>",
"     <li>",
"      Zargus (BR);",
"     </li>",
"     <li>",
"      Zofredal (ID);",
"     </li>",
"     <li>",
"      &Ntilde;orispez (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Risperidone is a benzisoxazole atypical antipsychotic with mixed serotonin-dopamine antagonist activity that binds to 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     -receptors in the CNS and in the periphery with a very high affinity; binds to dopamine-D",
"     <sub>",
"      2",
"     </sub>",
"     receptors with less affinity. The binding affinity to the dopamine-D",
"     <sub>",
"      2",
"     </sub>",
"     receptor is 20 times lower than the 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     affinity. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects. Alpha",
"     <sub>",
"      1",
"     </sub>",
"     , alpha",
"     <sub>",
"      2",
"     </sub>",
"     adrenergic, and histaminergic receptors are also antagonized with high affinity. Risperidone has low to moderate affinity for 5-HT",
"     <sub>",
"      1C",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors, weak affinity for D",
"     <sub>",
"      1",
"     </sub>",
"     and no affinity for muscarinics or beta",
"     <sub>",
"      1",
"     </sub>",
"     and beta",
"     <sub>",
"      2",
"     </sub>",
"     receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Rapid and well absorbed; food does not affect rate or extent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection: &lt;1% absorbed initially; main release occurs at ~3 weeks and is maintained from 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1-2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Risperidone 90%; 9-hydroxyrisperidone: 77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2D6 to 9-hydroxyrisperidone (similar pharmacological activity as risperidone);",
"     <i>",
"      N",
"     </i>",
"     -dealkylation is a second minor pathway",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 70%; Tablet (relative to solution): 94%; orally-disintegrating tablets and oral solution are bioequivalent to tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Active moiety (risperidone and its active metabolite 9-hydroxyrisperidone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 20 hours (mean)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extensive metabolizers: Risperidone: 3 hours; 9-hydroxyrisperidone: 21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Poor metabolizers: Risperidone: 20 hours; 9-hydroxyrisperidone: 30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection: 3-6 days; related to microsphere erosion and subsequent absorption of risperidone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: Risperidone: Within 1 hour; 9-hydroxyrisperidone: Extensive metabolizers: 3 hours; Poor metabolizers: 17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70%); feces (14%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo;",
"      <i>",
"       Obes Res",
"      </i>",
"      , 2004, 12(2):362-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/14981231/pubmed\" id=\"14981231\" target=\"_blank\">",
"        14981231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Armenteros JL, Whitaker AH, Welikson M, et al, &ldquo;Risperidone in Adolescents With Schizophrenia: An Open Pilot Study,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(5):694-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9136505/pubmed\" id=\"9136505\" target=\"_blank\">",
"        9136505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borison RL, Pathiraja AP, Diamond BI, et al, &ldquo;Risperidone: Clinical Safety and Efficacy in Schizophrenia,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 1992, 28(2):213-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/1381102/pubmed\" id=\"1381102\" target=\"_blank\">",
"        1381102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruggeman R, van der Linden C, Buitelaar JK, et al, &ldquo;Risperidone Versus Pimozide in Tourette's Disorder: A Comparative Double-Blind Parallel-Group Study,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2001, 62(1):50-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/11235929/pubmed\" id=\"11235929\" target=\"_blank\">",
"        11235929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buitelaar JK, &ldquo;Open-Label Treatment With Risperidone of 26 Psychiatrically-Hospitalized Children and Adolescents With Mixed Diagnoses and Aggressive Behavior,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):19-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/10755578/pubmed\" id=\"10755578\" target=\"_blank\">",
"        10755578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al, &ldquo;A Randomized Controlled Trial of Risperidone in the Treatment of Aggression in Hospitalized Adolescents With Subaverage Cognitive Abilities,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2001, 62(4):239-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/11379837/pubmed\" id=\"11379837\" target=\"_blank\">",
"        11379837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Byerly MJ, Greer RA, and Evans DL &ldquo;Behavioral Stimulation Associated With Risperidone Initiation,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(7):1096-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7540799/pubmed\" id=\"7540799\" target=\"_blank\">",
"        7540799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cardoni AA, &ldquo;Risperidone: Review and Assessment of Its Role in the Treatment of Schizophrenia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(6):610-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7545034/pubmed\" id=\"7545034\" target=\"_blank\">",
"        7545034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen LJ, &ldquo;Risperidone,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1994, 14(3):253-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7524043/pubmed\" id=\"7524043\" target=\"_blank\">",
"        7524043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coppola D, Russo LJ, Kwarta RF Jr, et al, \"Evaluating the Postmarketing Experience of Risperidone Use During Pregnancy: Pregnancy and Neonatal Outcomes,\"",
"      <i>",
"       Drug Saf,",
"      </i>",
"      2007, 30(3):247-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/17343431/pubmed\" id=\"17343431\" target=\"_blank\">",
"        17343431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dave M, &ldquo;Two Cases of Risperidone-Induced Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(8):1233-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7542837/pubmed\" id=\"7542837\" target=\"_blank\">",
"        7542837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis JM, Chen N, and Glick ID, &ldquo;A Meta-Analysis of the Efficacy of Second-Generation Antipsychotics,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2003, 60(6):553-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/12796218/pubmed\" id=\"12796218\" target=\"_blank\">",
"        12796218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dion Y, Annable L, Sandor P, et al, &ldquo;Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2002, 22(1):31-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/11799340/pubmed\" id=\"11799340\" target=\"_blank\">",
"        11799340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon L, Perkins D, and Calmes C,",
"      <i>",
"       Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia",
"      </i>",
"      , Arlington, Va: American Psychiatric Association, 2009. Available at file://www.psychiatryonline.com/content.aspx?aid=501001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Maxwell K, and Wiznitzer M, &ldquo;An Open Clinical Trial of Risperidone Monotherapy in Young Children With Autistic Disorder,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 1997, 33(1):155-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9133768/pubmed\" id=\"9133768\" target=\"_blank\">",
"        9133768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, McNamara NK, Branicky LA, et al, &ldquo;A Double-Blind Pilot Study of Risperidone in the Treatment of Conduct Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2000, 39(4):509-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/10761354/pubmed\" id=\"10761354\" target=\"_blank\">",
"        10761354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisman S and Steele M, &ldquo;Use of Risperidone in Pervasive Developmental Disorders: A Case Series,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1996, 6(3):177-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9231311/pubmed\" id=\"9231311\" target=\"_blank\">",
"        9231311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frazier JA, Meyer MC, Biederman J, et al, &ldquo;Risperidone Treatment for Juvenile Bipolar Disorder: A Retrospective Chart Review,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1999, 38(8):960-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/10434487/pubmed\" id=\"10434487\" target=\"_blank\">",
"        10434487",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gelders YG, &ldquo;Thymosthenic Agents, a Novel Approach in the Treatment of Schizophrenia,&rdquo;",
"      <i>",
"       Br J Psychiatry Suppl",
"      </i>",
"      , 1989, 5:33-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/2481482/pubmed\" id=\"2481482\" target=\"_blank\">",
"        2481482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goss JB, &ldquo;Concomitant Use of Thioridazine With Risperidone,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(9):1012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7543812/pubmed\" id=\"7543812\" target=\"_blank\">",
"        7543812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grcevich SJ, Findling RL, Rowane WA, et al, &ldquo;Risperidone in the Treatment of Children and Adolescents With Schizophrenia: A Retrospective Study,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1996, 6(4):251-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9231318/pubmed\" id=\"9231318\" target=\"_blank\">",
"        9231318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hardan A, Johnson K, Johnson C, et al, &ldquo;Case Study: Risperidone Treatment of Children and Adolescents With Developmental Disorders,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1996, 35(11):1551-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/8936923/pubmed\" id=\"8936923\" target=\"_blank\">",
"        8936923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumra S, Herion D, Jacobsen LK, et al, &ldquo;Case Study: Risperidone-Induced Hepatotoxicity in Pediatric Patients,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(5):701-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9136506/pubmed\" id=\"9136506\" target=\"_blank\">",
"        9136506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lombroso PJ, Scahill L, King RA, et al, &ldquo;Risperidone Treatment of Children and Adolescents With Chronic Tic Disorders: A Preliminary Report,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1995, 34(9):1147-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7559308/pubmed\" id=\"7559308\" target=\"_blank\">",
"        7559308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCracken JT, McGough J, Shah B, et al, &ldquo;Risperidone in Children With Autism and Serious Behavioral Problems,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(5):314-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/12151468/pubmed\" id=\"12151468\" target=\"_blank\">",
"        12151468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDougle CJ, Holmes JP, Bronson MR, et al, &ldquo;Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective Open-Label Study,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(5):685-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9136504/pubmed\" id=\"9136504\" target=\"_blank\">",
"        9136504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meylan C, Bondolfi G, Aubert AC, et al, &ldquo;Reversible Neutropenia During a Cold: Possible Involvement of Risperidone? A Case Report,&rdquo;",
"      <i>",
"       Eur Neuropsychopharmacol",
"      </i>",
"      , 1995, 5(1):1-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newport DJ, Calamaras MR, DeVane CL, et al, &ldquo;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(8):1214-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/17671284/pubmed\" id=\"17671284\" target=\"_blank\">",
"        17671284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicolson R, Awad G, and Sloman L, &ldquo;An Open Trial of Risperidone in Young Autistic Children,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(4):372-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9549957/pubmed\" id=\"9549957\" target=\"_blank\">",
"        9549957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry R, Pataki C, Munoz-Silva DM, et al, &ldquo;Risperidone in Children and Adolescents With Pervasive Developmental Disorder: Pilot Trial and Follow-Up,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1997, 7(3):167-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9466234/pubmed\" id=\"9466234\" target=\"_blank\">",
"        9466234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandor P and Stephens RJ, &ldquo;Risperidone Treatment of Aggressive Behavior in Children With Tourette Syndrome,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2000, 20(6):710-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/11106151/pubmed\" id=\"11106151\" target=\"_blank\">",
"        11106151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneider LS, Tariot PN, Dagerman KS, et al, &ldquo;Effectiveness of Atypical Antipsychotic Drugs in Patients With Alzheimer's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(15):1525-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/17035647/pubmed\" id=\"17035647\" target=\"_blank\">",
"        17035647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schreier HA, &ldquo;Risperidone for Young Children With Mood Disorders and Aggressive Behavior,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1998, 8(1):49-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/9639079/pubmed\" id=\"9639079\" target=\"_blank\">",
"        9639079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singer S, Richards C, and Boland RJ, &ldquo;Two Cases of Risperidone-Induced Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(8):1234.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7542838/pubmed\" id=\"7542838\" target=\"_blank\">",
"        7542838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swanson CL Jr, Price WA, and McEvoy JP, &ldquo;Effects of Concomitant Risperidone and Lithium Treatment,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(7):1096.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7540798/pubmed\" id=\"7540798\" target=\"_blank\">",
"        7540798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tang J, and Weiter JJ, &ldquo;Branch Retinal Artery Occlusion After Injection of a Long-Acting Risperidone Preparation,&rdquo;",
"      <i>",
"       Annals Intern Med",
"      </i>",
"      , 2007, 147(4): 283-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/17709768/pubmed\" id=\"17709768\" target=\"_blank\">",
"        17709768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tekell JL, Smith EA, and Silva JA, &ldquo;Prolonged Erection Associated With Risperidone Treatment,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(7):1097.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/33/11802/abstract-text/7540800/pubmed\" id=\"7540800\" target=\"_blank\">",
"        7540800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9868 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11802=[""].join("\n");
var outline_f11_33_11802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709402\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218658\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218659\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218704\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218663\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218683\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218664\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218665\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218666\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218631\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218617\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218635\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218634\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218700\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218713\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218702\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218638\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218621\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218697\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218625\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218655\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218627\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2888768\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218670\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218642\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218643\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218641\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218629\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218644\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218620\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218637\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9868\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9868|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/27/21942?source=related_link\">",
"      Risperidone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/5/32857?source=related_link\">",
"      Risperidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_33_11803="Risk factors for smoking initiation";
var content_f11_33_11803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected risk factors for tobacco use in children and adolescents that are potentially modifiable",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Individual factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Family/social factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"       <td>",
"        Parent/household smokers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor academic performance or learning disability",
"       </td>",
"       <td>",
"        No home smoking restriction policy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicotine dependence (which develops in some individuals after smoking as few as 100 cigarettes)",
"       </td>",
"       <td>",
"        Lack of parental supervision/family management issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antisocial behavior",
"       </td>",
"       <td>",
"        Family conflict and communication issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol or other substance abuse",
"       </td>",
"       <td>",
"        Adverse experiences (eg, parental separation or divorce, abuse)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11803=[""].join("\n");
var outline_f11_33_11803=null;
var title_f11_33_11804="AUDIT";
var content_f11_33_11804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AUDIT",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        How often did you have a",
"drink containing alcohol in the past year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider a drink to be a can or bottle of beer, a glass of",
"wine, a wine cooler, or one cocktail or a shot of hard liquor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Response:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Never: 0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monthly or less: 1 point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 to 4 times per month: 2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 to 3 times per week: 3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4 or more times per week: 4 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        How many drinks did you have",
"on a typical day when you were drinking in the past year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Response:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-2 drinks: 0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 to 4 drinks: 1 point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5 to 6 drinks: 2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7 to 9 drinks: 3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 or more drinks: 4 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        How often did you have 6 or",
"more drinks on one occasion in the past year?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Response:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Never: 0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Less than monthly: 1",
"point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monthly: 2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weekly: 3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daily or almost daily: 4 points",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A cutoff of 4 points or more identified 86 percent of patients with heavy drinking and/or active alcohol abuse or dependence with a specificity of 72 percent (false positive rate 18 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bush, K, Kivlahan, DR, McDonell, MB, et al. The AUDIT Alcohol Consumption Questions: An effective brief screening test for problem drinking. Arch Intern Med 1998; 158:1789.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11804=[""].join("\n");
var outline_f11_33_11804=null;
var title_f11_33_11805="Segmental potassium handling";
var content_f11_33_11805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Segmental handling of potassium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 159px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of K+ handling by the rat kidney as a function of the length of the proximal tubule and the cortical distal nephron (which mostly includes the cortical collecting tubule). Each point in these micropuncture experiments represents a separate sample. A reduction in the CK+/Cin ratio indicates reabsorption (as occurs in the proximal tubule), whereas an elevation in the ratio indicates secretion (as occurs in the cortical collecting tubule). The function of the loop of Henle and the medullary collecting tubule can be estimated from the difference between late proximal and early distal samples, and the difference between late distal and ureteral urine samples, respectively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Malnic, G, Klose, RM, Giebisch, G, Am J Physiol 1966; 211:529.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11805=[""].join("\n");
var outline_f11_33_11805=null;
var title_f11_33_11806="Pediatric version DASH diet";
var content_f11_33_11806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DASH (Dietary Approaches to Stop Hypertension) Diet: Servings per day by food group and total daily caloric intake",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food group",
"       </td>",
"       <td class=\"subtitle1\">",
"        1200 calories",
"       </td>",
"       <td class=\"subtitle1\">",
"        1400 calories",
"       </td>",
"       <td class=\"subtitle1\">",
"        1600 calories",
"       </td>",
"       <td class=\"subtitle1\">",
"        1800 calories",
"       </td>",
"       <td class=\"subtitle1\">",
"        2000 calories",
"       </td>",
"       <td class=\"subtitle1\">",
"        2600 calories",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serving sizes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples and notes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Significance of each food group to the DASH eating plan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grains*",
"       </td>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6-8",
"       </td>",
"       <td>",
"        10-11",
"       </td>",
"       <td>",
"        <p>",
"         1 slice bread",
"        </p>",
"        <p>",
"         1 oz dry cereal",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         1/2 cup cooked rice, pasta, or cereal",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        Whole wheat, bread and rolls, whole wheat pasta, English muffin, pita bread, bagel, cereals, grits, oatmeal, brown rice, unsalted pretzels, popcorn",
"       </td>",
"       <td>",
"        Major sources of energy and fiber",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vegetables",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        <p>",
"         1 cup raw leafy vegetable",
"        </p>",
"        <p>",
"         1/2 cup cut-up raw or cooked vegetable",
"        </p>",
"        <p>",
"         1/2 cup vegetable juice",
"        </p>",
"       </td>",
"       <td>",
"        Broccoli, carrots, collards, green beans, green peas, kale, lima beans, potatoes, spinach, squash, sweet potatoes, tomatoes",
"       </td>",
"       <td>",
"        Rich sources of potassium, magnesium, and fiber",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fruits",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        <p>",
"         1 medium fruit",
"        </p>",
"        <p>",
"         1/4 cup dried fruit",
"        </p>",
"        <p>",
"         1/2 cup fresh, frozen, or canned fruit",
"        </p>",
"        <p>",
"         1/2 cup fruit juice",
"        </p>",
"       </td>",
"       <td>",
"        Apples, apricots, bananas, dates, grapes, oranges, grapefruit, grapefruit juice, mangoes, melons, peaches, pineapples, raisins, strawberries, tangerines",
"       </td>",
"       <td>",
"        Important sources of potassium, magnesium, and fiber",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fat-free or low-fat milk and milk products",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        <p>",
"         1 cup milk or yogurt",
"        </p>",
"        <p>",
"         1.5 oz cheese",
"        </p>",
"       </td>",
"       <td>",
"        Fat-free milk or buttermilk, fat-free, low-fat, or reduced-fat cheese, fat-free/low-fat regular or frozen yogurt",
"       </td>",
"       <td>",
"        Major sources of calcium and protein",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lean meats, poultry, and fish",
"       </td>",
"       <td>",
"        3 or less",
"       </td>",
"       <td>",
"        3-4 or less",
"       </td>",
"       <td>",
"        3-4 or less",
"       </td>",
"       <td>",
"        6 or less",
"       </td>",
"       <td>",
"        6 or less",
"       </td>",
"       <td>",
"        6 or less",
"       </td>",
"       <td>",
"        <p>",
"         1 oz cooked meats, poultry, or fish",
"        </p>",
"        <p>",
"         1 egg",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        Select only lean; trim away visible fats; broil, roast, or poach; remove skin from poultry",
"       </td>",
"       <td>",
"        Rich sources of protein and magnesium",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Nuts, seeds, and legumes",
"       </td>",
"       <td>",
"        3 per week",
"       </td>",
"       <td>",
"        3 per week",
"       </td>",
"       <td>",
"        3-4 per week",
"       </td>",
"       <td>",
"        4 per week",
"       </td>",
"       <td>",
"        4-5 per week",
"       </td>",
"       <td>",
"        1 per day",
"       </td>",
"       <td>",
"        <p>",
"         1/3 cup or 1.5 oz nuts",
"        </p>",
"        <p>",
"         2 Tbsp peanut butter",
"        </p>",
"        <p>",
"         2 Tbsp or 1/2 oz seeds",
"        </p>",
"        <p>",
"         1/2 cup cooked legumes (dry beans and peas)",
"        </p>",
"       </td>",
"       <td>",
"        Almonds, filberts, mixed nuts, peanuts, walnuts, sunflower seeds, peanut butter, kidney beans, lentils, split peas",
"       </td>",
"       <td>",
"        Rich sources of energy, magnesium, protein, and fiber",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fats and oils",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        <p>",
"         1 tsp soft margarine",
"        </p>",
"        <p>",
"         1 tsp vegetable oil",
"        </p>",
"        <p>",
"         1 Tbsp mayonnaise",
"        </p>",
"        <p>",
"         2 Tbsp salad dressing",
"        </p>",
"       </td>",
"       <td>",
"        Soft margarine, vegetable oil (such as canola, corn, olive, or safflower), low-fat mayonnaise, light salad dressing",
"       </td>",
"       <td>",
"        The DASH study had 27 percent of calories as fat, including fat in or added to foods",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sweets and added sugars",
"       </td>",
"       <td>",
"        3 or less per week",
"       </td>",
"       <td>",
"        3 or less per week",
"       </td>",
"       <td>",
"        3 or less per week",
"       </td>",
"       <td>",
"        5 or less per week",
"       </td>",
"       <td>",
"        5 or less per week",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        <p>",
"         1 Tbsp sugar",
"        </p>",
"        <p>",
"         1 Tbsp jelly or jam",
"        </p>",
"        <p>",
"         1/2 cup sorbet, gelatin",
"        </p>",
"        <p>",
"         1 cup lemonade",
"        </p>",
"       </td>",
"       <td>",
"        Fruit-flavored gelatin, fruit punch, hard candy, jelly, maple syrup, sorbet and ices, sugar",
"       </td>",
"       <td>",
"        Sweets should be low in fat",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The Food and Drug Administration (FDA) and the Environmental Protection Agency are advising women of childbearing age who may become pregnant, pregnant women, nursing mothers, and young children to avoid some types of fish and shellfish and eat fish and shellfish that are low in mercury. For more information, call the FDA's food information line toll free at 1-888-SAFEFOOD or visit file://www.cfsan.fda.gov/~dms/admehg3.html.",
"    <div class=\"footnotes\">",
"     oz: ounce; Tbsp: tablespoon; tsp: teaspoon.",
"     <br>",
"      * Whole grains are recommended for most grain servings as a good source of fiber and nutrients.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Serving sizes vary between 1/2 cup and 1-1/4 cups, depending on cereal type. Check product's Nutrition Facts label.",
"       <br>",
"        &Delta; Since eggs are high in cholesterol, limit egg yolk intake to no more than four per week; two egg whites have the same protein content as 1 oz meat.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Fat content changes serving amount for fats and oils. For example, 1 Tbsp regular salad dressing = 1 serving; 1 Tbsp low-fat dressing = 1/2 serving; 1 Tbsp fat-free dressing = zero servings.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report.",
"     <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm#chap5\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm#chap5",
"     </a>",
"     (Accessed January 3, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_33_11806=[""].join("\n");
var outline_f11_33_11806=null;
var title_f11_33_11807="Contents: Behavior and development";
var content_f11_33_11807=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Behavior and development",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Behavior and development",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Attention deficit hyperactivity disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/18/26922\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/53/4954\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32730\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/34/23082\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14650\">",
"           Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Autism spectrum disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/20/15689\">",
"           Asperger disorder: Clinical features and diagnosis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41801\">",
"           Asperger disorder: Management and prognosis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4122\">",
"           Autism spectrum disorders in children and adolescents: Behavioral and educational interventions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/54/16234\">",
"           Autism spectrum disorders in children and adolescents: Complementary and alternative therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/54/872\">",
"           Autism spectrum disorders in children and adolescents: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/46/35562\">",
"           Autism spectrum disorders in children and adolescents: Pharmacologic interventions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/41/664\">",
"           Clinical features of autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38969\">",
"           Diagnosis of autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/1/14361\">",
"           Screening tools for autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/17/35097\">",
"           Surveillance and screening for autism spectrum disorders in primary care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4698\">",
"           Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cerebral palsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41768\">",
"           Epidemiology and etiology of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15962\">",
"           Management and prognosis of cerebral palsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Colic",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/27/10680\">",
"           Clinical features and etiology of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15177\">",
"           Evaluation and management of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/7/1140\">",
"           Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing; speech; and language",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30114\">",
"           Case illustrating the evaluation of speech and language impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10599\">",
"           Emergent literacy including language development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19050\">",
"           Etiology of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/57/21399\">",
"           Etiology of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26343\">",
"           Evaluation and treatment of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/62/5098\">",
"           Overview of expressive language delay (���������late talking���������) in young children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intellectual disability (mental retardation)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/4/34889\">",
"           Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26793\">",
"           Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5257\">",
"           Intellectual disability (mental retardation) in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40887\">",
"           Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17896\">",
"           Management of children and adolescents with fragile X syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Learning disabilities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/21/1370\">",
"           Clinical features and evaluation of reading difficulty in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37480\">",
"           Definitions of specific learning disability and laws pertaining to learning disabilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17592\">",
"           Interventions for children with reading difficulty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/16/6409\">",
"           Normal reading development and etiology of reading difficulty in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/57/32665\">",
"           Specific learning disabilities in children: Clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/27/37306\">",
"           Specific learning disabilities in children: Educational management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35944\">",
"           Specific learning disabilities in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44329\">",
"           Specific learning disabilities in children: Role of the primary care provider",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31097\">",
"           Childhood exposure to intimate partner violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/13/16602\">",
"           Comprehensive health care for children in foster care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/15/15607\">",
"           Developmental and behavioral implications for children of incarcerated parents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/15/43255\">",
"           Developmental and behavioral implications for military children with deployed parents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/51/27448\">",
"           Epidemiology of foster care placement and overview of the foster care system in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/43/39607\">",
"           Homesickness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/28/13770\">",
"           Overview of developmental coordination disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/5/30808\">",
"           Overview of fears and specific phobias in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/60/11209\">",
"           Promoting safety in children with disabilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40343\">",
"           Television and media violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/45/37592\">",
"           Toilet training",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         School issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17944\">",
"           The gifted child: Characteristics and identification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33240\">",
"           The gifted child: Educational interventions and primary care management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         School problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38185\">",
"           School readiness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sleep problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28473\">",
"           Sleepwalking and other parasomnias in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surveillance and screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/29/19928\">",
"           Developmental and behavioral screening tests in primary care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/49/26394\">",
"           Developmental-behavioral surveillance and screening in primary care",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-62696F8B5D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_33_11807=[""].join("\n");
var outline_f11_33_11807=null;
